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Introduction: Patients with COPD are characterised by symptoms of 
dyspnoea, limited exercise tolerance and low levels of physical activity which 
can lead to reduced quality of life. Pulmonary rehabilitation (PR) is 
recommended, however, not all are able to participate and there is a large 
dropout rate from this service. Home-based programmes aiming to enhance 
self-management skills can potentially provide an alternative model of 
delivery, allowing increased options for treatment. As one of the key 
components of PR is to enhance exercise endurance and physical activity, 
valid and reliable measures are needed to determine programme 
effectiveness. Therefore, the first aim of this thesis is to determine the validity, 
reproducibility and sensitivity of the SenseWear Pro 2 Armband, activity 
monitor (SWM) to be used in the main trial. The primary aim of this thesis is to 
describe the noninferiority randomised control trial of the effectiveness of the 
home based Self-management Programme of Activity Coping and Education 
(SPACE for COPD) in comparison to PR in patients with COPD. 
 
Methods: Validation of methods; One subject (EH) completed a battery of 
repeated walking tests using the speeds from the endurance shuttle walk test. 
Minute by minute energy expenditure (EE) and step counts were recorded 
from 9 SWM and indirect calorimetry was used as the criterion measure to 




Noninferiority randomised controlled trial; 287 (187 male: mean (SD) age 
67 (9) yrs; FEV1 1.25 (0.55); BMI 27.63 (6.22) kg/m
2) patients with COPD 
were recruited from referral to PR and randomised to either the SPACE for 
COPD programme or conventional PR. The primary outcome was the self-
reported measure of dyspnoea from the chronic respiratory questionnaire. 
Secondary measures included exercise performance (incremental and 
endurance shuttle walk tests (ISWT and ESWT), anxiety, depression and self-
efficacy. Daily physical activity was measured over five days using the SWM 
in a subgroup of 154 patients. Outcome measures were taken at baseline, 
post intervention (seven weeks) and six months. 
 
Results: The SWM was shown to be acceptable at measuring slow 
standardised walking speeds. However, reproducibility and sensitivity was 
more acceptable when using step count rather than EE.  
 
There was a significant improvement in dyspnoea (mean (95% CI) 0.58 (0.28 
to 0.88) units; p<0.001) and endurance capacity (ISWT 18 (3 to 32) m, 
p=0.015; ESWT 212 (139 to 284) sec, p<0.001), at seven weeks in the 
SPACE for COPD group that was to a similar level in the PR group (dyspnoea 
between group difference (95% CI) -0.032 (-0.71 to 0.08), p0.113), although it 
remains unclear as to the level of noninferiority. At six months some of the 
initial benefits in the ESWT were maintained in the SPACE for COPD group. 
However the other outcome measures (dyspnoea and ISWT) declined to 




Daily PA was low at baseline in those recruited to the trial and reduced as 
dyspnoea symptoms increased (mean (SD) steps; MRC 2 5824 (3027); MRC 
3 3908 (2162); MRC 4 3278 (2351); MRC 5 2382 (2046)). 51 patients had 
complete data sets at each measurement time point from the main trial. Those 
in the SPACE group significantly increased their PA above the PR group at 
seven weeks (mean (SD) between group difference for step count 1463 (280 
to 2645) p0.020). By six months PA had decreased towards baseline levels in 
both groups. 
 
Conclusion: SPACE for COPD does provide a number of health benefits so 
has the potential to be offered as an alternative to those who decline PR. As 
these benefits were not sustained at six months future work needs to be 
focussed on strategies to provide continued support for these patients.
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Chapter 1 - Introduction 
 
This chapter briefly introduces the issues examined in this thesis and provides 
a context and rationale for the research. This chapter is divided into three 
sections. The first (1.1) focuses on Pulmonary Rehabilitation (PR) in the UK 
and the need to investigate alternative models of care for those with Chronic 
Obstructive Pulmonary Disease (COPD). Home-base and programmes 
supported by self-management (SM) training may provide this opportunity. 
This discussion sets out a justification for the study and supports the origin of 
the aims and objectives outlined in the second section (1.2). The third section 
(1.3) describes the structure of the thesis and briefly explains the purpose and 
content of chapter’s two to nine. 
 
1.1 Study context and rationale 
 
COPD is a growing cause of morbidity, mortality and healthcare utilisation in 
the UK (National Clinical Guideline Centre; NICE 2010) and is predicted to be 
the 3rd leading cause of death by 2020 (World Health Organisation 2006). 
 
The management of COPD (NICE 2010) involves providing a treatment 
strategy which often includes smoking cessation, optimising medication and 
PR. Those with limited functional capacity and muscle weakness can benefit 
from PR, with findings also suggesting PR is effective at reducing hospital 
admissions and mortality (Lacasse et al. 2007).  
2 
 
PR provides a framework to deliver exercise training, education and support 
and develop self-management skills. It is normally offered as a 6-7 week 
outpatient programme with supervised exercise and education sessions. A 
recent audit of PR provision in the UK demonstrated that only 58% of Acute 
Trusts provided PR to all eligible patients and a further 32% had limited 
provision. Furthermore many PR programmes failed to meet the full 
guidelines recommended by the National Institute of Clinical Excellence 
(Yohannes et al. 2011). 
 
A potential opportunity to improve the scope of PR for patients with stable 
COPD and to increase patient choice of treatment options is a home based 
programme. Home based PR programmes have been shown to have similar 
improvements in exercise performance (Maltais et al. 2008) and self-reported 
dyspnoea (Güell et al. 2008, Puente-Maestu et al. 2000)  in comparison to 
outpatient PR. However, these studies had initial hospital based education 
sessions before the commencement of exercise training and the former study 
provided exercise equipment in the patients home (Maltais et al. 2008).  
 
The healthcare system in the UK is moving towards patients having a more 
active role in their own healthcare provision. Engaging patients in this process 
can be encouraged by improving SM skills. SM support aims to improve 
knowledge of the disease, self-efficacy and the development of skills and 
behaviours to enhance health (Bourbeau 2004). Supported SM programmes 
are established in other long term conditions in the UK (Lewin et al. 1992, 
Skinner et al. 2006). However, its effect in patients with COPD is unclear 
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(Barlow et al. 2002). There is potential for SM to enhance the delivery of 
home based programmes to elicit behaviour modification for long term 
maintenance. 
 
The key challenge in interpreting the literature surrounding SM programmes 
for patients with COPD is in the various definitions and interpretations of its 
implementation. Whereby some SM programmes are brief action plans or 
brief advice (Watson et al. 1997), others are comprehensive supervised 
education and exercise programmes lasting two years (Monninkhof et al. 
2003a). In addition to the inconsistency in SM programmes in the literature 
there is also variation in what outcome measures are reported. Health related 
quality of life (HRQoL), exercise capacity and walking capacity have been 
described, however, the impact on changing physical activity behaviour is 
lacking in the COPD population. To enable the assessment of PA, activity 
monitors need to be valid measures and sensitive enough to detect small 
changes in walking speeds given that walking pace is slower in patients with 
COPD in comparison to healthy controls (Troosters 2009). At present there 
has been no study investigating a home based supported SM programme in 








1.2 Aims and Objectives 
 
The aim of this thesis is to contribute to the literature on the effectiveness of a 
home based supported SM programme in comparison to conventional PR in 
patients with stable COPD. 
 
A Self-Management Programme of Activity Coping and Education, or SPACE 
for COPD, manual has been developed by the University Hospitals, Leicester 
NHS Trust. This thesis evaluates the effectiveness of this home based 
SPACE for COPD programme in a randomised noninferiority controlled trial in 
comparison to conventional PR.  
 
The primary outcome measure was self-reported dyspnoea with secondary 
measures of HRQoL, self-efficacy, exercise performance and daily physical 
activity patterns. 
 
The specific aims of this thesis were to: 
 
 Determine the reproducibility, sensitivity and validity of the SenseWear 
Pro2 Armband (SWM) in detecting and distinguishing between slow 
speeds of walking. 
 Explore the impact of the SPACE for COPD programme on HRQoL, 
exercise performance and self-efficacy after a seven week intervention 
and then a six months follow up in comparison to conventional PR. 
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 Explore the PA patterns of patients with COPD in relation to disease 
impact and to determine if they meet the national and international 
guidelines for PA participation. 
 Explore the effect of the SPACE for COPD programme on PA levels at 
seven weeks and six months.  
 
It was hypothesised that the SPACE for COPD would be noninferior to PR in 
regards to HRQoL. 
 
1.3 Structure of the thesis 
 
Chapter 2 focusses on a review of the current pertinent literature on the 
delivery of PR and provides a rationale for the thesis. The methods used in 
this experimental work are described in chapter 3. Chapter 4 provides data on 
the validity, sensitivity and reproducibility of the Seanswear Pro 2 Armband 
used to monitor PA in the main trial. The effectiveness of the SPACE for 
COPD programme at seven weeks in comparison to PR will be presented in 
chapter 5 and the six months findings in chapter 6. Both chapters 5 and 6 
examine data on HRQoL, exercise performance, psychological functioning 
and self-efficacy. Chapter 7 describes the PA levels of the participants across 
the various impact categories of the disease and contrasts these PA levels 
with national and international guidelines. Chapter 8 explores the impact of 
the SPACE for COPD programme on PA levels at seven weeks and six 
months. This thesis ends with chapter 9 which evaluates the key findings of 




Chapter 2 - Literature Review 
 
This chapter introduces the issues examined in the thesis and provides a 
context and rationale for the research. A more detailed exploration of the 
points outlines here are presented throughout the thesis. This chapter is 
divided into 3 sections. The first section (2.1) describes chronic obstructive 
pulmonary disease (COPD), in terms of what it is and what issues it raises for 
both the individual and healthcare system. The second section (2.2) explores 
a key theme for this thesis, physical activity (PA). Here the national and 
international PA guidelines will be outlined, levels of PA in patients with 
COPD, and how to measure PA in patients with low levels of daily PA will be 
analysed. The final section (2.3) describes the treatment for COPD and 
provides evidence for usual care Pulmonary Rehabilitation (PR). The location 
of rehabilitation will be addressed and the use of supporting programmes with 
self-management (SM) will be introduced. The chapter will conclude with a 
summary of the salient issues relevant to this thesis. 
 
2.1 Chronic Obstructive Pulmonary Disease 
2.1.1 Definition of Chronic obstructive Pulmonary Disease 
Chronic obstructive pulmonary disease (COPD) encompasses a group of lung 
conditions that cause a narrowing of the airways, leading to shortness of 
breath. Chronic bronchitis and emphysema are the most common forms of 




abnormal inflammatory responses of the lungs (Rabe et al. 2007).  One of the 
main symptoms of COPD is breathlessness and the predominant risk factor 
for the condition is long-term cigarette smoking. Individual with COPD 
frequently become trapped in a vicious cycle of inactivity, social isolation and 
depression. Disabling breathlessness most frequently instigates his decline.  
 
2.1.2 Aetiology 
The primary risk factor for COPD is cigarette smoking and develops from 
exposure of the lungs to noxious particles found in cigarettes (Vestbo et al. 
2013). Smoking accounts for 80-90% of all cases of COPD and smokers are 
ten times more likely to die from the disease than non-smokers (Doll et al. 
1994). The risk for COPD in smokers is dose related (Burrows et al. 1977) 
with age at starting to smoke, pack years and current smoking status also 
being predictive of COPD mortality. However, if a patient with COPD stops 
smoking, the rate of decline in lung function returns to that of a non-smoker 
(Fletcher and Peto 1977). Passive smoking may also contribute to the 
development of COPD (Eisner et al. 2005). 
 
Other risk factors associated with COPD are; Age, prevalence of the condition 
increase in the older age groups, but it is not clear if age itself is a risk factor 
or whether it reflects the accumulative exposure throughout life (Vestbo et al. 
2013). The deficiency of the antiprotease enzyme, α1-antitrypsin may lead to 
lung tissue disruption and eventually COPD.  Occupational exposure to 
airborne pollutants, including organic and inorganic dust particles, and 




(Matheson et al. 2005). There is also considerable evidence that those with 
lower socioeconomic status have a higher risk of developing COPD (Prescott, 
Lange and Vestbo 1999). It is not clear, however, to its true relationship or 
whether it really reflects exposure to pollutants, crowding, poor nutrition or 
infection (Vestbo et al. 2013). Those that have a history of childhood 
respiratory infection, and asthma also have an increased risk of developing 
COPD (Vestbo et al. 2013). 
 
2.1.3 Pathophysiology 
COPD is caused by two key mechanisms: chronic inflammation of the small 
airways and gradual destruction of the alveoli (Rabe et al. 2007). Pathological 
changes within the lung tissue are largely attributed to cigarette smoke. The 
pathological damage to the lung tissue is initiated long before signs and 
symptoms are present (Sutherland and Martin 2003) , and even after smoking 
cessation the inflammatory process continues (Willemse et al. 2005). 
 
Inhaled cigarette smoke and other noxious particles cause lung inflammation, 
a normal response which appears to be amplified in patients with COPD.  
Lung inflammation can also lead to damage of the elasticity and support of the 
alveoli, which result in loss of elastic recoil (Sutherland and Martin 2003). 
COPD is also characterised by mucus hypersecreation which block 





2.1.4 Prevalence  
COPD is a leading cause of mortality, morbidity and healthcare usage 
worldwide and in the UK (Britton 2003). This, therefore, results in a huge 
burden both economically and individually. COPD is currently the fourth most 
common cause of death worldwide and the World Health Organisation 
anticipates that by 2020 it will have become the third, primarily related to the 
changes in smoking behaviour in the developing world (World Health 
Organisation 2006).  A systematic review estimated the prevalence of 
physiologically defined COPD in the over 40’s is 9-10% worldwide (Halbert et 
al. 2006). In 2004 over 27,000 people in the UK died from COPD (British 
Thoracic Society 2006), however, mortality data may underestimate the 
impact of COPD as it is often listed as a contributing factor towards death or 
not listed at all (Pauwels et al. 2001). 
 
The precise number of individuals with a current diagnosis of COPD in the UK 
is difficult to ascertain but it is reported to be around 900,000 (NICE 2010). 
This number is considerably lower than the prevalence rate of 3 million as 
estimated by (Stang et al. 2000) based on smoking rates. The discrepancy in 
these figures has become known as the ‘missing millions’ and refers to the 
millions of people that have undiagnosed COPD (Department of Health 2010). 
 
2.1.5 Diagnosis of COPD 
There is no single diagnostic test for COPD, therefore, diagnosis is based on 
clinical symptoms, heath status, exercise capacity, and presence of airflow 




COPD should be considered in patients over 35 who have a risk factor 




Regular sputum production 
Frequent winter bronchitis  
Wheeze 
 
Spirometry results indicating COPD would be: 
 A reduced Forced Vital Expiratory volume in one second (FEV1) of less 
than 80% of predicted values and  
 A reduced FEV1/Forced Vital Capacity (FVC) ratio less than 70% 
 
2.1.6 Signs and symptoms of COPD 
The most commonly reported symptom of CODP are dyspnoea 
(breathlessness), a productive cough, reduced exercise tolerance and fatigue 
(Department of Health, 2010). Symptoms may be mild or even absent in the 
early stages of disease and therefore patients often don’t present to their GP’s 
until the condition has progressed further and symptoms become more 
severe. Symptoms can change from day to day and the severity of symptoms 
does not always correlate to the severity of disease (Vestbo et al. 2013). 
Dyspnoea has been shown to be a key determinant of quality of life (Bentsen, 




2004). Dyspnoea commonly leads to avoidance of physical activity and 
exercise which result in reduced exercise tolerance and muscle weakness 
 
2.1.7 Classification of COPD  
The severity of dyspnoea can be classified by the Medical Research Council’s 
(MRC) Dyspnoea scale (Fletcher et al. 1959). The scale is used to grade 
breathlessness according to the level of exertion required to elicit it (table 2.1). 
 
Table 2.1 Medical Research Council Dyspnoea scale (Fletcher et al. 1959) 
 
Grade Level of breathlessness 
1 Not troubled by breathlessness except on strenuous exercise 
2 Short of breath when hurrying or walking up a slight hill 
3 Walk slower than contemporaries on level ground because of 
breathlessness, or has to stop for breath when walking at own 
pace 
4 Stop for breath after walking about 100 yards or after a few 
minutes on level ground 
5 Too breathless to leave the house, or breathless when dressing 
or undressing 
 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) have 
classified the severity of airflow limitation using spirometry (Vestbo et al. 2013; 
Table 2.2). Together with exacerbation frequency, MRC dyspnoea score or 




a model has been develop to assist in stratifying patients by severity and 
symptoms in order to aid treatment plans (Vestbo et al. 2013 table 2.3) 
 
 
Table 2.2 Vestbo et al. (2013) classification of disease severity 
 
GOLD stage  
Stage 1: Mild FEV1/FVC <0.70 
FEV1 ≥ 80% predicted 
Stage 2: Moderate 
 
FEV1/FVC <0.70 
50% ≤ FEV1 < 80% predicted 
Stage 3: Severe FEV1/FVC <0.70 
30% ≤ FEV1 <50% predicted 
Stage 4: Very severe FEV1/FVC <0.70 
FEV1 < 30% or FEV1 <50% predicted 







































Figure 2.1 GOLD assessment of COPD disease stratification (Vestbo et al. 
2013) 
 
2.1.8 Burden of COPD 
Burden to the Healthcare System 
The Chief Medical Officer has estimated that COPD accounts for more than 
£800 million in direct health care costs, 1.4 million primary care consultations 
and one million in-patient bed days per year. With more severe cases 
resulting in greater cost. COPD is one of the most expensive conditions to be 


















2010). A significant proportion of this cost of managing COPD is due to the 
high rates of hospitalisation, with the second largest cause of emergency 
admissions in the UK being due to COPD (British Lung Foundation 2007). It 
also has a high readmission rate of 33% and a median length of stay of 5 
days as recorded in 2008 by the Royal College of Physicians of London 
(2008). Patients with COPD also have significantly higher numbers of visits to 
see their GP, with 74% of patients contacting their GP once and 31% 
contacting their GP 3 or more times before a hospitalisation (National Institute 
for Health and Clinical Excellence 2010). 
 
In addition, the indirect cost of this chronic condition are substantial impacting 
on annual productivity with an estimated 24 million workdays lost to COPD at 
a loss of £2.7 billion to industry (Department of Health and Chief Medical 
Officer 2005). 
 
Burden to the individual 
The burden to the individual is significant and can greatly impact on everyday 
life (Braido et al. 2011) and health related quality of life (Ferrer et al. 1997). 
The symptoms of COPD as described in section 2.1.6 result in reduced 
exercise capacity (Killian et al. 1992) and daily physical activity in comparison 
to healthy older adults (Pitta et al. 2005a) which can lead to disability in many 
patients with COPD (Braido et al. 2011). Physical activity levels will be 
discussed in detail in section 2.1.10. Health related quality of life is also lower 
in this group in comparison to the general population (Schlenk et al. 1998) 




al. 2008). The risk of depression in patients with COPD has been shown to be 
associated with disease severity with an overall incidence rate of 6.1% (van et 
al. 2009), and the prevalence of anxiety in these patient is generally 
considered to be high with rates ranging from 10-33% (Dowson, Kuijer and 
Mulder 2004, Hynninen et al. 2005). Causes of anxiety are often attributed to 
dyspnoea (Hill et al. 2008), limited functional performance, poor coping 
strategies and reduced self-efficacy (McCathie, Spence and Tate 2002). 
There is also a significantly higher risk of hospital readmissions in those with 
anxiety and depression (Dahlén and Janson 2002).  
 
Physical Activity 
2.1.9 Exercise recommendation 
The Department of Health, The British Association of Sport and Exercise 
Sciences and the American College of Sport and Exercise Sciences  
recommend that all adults (19-64 years and 65+ years) should take part in a 
minimum of 150 minutes of moderate intensity (3-6 METs: Metabolic 
Equivalent) aerobic activity per week to develop and maintain health related 
fitness. A MET is the ratio of work metabolic rate to a standard resting 
metabolic rate. Metabolic rate is the rate at which a person uses energy, 1 
MET is considered to be resting metabolic rate. Moderate to vigorous activity 
is considered to be between 3 to 6 METs. Aerobic activity should be 
completed in bouts of at least 10 minutes and should be performed 5 or more 
days per week (Department of Health 2011, Nelson et al. 2007, O'Donovan et 
al. 2010). Adults should also undertake strength training 2x week and reduce 




incorporate PA to improve balance and co-ordination twice a week. Those not 
meeting these guidelines have higher risk of all-cause mortality (Fogelholm 
2010).  
 
The scientific evidence at the basis of the physical activity guidelines supports 
a dose-response relationship between PA and health benefits. In that as the 
volume of activity (intensity, duration or frequency) increase this yields greater 
or additional health benefits. Evidence indicates that all-cause mortality (Lee 
and Skerrett 2001), cardiovascular disease mortality (Wannamethee and 
Shaper 2001) and the development of type 2 diabetes (Gill and Cooper 2008) 
are significantly lower in adults reporting a volume of 120 to 150 minutes per 
week of MVPA. However, significantly lower rates of colon cancer (Samad et 
al. 2005), breast cancer (Monninkhof et al. 2007) and obesity (Hill and Wyatt 
2005) occur at 180 to 300 minutes of MVPA per week. Due to the differing 
amounts require for different outcomes and the need to keep guidelines as 
simple as possible, the UK together with other international bodies have 
retained a single recommended dose of PA. Achieving the adequate volume 
of MVPA appears to be more important composite of health benefits than 
does a specific mode of activity, its intensity or session frequency (Physical 
activity advisory committee 2008). However, the guidelines state that for 
MVPA to ‘count’ towards the 150 minutes per week, it must be in bouts of at 
least 10 minutes. A review of the literature compared selected fitness 
measures, fatness parameters and biomarkers with multiply shorter bouts of 
exercise (10 minutes) to one longer 30-40 minute session and found there to 




exercise are more likely to be appealing to many and easier to achieve. 
Evidence for shorter bouts of exercise (less than 10 minutes) is lacking and 
therefore national and international guidelines state bouts need to be a 
minimum of 10 minutes (Department of Health 2011, Nelson et al. 2007). 
 
Another common measure of reporting PA levels is step count (Troosters et 
al. 2010, Waschki et al. 2012, Watz et al. 2009). This is perhaps due to ease 
of measuring with inexpensive pedometers and a measure that is easily 
interpreted by patients and the general population. Accumulating 10,000 steps 
has previously been reported to be the recommended daily target (Tudor-
Locke and Bassett Jr. 2004). However it is difficult to quantify what this 
threshold equates to in terms of volume of PA. ACSM report (Nelson et al. 
2007) that intensity of PA is important to stimulate a physiological adaptation 
and therefore a health benefit, but steps can be accumulated at all levels of 
intensity. Until current developments in more sophisticated PA monitors, it 
was unknown how many steps equated to 30 minutes of moderate to vigorous 
activity (MVPA). Tudor-Locke et al (2011) reported that 30 minutes of MVPA 
is associated with 3,000 steps. However, daily step count includes many free 
living activities which are incorporated into this measure. Therefore, they 
concluded that 7,000 to 8,000 steps per day may be a more accurate 
threshold to indicate 30 minutes of MVPA has been achieved.   
 
The physical activity level (PAL) has become a recognised method of 
expressing total daily energy expenditure (TEE) in multiples of resting 





PAL = TEE 
            RMR 
 
An individualised PAL can give an indication of how physically active they 
have been during a 24 hour period. Table 2.3 show the classifications of PAL 
(Food and Agriculture Organization of the United Nations, 2004). 
 
Table 2.3 Classification of PALs 
Activity Level PAL 
Extremely Sedentary / Inactive <1.40 
Sedentary 1.40-1.69 
Moderately active 1.70-1.99 
Vigorously active 2.00-2.40 
Extremely active >2.4 
 
Therefore, daily recommendations of PAL are >1.70 (Food and Agriculture 
Organization of the United Nations, 2004). 
 
2.1.10 Physical activity in patients with COPD 
Physical activity (PA) is defines as any bodily movement by skeletal muscle 
that results in energy expenditure beyond resting energy expenditure. Level of 
PA is an important clinical outcome and low PA levels have been shown to 
negatively impact on hospital admissions (Garcia-Aymerich et al. 2006), 




exercise performance and muscle weakness (Pitta et al. 2005a). Exercise 
capacity and PA is reduced in patients with COPD (Pitta et al. 2005b, 
Sandland et al. 2005). Watz et al. (2009) reported that only patients with mild 
COPD (modified MRC grade 0) met the recommended guidelines (section 
2.1.9), and physical activity levels declined as the severity of COPD 
increased. It is also apparent that these patients also walk more slowly than 
healthier subjects (Troosters et al. 2010, Watz et al. 2009). A review of 
objectively monitored PA in COPD (Vorrink et al. 2011), which analysed 11 
studies concluded that patients with COPD had significantly reduced PA 
levels in terms of duration, intensity and activity counts of daily living in 
comparison to healthy controls. However, the level of PA was not strongly 
correlated with disease severity. 
 
Time spent in moderate to vigorous activity has been shown to decline with 
age in the general population (British Heart Foundation 2012), with only 33% 
of 55-64 years, 20% of 65-74 years and 9% of 75+ year old men meeting the 
recommended guideline for self-reported PA. These figures are even lower in 
the female population (28% 55-64 years, 17% 65-74 years and 6% 75+ year 
old). Therefore, low PA levels are already a public health concern in the 
normal population which are further reduced in patients with COPD.   
 
What is not clear from many of the studies is what the pattern of PA that 
patients with COPD partake in and whether patients are completing enough 
exercise to meet national guidelines and therefore improve health. The 




minutes, but has mainly been reported as step counts (Waschki et al. 2012), 
PAL (van Gestel et al. 2012, Waschki et al. 2012), total energy expenditure or 
time above 3 METs (van Gestel et al. 2012). It is important to be able to 
describe the pattern of daily PA as many short bouts (<10 minutes) of activity, 
despite adding up to over 30 minutes per day, may not be sufficient to meet 
the guideline and therefore not result in the desired health improvements. It is 
therefore essential that studies clearly report how activity is reported and that 
the data is interpreted with this in mind. Van Remoortel et al. (2013) 
investigated the effect of describing PA of patients with COPD and health 
subjects by different cut points from various guidelines. Cut points used were 
≥ 3 METs for all ages, ACSM (2007); ≥ 3 METs for ≤ 65years and ≥ 50% VO2 
reserve for > 65 years, ACSM (2007); 50% VO2 reserve for all ages, ACSM 
(2011); and ≥ 4 METs  for ≤ 65 years ≥3.2 METs for > 65 years ACSM (2011). 
The data was analysed using total time above the given cut point and total 
time above the given cut point in at least 10 minute bouts. Findings revealed a 
significant difference between the bout and non-bout data and not surprising 
there was a difference between the different cut points used. Their data also 
showed that 80 minutes of non-bout PA is associated with 30 minutes of bout 
PA. This new threshold of 80 minutes recommended to meet the national 
guidelines may be of use when reporting and interpreting research trials were 
evaluating minute by minute data is not possible. However, it is clinically 
limited as the recommendations are still that adults should accumulate at least 
30 minutes of moderate intensity PA in consecutive bouts of at least 10 





One study that has attempted to describe the PA patterns of patients with 
COPD using bouts of PA recruited 177 participants from 9 tertiary hospitals in 
Spain (Donaire-Gonzalez et al. 2012). The study found that 50% met the 
guidelines of over 150 minutes at 3 METs in at least 10 minute bouts. They 
also defined moderate PA to be activity above 2.6 METs, calculated as 50% 
of maximal oxygen uptake on performing an incremental exercise test. When 
using 2.6 METs as the threshold for meeting the guidelines the figure 
increased to 61%. These figures appear to be considerably higher to the 
general UK population let alone to the reduced capacity of UK COPD patients.   
 
Overall it is clear that PA is reduced in patients with COPD to a level which 
adversely impacts on health status and hence increases the demands on 
NHS resources. What is not fully understood is the precise pattern of PA that 
these patients undertake. Making what PA that they do more effectively met 
the guidelines could be attractive to those with limited capacity and led to 
health improvements. In order to monitor PA levels and patterns accurate 
measures need to be considered.     
 
2.2 Measuring Physical activity 
The assessment of physical activity can be challenging and methods of 
measuring it are currently of great interest. Although double-labelled water 
and calorimetry are considered the gold standard for physical activity 
assessment they can be time consuming, costly and not suitable for large 




provide limited information. Common methods reported in the literature are 
questionnaires, pedometers and activity monitors (accelerometers). 
 
Questionnaires 
Self-reported measures such as questionnaires are regarded as not 
accurately quantify the amount of daily physical activity and therefore have 
had limited use in patients with COPD (Pitta et al. 2006). There is a great 
potential for either over estimation or underestimation of the amount of 
physical activity performed (Westerterp 2009) when using questionnaire so 
caution is needed when interpreting the results. Garfield et al. (2012) 
evaluated four questionnaires (Stanford seven day recall, Baecke, Physical 
Activity Scale for the Elderly and Zutphen physical activity questionnaire) with 
the SenseWear armband accelerometer in 43 patients with COPD. A 
significant correlation between methods was only seen with the Stanford 
seven day recall questionnaire, which is the only questionnaire delivered by a 
semi structured interview. Although questionnaires are relatively easy to 
administer and give useful data of what specific activities are being 
undertaken more accurate measures to quantify PA are required. 
 
Pedometers 
Pedometers provide step counts which have been shown to have some 
reproducibility in patients with COPD but it may not be as accurate in patients 
as it is in health individuals (Schönhofer et al. 1997, Tudor-Locke et al. 2002). 
It is possible that the pedometer is not sensitive enough to detect the lower 




investigated the reliability of several pedometers to measure step count in 
patients with COPD. Pedometers were found to be reliable at faster walking 
speeds however significantly undercounted steps at slow to moderate walking 
speeds (p<0.01). Activity monitors are more sensitive and sophisticated 
devices that can measure movement in more than one plane and have the 
potential to more accurately monitor PA levels. 
 
Activity Monitors 
Activity monitors aim to capture body movement to estimate energy 
expenditure (EE), activity counts or vector magnitude units. They measure 
acceleration in either one, two or three planes (uniaxial, biaxial or triaxial 
activity monitors). A number of them are also able to detect step counts from 
the vertical plane. Several activity monitors are commercially available and 
have be validated in patients with COPD. It is important that they are validated 
in patients with COPD and not just healthy individuals as previously describe 
patients with COPD have lower activity levels and move more slowly (Trooster 
et al. 2010). Activity monitors therefore need to detect even modest changes 
in PA in these patients.  
 
A multi-sensor activity monitor, SenseWear Pro Armband (SWM; BodyMedia, 
Pittsburg, USA) has been developed that measures physical activity in terms 
of EE (Kcal), METs and step counts. The monitor integrates biaxial 
accelerometry (longitudinal and transverse planes) with multiple physiological 
measures including galvanic skin resistance, heat flux, body temperature and 




back of the upper right arm over the triceps muscle mid-way between the 
acromion and the olecranon processes and can collect data continuously for 
up to 14 days. The monitor includes a time stamp button, that when pressed, 
can signify specific activities and therefore aid in accurate documentation. 
Preliminary studies in normal healthy subjects suggest that this device is 
reliable and valid at estimating EE in the laboratory setting (Fruin and Rankin 
2004, Jakicic et al. 2004, King et al. 2004). However, as patients with COPD 
have much lower activity levels and walk at slower speeds we cannot assume 
these devices can capture subtle changes in activity at the lower level. The 
increasing interest in measuring daily activity has driven the development of 
activity monitors to assess the effect of PR programmes and other PA 
interventions. However, we must first ensure the validity and reliability of such 
devices in the COPD population. 
 
Patel et al. (2007) assessed the validity and reproducibility of the SWM during 
the 6 minute walk test (6MWT) and incremental shuttle walk test (ISWT) in 
patients with COPD. Although they suggested it was valid and reliable they 
reported cumulative activity, rather than the accuracy of the monitor at slow 
speed of walking and hence potentially missing out phases of reduced 
activity.   Another trial (Furlanetto et al. 2010) evaluated the SWM for step 
counts and EE using a treadmill walking protocol corresponding to 30%, 60% 
and 100% of the average speed COPD patients and healthy adults achieved 
during a 6MWT. They use indirect calorimetry and videotape as criterion 
measures of EE and step counts. They reported that the SWM did not 




being worn on the arm rather than the leg. However, they did find it to be 
accurate at estimating EE at all speed in the healthy adults and at the 
intermediate and higher speeds in the patient group. Furlanetto et al. (2010) 
study did not use standardised walking speeds making it difficult to conclude 
whether they can distinguish between speed, and subjects were only 
monitored for 1 minute intervals and hence steady state could not have been 
reached. They also used a treadmill walking to assess the SWM, but it is 
important to test the device during free walking on the ground as gait and 
energy requirements are different during treadmill walking (Murray et al. 1985, 
Pearce et al. 1983, Stolze et al. 1997) and may not truly reflect domestic 
physical activity. 
 
Hill et al. (2010) reported the device as being able to detect changes in 
different types of physical activity, lying, sitting, standing and walking. These 
walking speeds were selected by the individual as either slow or fast so were 
not standardised. They concluded that the SWM was sensitive to small 
changes in EE and was a valid measure in comparison to indirect calorimetry. 
Interestingly the self-selected (mean (SD)) slow (51 (11) m/min) and fast (65 
(12) m/min) speeds of walking reported in Hill and colleagues’ paper 
generated 77 and 93 steps per minute, these values correspond roughly to 
levels 3 (50 m/min) and 4 (61 m/min) of the ISWT (Smith et al. 2007). Van 
Remoortel et al (2012) investigated the validity of 6 activity monitors including 
the SWM with indirect calorimetry (VO2) in a similar study design to Hill. 
Participants completed a battery of structured activities included self-selected 




highest correlation with metabolic cost as measured form indirect calorimetry 
(r = 0.76). However the self-selected slow speeds of walking was (mean (SD)) 
3.27 (0.47) km/hr. Both these studies, therefore, have not assessed the SWM 
in the full range of ability seen in COPD patients, and in particularly not at the 
low speeds of walking characteristic of patients with COPD. 
 
Given that individuals disabled by COPD walk slowly (Troosters et al. 2010) it 
is essential to be confident that the device is reliable and able to register 
activities of a slow velocity. This is important for a number of reasons, 
detection of physical activity is an increasingly important outcome for this 
population who are fairly sedentary and adopt slow speeds of walking, and 
therefore the device must be sensitive to low levels of activity.  The device, 
ideally, should also be able to discriminate different speeds of walking, within 
a narrow range. Within the context of rehabilitation the devices may have a 
number of applications. Firstly as an outcome measure but also as an aid to 
exercise prescription and monitoring as walking forms the foundation of many 
rehabilitation exercise programmes. It is therefore important to understand the 
properties of the devices at various slow speeds of walking commonly 
replicated during a rehabilitation programme and everyday life. It is not 
uncommon to prescribe a walking programme from performance on the ISWT 
(Liu et al. 2008, Sewell et al. 2005), if we can therefore generate a value for 
EE and steps at a particular speed, prescription and monitoring becomes 





2.3 Treatment of COPD 
The management options for COPD are comprehensively described in the 
NICE guidelines for COPD (2010) 
 
According to the GOLD recommendations (Vestbo et al. 2013), effective 
management should achieve the following objectives: 
Relieve symptoms 
Prevent disease progression 
Improve exercise tolerance 
Improve health status 
Prevent and treat exacerbations 
Reduce mortality 
 
A typical treatment strategy would include the following: 
 
2.3.1 Smoking cessation 
Smoking is the leading cause of COPD and significantly contributes to 
reduced lung function (Anthonisen et al. 2002). Smoking cessation is one of 
the most important strategies in the management of the condition and has 
been shown to reduce the rate of decline in FEV1 (Scanlon et al. 2000) and 
has a positive effect on symptoms (Kanner et al. 1999). A review of smoking 
cessation and mortality concluded that smoking cessation improved survival 
compared to those continuing to smoker but was still higher than those who 





2.3.2 Medication (e.g. bronchodilators and corticosteroids) 
The aim of pharmacological therapy is to maintain control of symptoms and 
prevent exacerbations. Although COPD is irreversible certain medication can 
improve FEV1 and static and dynamic hyperinflation in patients with COPD 
(NICE, 2010). Commonly prescribed inhaled therapies include beta2-agonists, 
antichollinergics (both short- and long-acting) and inhaled corticosteroids. 
 
2.3.3 Oxygen therapy 
Supplementary oxygen can be prescribed for COPD patients that experience 
extreme breathlessness and hypoxia. It can be administered as long term 
oxygen therapy, whereby the patient would breathe supplementary oxygen for 
at least 15 hours per day. Ambulatory oxygen therapy can be considered for 
those who oxygen levels de-saturated and become excessively breathless 
during exercise or activity. Short burst oxygen therapy is only considered for 
severe breathlessness where other treatments have failed to be of benefit. 
 
2.3.4 Pulmonary Rehabilitation (PR) 
 
Definition of Pulmonary Rehabilitation 
The American Thoracic Society and the European Respiratory Society have 
adopted the following definition of pulmonary rehabilitation: "Pulmonary 
rehabilitation is a comprehensive intervention based on a thorough patient 
assessment followed by patient tailored therapies that include, but are not 
limited to, exercise training, education, and behaviour change, designed to 




respiratory disease and to promote the long-term adherence to health-
enhancing behaviours." (Spruit et al. 2013).  
 
There is overwhelming scientific evidence to support the delivery of exercise 
training in the form of PR. There is also increasing interest in the delivery of 
exercise training via a number of different modes including home based, and 
supportive self-management programmes.   
 
PR is now an established treatment for patients with COPD and is recognised 
as such by the National Institute for Health and Clinical Excellence (2010) in 
the UK. The aim of PR is to return patients with COPD to optimum functional 
capacity, therefore the key components of a comprehensive programme are 
exercise testing, exercise training and education with psychological and social 
support. There is strong evidence for PR and is based on studies that have 
demonstrated improvements in exercise capacity and health status (Lacasse 
et al. 2007, Nici et al. 2006). Evidence suggests that a single PR course can 
improve exercise capacity in terms of VO2peak (Foglio et al. 1999) , exercise 
duration time  (Goldstein et al. 1994, Singh et al. 1998) and walk distance 
(Finnerty et al. 2001, Goldstein et al. 1994, McGavin et al. 1977, Singh et al. 
1998). The evidence for the benefit of a single course of PR also extends to 
improving HRQoL (Finnerty et al. 2001, Goldstein et al. 1994, Griffiths et al. 
2000, Singh et al. 1998) and decrease healthcare utilization (Garcia-Aymerich 
et al. 2006, Griffiths et al. 2000). Guidelines have emphasised the importance 
of PR in the treatment of COPD (NICE 2010). However, the precise elements 




The focus of PR is on improving patients health related quality of life (HRQoL) 
by optimising exercise capacity thereby reducing the disability associated with 
the disease. The emphasis moves away from trying to reverse the 




The British Thoracic Society (Bolton et al. 2013) state that PR is effective in 
numerous settings including hospital inpatient, hospital outpatient, and the 
home.   
 
Inpatient Pulmonary Rehabilitation 
Inpatient PR in not common in the UK but is more widespread in Europe and 
the USA. Goldstein et al. (1994) demonstrated that a 2 month inpatient 
programme followed by outpatient PR programme improved exercise capacity 
and dyspnoea over 6 months. Inpatient PR is considered to be more 
expensive than outpatient PR and is not a model of care seen in the UK. It 
could also be argued that inpatient care may not be an appropriate setting to 
instil behavioural lifestyle changes needed to adhere to regular exercise. 
 
Outpatient Hospital Based Pulmonary Rehabilitation 
Outpatient is the most common location for PR in the UK. The benefits of 
outpatient hospital based PR are accepted and widely reported (Lacasse et 
al. 2007). The BTS guidelines (Bolton et al. 2013) recommends that a PR 




which should be supervised. Ringbaek et al. (2000) reported that 2 exercise 
sessions per week was inadequate at improving exercise tolerance in COPD 
patients, highlighting the importance of completing regular weekly sessions at 
the recommended frequency. A number of randomised controlled trials have 
demonstrated positive outcomes of outpatient PR (Griffiths et al. 2000, Ries et 
al. 1995, Ries et al. 2003, Spencer, Alison and McKeough 2010, Troosters, 
Gosselink and Decramer 2000). Outpatient programmes reduce the disruption 
to daily living in comparison to inpatient programmes and allow patients the 
comfort of being in the own environment.  
 
Despite the substantial evidence of the benefit of outpatient PR only 58% of 
Acute Trusts in the UK have provision for all eligible patients (Yohannes et al. 
2011). Moreover, not all patients that are referred to PR receive the treatment 
as intended. Up to 50% of patients refuse to attend their initial consultation 
(Taylor et al. 2007) , or dropout before the end of the programme. Jones et al. 
(2014) recently reported on referral and uptake of PR after hospitalisation for 
an acute exacerbation of COPD over a one year period. This study reported 
that of the 286 patients that were eligible, 90 were referred to PR and only 43 
received and completed the PR programme. Singh et al. (1998) reported less 
than half of participants completed the full course of PR. Dropout rates 
reported from clinical trials are generally not as high as this figure, but this 
could be due to the effect of being part of a trial (Arnold, Bruton and Ellis-Hill 
2006). Common reasons reported for non-attendance and poor adherence to 




2007, Keating, Lee and Holland 2011, O'Shea, Taylor and Paratz 2007, Sabit 
et al. 2008).  
 
Home based programmes could overcome this travel issue and potentially 
allow increased participation and reduced healthcare costs as programmes 
are based in patients own homes (Güell et al. 2008, Maltais et al. 2008, 
Puente-Maestu et al. 2000, Strijbos et al. 1996). Home based rehabilitation 
will now be discussed.     
 
Home Based Pulmonary Rehabilitation 
Literature (PICO) search terms are listed in Appendix A.  
 
Five studies have directly compared home based programmes with outpatient 
PR. Strijbos et al. (1996) compared 12 weeks hospital based PR with a 
supervised home based programme and a control group that received 
standard care in 45 patients with moderate to severe COPD (mean (SD) age 
61 (6), 60 (8), 63 (5) years; FEV1 % predicted 40 (20), 46 (7), 43 (9) for the 
hospital based group, home based group and control group respectively). 
Exercise tolerance was assessed at 6, 12 and 18 months after the 
intervention. Data showed that exercise tolerance improved at 6 months in 
both PR groups, however, by 18 months the home PR group had continued to 
improve but the hospital group exercise tolerance had returned to baseline. 
The authors concluded that those completing a home based PR may have 
found it easier to continue unsupervised after the initial PR programme. Gűell 




exercise tolerance and dyspnoea symptoms than hospital based PR (mean 
(SD) age 63 (7), 66 (6) years; FEV1 % predicted 38 (7), 39 (8); 6MWT 448 
(80), 467 (47) metres for the hospital and home group respectively). Although 
the 9 week home programme was unsupervised both the PR groups and 
home based group had ‘front loaded’ supervised information sessions and 
physical therapy sessions.  Puente-Maestu et al. (2000) compared the effects 
of supervised training to self-monitored training in 41 patients with moderate 
to severe COPD (mean (SD) age 63 (4), 66 (5) years; FEV1 % predicted 41 
(6), 40 (6); V02max 1.24 (0.24), 1.25 (0.29) L.min
-1 for the supervised and 
unsupervised group respectively). The self-monitored group were given a 
pedometer and asked to walk 3 to 4km within a 1 hour period on 4 days a 
week for 8 weeks (pedometer gave distance travelled). Patients were required 
to attend a weekly clinic to have their records checked and to encourage 
adherence to the programme. Both interventions had significant increase in 
HRQoL and exercise endurance, however, only the supervised group 
demonstrated improvements in peak exercise tolerance. Researchers were 
also not blinded to which treatment patients had received. These studies 
showed that home based programmes are safe, but as small numbers were 
involved they were highly likely to be under powered. 
 
In a study by Maltais et al. (2008) patients underwent a 4 week education 
programme before being randomised into either a home based or hospital 
based PR group. This study was powered for noninferiority and included 252 
patients with moderate to severe COPD (mean (SD) age 66 (9), 66 (9) years; 




hospital based and home based groups respectively) . PR at home consisted 
of endurance and strength training 3 times per week for 8 weeks including 
cycling at 60% of peak workload for a target of 40 minutes. Results showed 
that the self-monitored home based group improved as much as the hospital 
based group in terms of the dyspnoea subscale of the CRQ (P<0.001) and 
cycle endurance time (P<0.001). This study demonstrates that patients are 
able to self-monitor their home exercise programme. However, the study 
involved an exercise specialist initiating the programme at the patients’ home 
and patients were also loaned a portable cycle ergometer.  
 
A Brazilian study (Mendes de Oliveira et al. 2010) compared outpatient PR 
with self-monitored home rehabilitation  of 12 weeks in 117 patients with mild 
to severe COPD (mean (SD) age 66 (10), 71 (7), 71 (9) years; FEV1% 
predicted 48 (23) %, 52 (24) %, 41 (18) % for the home, hospital and control 
groups respectively). Both intervention groups initially received an educational 
programme at the start of the intervention. Both groups showed a significant 
improvement in 6MWT (mean (SD) increase in 6MWT distance outpatient 
93.6 (70.6) metres, p<0.05; home 73.2 (50.2) metres, p<0.05) and there was 
no difference between these groups at 12 weeks (p=0.44), however, the 
researchers were not blinded to which group the patients had been assigned.    
 
Although these studies investigated home based programmes none were truly 
unsupervised and four required attendance at the hospital for education 
sessions (Güell et al. 2008, Maltais et al. 2008, Mendes de Oliveira et al. 




barrier of travel and transport to adherence to rehabilitation programmes. A 
comparison between outpatient hospital based PR and an equivalent home 
based unsupervised programme is therefore warranted. Holland et al. (2013) 
recently published a study protocol which aims to complete an equivalence 
trial of the benefits and costs of a home based programme in comparison to 8 
weeks PR. 
 
There are also a number of clinical trials of home based rehabilitation in 
comparison to a control group that has received usual care. These, together 






Table 2.4 Summary of home based pulmonary rehabilitation studies 
Study Country Methods Outcome 
measures 
Patient characteristics Intervention Duration Outcome (change) 

















              I             C 
Age       78           76  
Male      11          15 
FEV1%   41          38 





no. of  home 
visits over 12 
weeks = 11. 
12 weeks              I        C          p     
6MWD  39     4.2   0.023 
SGRQ-T-5.8 -1.4   0.020 














6MWT, SGRQ               I              C 
Age       66           70  
FEV1% 33           38  
6MWT  302         315 
All LTOT 
Supervised 
education, 2x 1hr 
in hospital. 1hr 
exercise per day, 
5 days per wk. 
Twice monthly 
home visits for 2 
mths. 1x mth visit 
for 9 mths 
12 
months 
              I                   C 
6MWD 79 p0.0001   13 NS 
















             I               C 
Age      57            56  
FEV1% 36            29 




exercise. 4 x 1hr 
education whilst 
inpatient 
2 months Treatment effect at 2 mths 
6MWD: 58.15 (11.23), 
p=<0.001. CRQ-D: 5.5  3.0 
to9.0), p=0.003. CRQ-F: 5.3 
(1.9 to 9.8), p=0.004. CRQ-
E: 8.7 (2.5-15.0), p=0.008. 









6MWT, CRQ               I               C 
Age      63             66 
FEV1% 38            39 
6MWT  448          467       
Both groups had 
2 information 





9 weeks 9 wk diff; CRQ-D 0.21 (NS), 
6MWT 8.69 (NS). 6 mths 
diff; CRQ-D 0.13 (NS), 




Study Country Methods Outcome 
measures 














FU 12 mths 
CRQ, 6MWT              I               C 
Age      66             66 
Male%  54             57 
FEV1% 43             46 
6MWT  368          370 
Supervised 
Education, 2x 
week for 4 
weeks. Followed 
by unsupervised 
exercise for 8 
weeks. Phone 
calls 
12 weeks Between gp diff at 3mths, 
CRQ dyspnoea 0.05, p0.74. 
6MWT -3 p0.68. 
Between gp diff at 12 mths, 
CRQ dyspnoea 0.16 
















6MWT, BODE               I      Hosp   C  
Age       66     71     71 
Male      27    19     19 
FEV1%  69     79     70 
Supervised 
Education x 1. 
Unsupervised 
exercise 3x week 
for 3 months. 
Telephone calls 
3 months 6MWT change at 3 months 
73.21 (50.21) m p<0.05. 













CRQ, VO2 max 
               I             C 
Age       66           63 
FEV1%  40           41 
VO2max    1.25        1.24 
Home walking 
programme. 
Weekly visits to 
clinic 
8 weeks Similar increase in CRQ (C 
0.72; I 0.8). C significantly 
increased work rate. Some 
















              I     Hosp    C 
Age      60     61      63 
Men     14     13      12 





12 weeks Equal improvements in 
exercise capacity and Borg 
dyspnoea at 3 & 6 months. I 
gp significantly improved to 
18 months above Hosp. 




Home based programmes offer promised to the increasing demands on PR 
and increase the treatment options available to patients. In addition, they may 
also enhance long term adherence to positive health behaviour. There is 
substantial evidence that benefits for PR decline over the 12 months 
preceding the intervention (Arnardóttir et al. 2006, Bestall et al. 2003, Foglio 
et al. 1999, Griffiths et al. 2000, Maltais et al. 2008, Ries et al. 1995, Singh et 
al. 1998) which has been attributed to the decline in the participation of 
regular exercise  after supervision has cessed  (Griffiths et al. 2000). 
Programmes delivered in the home have the advantage of not having a 
transition period where patients have to adapt to a new environment to 
participate in PA. Home based programmes integrate PA in to the normal 
daily lives and therefore have potential to be maintained in the long term.  
 
Home programmes need to be comprehensively developed and supported in 
order for long term health behaviours to improve. To modify behaviour self-
efficacy and SM skills need to be enhanced. PR in the UK incorporates 
education sessions which aim to enhance these skills. Therefore equivalent 
training needs to be incorporated into home based programmes. SM could 
potentially be used to support home programmes to provide optimal care. A 
number of SM programmes have been developed in a number of countries 
and will now be discussed.  
 
2.2.5 Supporting rehabilitation with Self-Management (SM)  
SM has often been regarded as the way forward to reduce increasing 




not a goal or outcome in itself, but one element of integrated care. 
Interpretations of SM are diverse across the literature and the next sections of 
this chapter aim to define and contextualise SM and discuss various studies 
that have used SM to enhance rehabilitation programmes. 
 
Definition of Self-Management 
There is no ‘gold standard’ definition of SM. Barlow (2002) defines SM as 
‘individuals’ ability to manage the symptoms, treatment, physical and 
psychosocial consequences and life style changes inherent living with a 
chronic condition’ and health professionals play a key role in facilitating SM to 
patients. SM goes further than patient education, which is often information 
giving and development of technical skills. SM is problem focused, action 
orientated and emphasise patient generated care plans (Lorig and Holman 
2003). Comprehensive SM programmes, therefore, aim to improve self-
efficacy, problem solving and decision making skills and confidence in 
individuals with long term conditions to enable them to take control and 
management their own health. It can be argued that everyone with a long 
term condition self manages to an extent, but successful SM programmes 
support individuals to be more effective in their health behaviour decisions 
(Lorig and Holman 2003). 
 
Self-Management theory 
 The model of SM is based on the theory of self-efficacy first proposed by 
Bandura (1977). Self-efficacy is a key component of social cognitive theory. It 




perform a given task or specific behaviour or successfully changing a specific 
cognitive state (Bandura 1977). Self-efficacy is task specific hence, an 
individual can have high self-efficacy for one task or behaviour but low self-
efficacy for another. Perceived self-efficacy influences an individual’s decision 
making and plays an important role in SM activities, adopting and maintaining 
health behaviour changes, resulting in improved health outcomes (Marks, 
Allegrante and Lorig 2005a).  
 
Perceived self-efficacy can be enhanced by 4 main factors 1) past 
performance, 2) vicarious experiences, 3) verbal persuasion and, 4) 
physiological state (Bandura 1977). Using these constructs to build a 
behavioural intervention and education programme can effectively improve 
self-efficacy and SM behaviours of patients with chronic disease (Marks, 
Allegrante and Lorig 2005a, Marks, Allegrante and Lorig 2005b). 
 
Self-efficacy has been demonstrated to be a significant influence on exercise 
initiation and adherence in the elderly population (Rhodes et al. 1999). A 
review of studies which monitored self-efficacy in smoking cessation, weight 
control, contraception, alcohol misuse and exercise concluded that self-
efficacy was strongly related to health behaviour and enhancing self-efficacy 
impacts on improvements in health behaviour (Strecher et al. 1986). As self-
efficacy is a key component to behaviour change, SM must incorporate 
strategies to enhance it. In addition, as self-efficacy is task specific it is 
essential that any measurement tool is accurately measuring what it purport to 




Bourbeau, Nault and Dang-Tang (2004; Figure 2.2) proposed that knowledge 
and skills influence self-efficacy and therefore there enhancement needs to be 
incorporated into intervention to improve self-efficacy. 
 
 
Figure 2.2 Bourbeau, Nault and Dang-Tang (2004) model of behaviour 
change 
 
Self-Management in COPD 
Literature (PICO) search terms are presented in appendix A.  
 
With the healthcare system dealing with more long term conditions there is 
growing interest in fostering the means by which individuals with long term 
conditions can participate effectively in managing their condition (Lorig et al. 
2001). SM programmes are distinct from patient education or skills training, in 
that they are designed to encourage individuals with chronic disease to take 





The evidence base to support the use of COPD SM programmes is now 
emerging, but many of the methodological issues inherent in delivery of a 
complex intervention are evident. There is diversity in the interpretation of SM 
throughout the literature, with programmes offering a range of both exercise 
and education sessions from none at all to fully supervised lengthy 
programmes requiring a high level of healthcare professional’s time. A 
number of the SM programmes offer a more comprehensive programme than 
some tradition outpatient PR programmes in the UK. In order to contextualize 
SM and PR Wagg (2012) has developed a model of the spectrum of COPD 
support (figure 2.2). The model extends from the most basic action plan 
through supportive SM and PR. Using Wagg’s (2012) model a critical review 
to contextualize SM programmes will now be discussed. In the context of this 
thesis studies aimed at enhancing SM skills will be evaluated and not just 





Figure 2.2 Wagg’s (2012) Spectrum of support for COPD 
 
A Cochrane systematic review of SM in COPD (Zwerink et al. 2014) evaluated 
29 trials concluded that it is likely that SM is associated with reduced hospital 
admissions, improved health related quality of life and improved dyspnoea. 
Clear recommendations regarding the most effective form and content of SM 
in COPD could not be made due to the heterogeneity of SM interventions, 
outcome measures and follow up times among the studies. This review 
highlights the need for large randomised controlled trials with long term follow 





A summary of the SM studies discussed in this chapter are presented in table 
2.4. Studies are listed alphabetically and those highlighted in grey show those 




Table 2.4 Summary of SM studies 
















            SM    RC     UC 
Age      66      66      64 
Male%  67     76      51 
FEV1% 66     63       67 
Supervised 
education for 2-4 
sessions. Phone 
calls x6. Action 




CRQ D: -0.6 (-0.54 to 
0.21), CRQ F: -0.17 (-
0.62 to 0.27), CRQ E: -
0.31 (-0.66 to 0.039), 

























                I            C 
Age        69          70 
Male%   52           59 
FEV1      1.0          0.98 
6MWD   282         280 
    (m) 
Supervised 
education, 1hr per 
week for 7 to 8 




phone calls for 8 
wks, monthly calls 




Treatment difference at 
12mths for COPD 
admission -39.8, p0.01. 
Bed days -42.4, p0.01. 
SGRQ 4mths treatment 
diff in impact -6.2 and 
total score -4.2, at 



















                  I             C 
Age          70           68     
Male%     38           35 




for 2 months, 
every 6 weeks fo 
10 months (40 
mins per visit) 
12 
months 
No effect on readmission 
or death, treatment effect 
1.05, (95% CI 0.80 to 
1.38 p=0.725). SGRQ 
total: -4.52 (-9.07 to 
0.04), p=0.052. HADS-A: 
-1.06 (-2.08 to -0.03) 
p=0.044. No change 
HADS-D or CSES 





Table 2.4 continued..       
Study Country Methods Outcome  Patient characteristics Intervention Duration Outcome 

















                   I           C 
Age           63         64 
Male%       58         58 
FEV1%      50         51  
ISWT        388       341 




week for 6mths, 
2x week for 
5mths. Control 





12 mo treatment effect: 
ISWT:35.1m (8.4 to 61.8) 
sig 
ESWT:145.8sec (-26.2 to 
317.8) 
CRQ-D:0.32 (-0,03 to 
0.67) sig 












mean FU 250 
days 







                  I           C 
Age           66        66 
Male%       98        96 
FEV1%       38       38 
4 weekly 90 min 
education session. 
Phone call once 
per mth for 3 mos, 





Study terminated early 
due to higher mortality 
in SM group  
Deaths: 28 (SM), 10 
(C), hazard ratio 3.00 





















                 I           C 
Age         66         67 
Male%     44         44    










Treatment effect at 
6mth, hospital 
admission: I -15, C-34, 
p0.01. SGRQ(T): -5.2 
p0.04. 
Treatment effect at 12 
months 
Hospital admission: I – 
26, C-64, p0.01. 
SGRQ(T):-3.8 p0.17 
        




Table 2.4 continued..       
Study Country Methods Outcome  Patient characteristics Intervention Duration Outcome 














              I            C 
Age      67          65 
Male%  45         50 











Treatment effect SGRQ 
-10.3 (-17 to -3.1) 
p=0.018 compared to C. 
Costs US$ -1401 (-6566 
to 3764) p=0.21 


















               I           C 
Age        70         72 
Male%    52         67 
FEV1%    55         53 
Primary care 
Action plan 12 
months 
Treatment effect SGRQ 
1.7 (SD 1.6; p=0.58 
compared to change in 
C) HADSA 0.15 (SD 
0.7; p=0.87 compared 
to change in C). 
HADSD 0.29 (SD 0.29; 
p=0.57 compared to 












SGRQ, 6MWT                  I           C 
Age          65        65 
Male%     85         84 
FEV1 %    56         58 
6MWT     428       442 
     (m) 
Supervised 
Education, 5x 2hr 











Treatment effect at 12 
months. SGRQ (T) -0.6 
(-2.8 to 1.7) NS 
6MWT-13 (7) m (I) vs -2 













ISWT, CRQ                 I             C 
Age        70           71 
Male %  40           60 
FEV1 %  40           42 




and DVD 4x week 
for 6 weeks 
7 to 8 
weeks 
Within group diff : ISWT 
45m p0.021 (I) vs -15m 
p0.256 (C): CRQ 
dyspnoea 0.5 p0.027 (I) 




        
Table 2.4 continued..       
Study Country Methods Outcome  Patient characteristics Intervention Duration Outcome 















                I             C 
Age         65          61 
Male        90          78 
FEV1 %   56          54 
6MWD   450         397 
   (m) 
Supervised 
education and 
exercise, 2 x 
week for 4 weeks 
1 month Between group diff at 
12 months: 6MWT 
50.5m  p0.04. SGRQ -
14 p<0.01 














                I           C 
Age        69          71 
Male%    98        98 










(0.15 to 0.52 visits 
(p=<0.0001 in 
comparison to C). I ↓ 
hospitalization by 28% 










SGRQ                 I             C 
Age         68        67 
Male %   62         67 
FEV1%    37         36 
Primary care 
Action plan 6 
months 
SGRQ change -4 NS 
with C 
I = intervention, C = control, FEV1% = FEV1% predicted, D = dyspnoea, F = fatigue, E = emotion, M = mastery, CSES = COPD 
Self-Efficacy Scale, HADS-A = HADS anxiety, HADS-D = HADS depression, CCQ = clinical COPD questionnaire, NS = not 




In the 1990’s Jean Bourbeau and Diane Nault developed a SM programme for 
COPD in Canada called ‘Living Well with COPD’. The course consists of 
weekly 1 hour sessions of skill-orientated teaching delivered by a health 
professional for 7 to 8 weeks. The sessions aim to develop patients’ 
knowledge and skills required to adjust and maintain behaviour changes. 
Exercise training does not begin until approximately 7 weeks into the 
programme and is initiated by a supervised session at the patients’ home. 
Exercise training is based on walking, stair climbing and cycling, with 
stationary cycles being loaned to patients. Patients also receive a workbook 
which includes the 7 modules below: 
Keeping a healthy and fulfilling lifestyle 
Preventing your symptoms and taking your medication 
Managing your breathing and saving your energy 
Integrating a plan of action into your life 
Long-term home oxygen therapy 
Managing your stress and anxiety 
Integrating an exercise programme into your life 
 
A number of studies have been presented using this model of SM in COPD. 
Bourbeau et al. (2003) first reported a randomised multicentre trial in 191 
patients with COPD (mean (SD) age; 69 (7), 70 (7) years; FEV1 1.00 (0.33), 
0.98 (0.31) litres; baseline 6MWT 282 (91), 280 (90) metres for the SM and 
usual care group respectively) and compared usual care with the Living well 
with COPD SM programme (as described above). The study demonstrated 




(p=0.01) in the SM group compared with the usual care group over 12 
months. The SM group also had a reduction in; hospital admissions for other 
health problems (57.1% p=0.01), visits to the emergency room (41% p=0.02) 
and unscheduled physician visits (58.9% p=0.003). The authors found that in 
the SM group the activity and impact subscale and total scores of the SGRQ 
significantly improved at four months. At 12 months only the impact subscale 
and total score was improved compared to baseline and the only difference 
between treatments was on the impact subscale. Interestingly, exercise 
capacity as measured by the 6MWT did not change significantly within or 
between the SM and usual care group at four and 12 months. These findings 
would question the effectiveness of the exercise training component of their 
programme. Bourbeau et al. (2006) also presented the economic benefits of 
the study showing that cost savings could be made on the reduced hospital 
admission even when accounting for the cost of the SM programme.  Gadoury 
et al. (2005) did a follow up of these patients 2 years after the SM programme. 
This study found that all cause hospital admissions had reduced by 26.9% 
and all cause emergency room visits reduced by 21.1% in the SM group as 
compared to usual care group.  
 
A number of further trials have shown a positive effect on various patient 
outcomes (Effing et al. 2011, Khdour et al. 2009, Koff et al. 2009, Moore et al. 
2009, Rice et al. 2010). Effing et al.(2011) reported on a comprehensive SM 
programme involving 159 patients with COPD (SM and Control respectively, 
mean (SD); age 63 (8), 64 (8) years; FEV1% predicted 50 (14)%, 51 (17)%; 




SM sessions a six month ‘compulsory’ period of three exercise sessions per 
week delivered in the community by a physiotherapist and subsequently twice 
weekly exercise sessions for five months which was ‘optional’. At 12 months 
there was a statistically significant difference in the change in ISWT in 
comparison to the control group (mean (95% CI) 35.1 (8.4 to 61.8) metres) 
and CRQ dyspnoea (0.32 (-0.03 to 0.67) p=0.04), although neither of these 
improvements met the MCID for their relative measures. A significant 
treatment effect was also reported in the number of steps at 12 months (mean 
(95%) CI 1,190 (255 to 2125)) as measured by a pedometer. Only a small 
improvement in the ISWT was detected in the intervention group in this study, 
at seven months the ISWT distance had increased by a mean of 12 meters 
and by 12 months it was 11 meters, therefore the difference seen between the 
intervention group and control group (35 m; 95% CI 8 to 62 m)  was largely 
due to the decline in the control group. In principle this is of value, but in 
regards to the comprehensive intervention this would be considered a rather 
limited improvement in exercise capacity. 
 
Although a number of studies have shown positive effects of SM programmes 
these intervention have not included an exercise component as part of the 
intervention (Khdour et al. 2009, Koff et al. 2009, Rice et al. 2010). 
Considering the importance place on exercise and physical activity in the 
management and long term outcome of patients with COPD (NICE, 2010) this 





A novel approach to SM and exercise training was adopted by Moore et al. 
(2009). This study delivered exercise training and SM via a DVD and 
therefore was unsupervised. This study was based in the UK and although 
small (n=29; mean (95% CI or SD) control and intervention respectively; age 
71 (58 to 79), 70 (13) years; FEV1 % predicted 42 (30 to 55), 40 (37 to 49) %; 
ISWT 190 (45 to 85), 110 (30 to 270) metres) at six weeks detected a 
significant improvement in ISWT in the SM group compared to the control. 
This improvement in the SM was also seen in the CRQ domains of dyspnoea, 
fatigue and emotion. 
 
In contrast to these studies demonstrating a positive impact of SM training a 
number of studies have reported mixed or negative results. Monninkhof et al 
(2003a) evaluated a comprehensive SM and fitness programme in 
comparison to standard care and involved 248 participants (mean (SD) Age 
65 (7) years; FEV1 % predicted 57 (15)%; 6MWT 428 (91) meters in the SM 
group). The intervention consisted of five two hour education sessions 
completed over four months and a supervised exercise programme that was 
assessed over the year. Patients were also provided with a booklet with 
background information on their condition. Exercise sessions were supervised 
by a physiotherapist near the patients’ home and exercise was recorded in an 
exercise log book. Despite regular contact with health professionals and 
supervised exercise sessions this study failed to influence either HRQoL or 
exercise capacity. It is possible that an impact did not occur with these 
patients as they had mild disease severity (FEV1% predicted 56%) and a 




also be likely that exercise capacity did not change due to the intensity of the 
exercise programme not being high enough to elicit a training response. 
Patients determined their training goals with their physiotherapist and it was 
not standardised or clinically prescribed. Furthermore, they also concluded 
that the SM was twice as expensive and was not economical due to no 
measurable benefits (Monninkhof et al. 2004). 
 
Bucknall et al. (2012) completed a SM study in Scotland with 464 patients 
with COPD (mean (SD) Age 69 (9) years; FEV1 % predicted 41 (14)). This 
study used the ‘Living well with COPD’ model of intervention as reported by 
Bourbeau et al (2003). This study involved no formal exercise again a 
significant limitation to the study design. Bucknall found no difference in 
COPD hospital admissions or deaths. However, this study did identify 42% of 
its intervention group as successful self-managers that were characterised by 
being younger (p=0.012), and more likely to be living with others (p=0.010). 
This subgroup had a significant reduction in hospital admission (p=0.003). A 
number of other studies using SM theory to enhance health behaviour but no 
exercise also found no significant effect (Bischoff et al. 2012, Fan et al. 2012, 
McGeoch et al. 2006, Watson et al. 1997). Although exercise performance 
was not an outcome measure in these studies, physical activity is an 
important component in the treatment and management of COPD and has 
been shown to be a predictor of all-cause mortality (Waschki et al. 2011).  
 
With the contradictive outcomes of these SM trials it becomes apparent that 




important observation is that patients in the positive trials tend to have 
advanced COPD and lower baseline outcome scores and therefore had more 
potential for improvement. Perhaps the only exception to this is Effing and 
colleagues study who had patients with moderate COPD (mean (SD) age 63 
(8), 64 (8) years; FEV1% predicted 50 (14), 51 (17); ISWT 388 (165, 341 (152) 
meters for the SM and control groups respectively), however, although a 
significant improvement was detected in the SM group increases were small 
and did not meet the MCID for each measure. Furthermore, patients in these 
positive studies had a high level of health professional contact (e.g. phone 
calls) and perhaps acted proactively under the guidance of a healthcare 
professional and not as a result of their own behaviour. It is clear that 
supervision can enhance outcomes (Puente-Maestu et al. 2000) and perhaps 
these programmes have not clearly developed patients SM skills. The 
complex nature of SM and the diversity of SM trials reported makes it difficult 
to determine the most effective strategy to improve patient SM. Interestingly 
Bischoff et al (2012) and Bucknall (2012) reported that even though no overall 
effect was detected in their SM groups there was a sub-group of apparently 
successful self-managers, representing about 40% of patients with COPD. 
This sub-group was characterised by being relatively younger, living with 
others and having severe airflow obstruction. Bucknall et al. (2012) also 
showed that dedicated health professional, spouse or family member makes 






Despite recruiting similar patients to Bourbeau et al. (2003) and Rice et al. 
(2010), who reported positive findings the Fan et al. (2012) study was stopped 
early due to increased mortality in the SM group. The reason for this 
excessive mortality is poorly understood, although one school of thought is 
that the SM was ‘too’ effective as medication was stable and did not change 
during the intervention. One important difference in the Fan and colleagues 
study might have been the number of telephone calls received. Bourbeau and 
Rice called patients every month for one year, whereas Fan made calls on a 
monthly basis for the first three months then only every three months 
thereafter. Therefore, patients may have delayed reporting their symptoms as 
they were waiting for a telephone call to report them. SM should not replace 
integrated care but should be an adjunct which enhances health behaviours 
and teaches patients when it is appropriate to seek healthcare advice. SM 
support should be integrated into the mode of delivery of rehabilitation and not 
an isolated component.   
 
In order to enhance home based rehabilitation it may be important to support 
this mode of delivery by improving patients SM skills. A model that is feasible 
in the UK system and incorporates PA training, which has been shown to 
reduce hospital admissions (Garcia-Aymerich et al. 2006) and all-cause 
mortality (Waschki et al. 2011), improve dyspnoea (Watz et al. 2009) in 








COPD is a disabling, irreversible airways condition characterised by 
dyspnoea, chronic cough, sputum production, muscle weakness and reduced 
daily physical activity. It poses a significant burden to the individual and the 
healthcare system in the UK. There are a number of treatment options 
available including smoking cessation, pharmacotherapy and PR. PR has a 
strong evidence base for improving and managing commonly experienced 
symptoms. Despite this accumulation of convincing evidence there is an 
inadequate provision of pulmonary rehabilitation in the UK. There is not the 
capacity in the UK for all patients with COPD to be offered such a model of 
care.  It could also be argued that not all patient’s need to follow the ‘hospital 
based’ model especially those with mild disease, and due to local geography 
it may not be practically possible for all patients to access hospital or 
community based services.  There are also limited options for patients with 
COPD and there is a need to increase choice for these patients. In cardiac 
disease there is a ‘menu’ of treatments available and together with outpatient 
hospital rehabilitation, home based rehabilitation, and the ‘Heart manual’ is 
available (Lewin et al. 1992) which is fully integrated into patient care. Home 
based PR programmes have shown some initial promise, but the present 
studies are not fully based in the patients’ home and require attendance for 
part of the programme at hospital. 
 
Alongside this increased demand for rehabilitation there is a philosophical 
shift within the healthcare system encouraging patient to become more 




the healthcare provider to the individual. This is particularly important for long 
term disease management requiring individuals to engage actively in health 
related decisions and moving away from the paternalistic model of healthcare. 
Although every patient with a long term condition self-manage their health, 
supportive SM could provide patients with the knowledge and skills require to 
make decisions that optimise their health and quality of life.  Comprehensive 
SM programmes should promote the knowledge and skills for patients to 
make informed decisions in regards to smoking cessation, physical activity, 
breathing control, chest clearance and managing exacerbations. 
 
There are a number of studies published on SM in patients with COPD with 
varying interpretations and interventions. Studies that are labelled as SM vary 
from simple action plans to programmes involving supervised education and 
exercise sessions over a substantial period of time. A number of the SM 
programme which involve high levels of supervision offer a more 
comprehensive programme that what is offered under outpatient  PR in the 
UK and other countries. Moreover, it appears that the more comprehensive 
and longer interventions do not necessarily result in greater gains. Studies 
with a positive impact tend to have recruited patients that are more severe 
and have poorer baseline outcome measures and hence have more to gain. 
Therefore, it is still not clear in the literature as to the optimum content and 
delivery of such programmes. As the definition and interpretation of what SM 
is and what it involves is different from country to country and the fact that 
healthcare systems vary greatly around the world, it is important to investigate 




As the studies on home based rehabilitation and SM are either not 
appropriate for the UK healthcare system, have shown a lack of improvement 
or had poor methodical quality there is a need for evidence of a 
comprehensive home based SM programme which is suitable in the UK. 
Therefore, the aim of this thesis is to evaluate the effect of a novel home 
based SM programme called a Self-management Programme of Activity 
Coping and Education (SPACE for COPD). The programme was developed to 
be delivered without supervision after an initial introductory session and aims 
to promote exercise, knowledge and the skills required to successfully 
manage COPD symptoms. The programme is described in more detail in 
chapter 3. The outcome measures chosen enable the assessment of skill 
development and behaviour change that may be reflected in clinical 
outcomes. It was hypothesised that SPACE for COPD would be noninferior to 
traditional PR. Noninferiority trials seek to determine whether a new 
treatment, in this case SPACE for COPD, is not worse than the reference 
treatment, PR, by more than an acceptable amount. This acceptable amount 
referred to as the noninferiority margin is set as the minimal clinical important 
difference (MCID) where available. The study was designed to determine 




Chapter 3 – Methods of the Randomised Control Trial 
3.1 Introduction 
This chapter will describe the methods utilised in the main study design 
(chapters 5, 6, 7 and 8). These chapters explore the main components of the 
randomised controlled noninferiority trial described in this thesis, including 
collection of the baseline data, outcome measures of the 7 week trial (chapter 
6) and outcome measures six months after the intervention (chapter 7). The 
scope of this chapter is to address the study design, details of patient 
recruitment, and a description of all outcome measures used. It also describes 
the pulmonary rehabilitation (PR) programme and the self-management (SM) 
manual (SPACE for COPD) used in the controlled trial. An outline of statistical 
methods will also be explained. The CONSORT checklist for noniferiority trials 
is presented in Appendix B 
 
3.2 Study design 
This was a single blinded randomised noninferiority trial. Patients were 
randomised into either a hospital base PR programme (usual care) or a home 
based group which was supported by a SM manual (SPACE for COPD). Due 
to ethical reasons no true control group, with no treatment, was considered 
appropriate. Patients randomised to the PR group completed the usual 
prescribed treatment of a twice weekly hospital based supervised exercise 
and education programme over seven weeks. Patients randomised to the 




manual and were given their exercise prescription. Patients in this group 
received two calls from the researcher over seven weeks to assess their 
progress, give motivation to continue and to answer any questions.  Outcome 
measures were taken in all patients at three time points; at baseline on 
referral to PR, seven weeks post intervention and six months after completion 
of the intervention. The researcher conducting the outcome measures were 
blinded to which treatment group the patient was assigned to. All patients 
completed the outcome measures relating to health status and exercise 































Figure 3.1 Study design 
Baseline assessment 
n=287 
Consent obtained & activity 
monitor given to sub group 
Randomisation 
PR – usual care 
n=142 
SPACE n=145 
Phone call at 2 and 4 
weeks 
Manual introduction 
6 month assessment 
PR n = 70; SPACE n=75 
 
 
7 week assessment   
 PR n = 84; SPACE n= 94 
14 2 hour supervised 




3.3 Study recruitment 
Ethical approval for the study was obtained from the Leicestershire, 
Northamptonshire and Rutland Research Ethics Committee in 2007 
(Appendix B). Recruitment took place from November 2007 to July 2012. 
Patients presenting for pulmonary rehabilitation were asked by a member of 
their health care team to consider taking part in the study. A patient 
information sheet (Appendix C) was given to each patient along with a verbal 
explanation of the study. An appointment was then made with each patient to 
see the researcher the following week (A minimum of 48 hours were allowed). 
Informed written consent (Appendix D) was then obtained from each subject 
willing to take part. It was made clear to the patients at this point that refusal 
to take part in the study would not affect their future treatment. 
 
Inclusion criteria 
The principle inclusion criteria were patients presenting for a course of 
rehabilitation with a diagnosis of COPD and had an MRC (Medical research 
council) of grade of 2-5 on the dyspnoea scale. 
 
Exclusion criteria 
Patients excluded from the study were those patients that would routinely be 
excluded from rehabilitation if they had significant neurological or locomotive 
disorders or an unstable psychiatric history. Those patients who had poor 
English language skills were also excluded due to the manual only being 






Baseline assessment (Usual treatment) 
Prior to recruitment to the study patients attended an initial assessment 
conducted by a healthcare professional. Patients were referred to the 
pulmonary rehabilitation team via a number of routes including their GP, 
consultant, REDS (Respiratory Early Discharge Service) and SPRINT 
(Specialist Respiratory Intervention Team) and came from across 
Leicestershire and neighbouring counties. The initial assessment lasted 
approximately 1.5 hours during which demographic (height, weight, date of 
birth) and clinical data was recorded, along with past medical and smoking 
history. Forced expiratory volume in 1 second (FEV1) and forced vital capacity 
(FVC) were measured using a portable spirometer. Resting levels were also 
taken for heart rate, oxygen saturation and a rating of dyspnoea using the 
Borg breathlessness scale. Patients then completed the ISWT (Incremental 
Shuttle Walk Test) twice to allow for habituation to the test, the ESWT 
(Endurance Shuttle Walk Test) and each of the three questionnaires (CRQ-
SR, HADs and PRAISE). During this assessment the patients were asked to 
consider taking part in the study. 
 
Consent Appointment 
Patients that had shown an interest in taking part in the study were given the 
patient information sheet and an appointment with the researcher (Elizabeth 
Horton: EH) for the following week. During the consent appointment the study 




part, the aim of the study, what would be required of them if they took part, 
and highlighting that the study was voluntary. Patients were given the 
opportunity to ask questions and written informed consent taken. If available, 
a Senswear® activity monitor was given to each patient and they were asked 
to wear it for five full days (including 2 weekend days) and collection of the 
monitor was arranged at either their manual introduction for the SPACE group 
or their first PR session. The patient’s details were then passed on to another 
researcher (Vicki Warrington; VW) for randomisation to enable EH to be 
blinded as to which group each patient was recruited to. 
 
Randomisation and Blinding 
Patients were randomised into a group by using sealed envelopes. VW an 
unblended member of the clinical and research team completed the 
randomisation.  If they were randomised into the hospital based pulmonary 
rehabilitation group they would be given an appointment to start PR the 
following week. If they were randomised into the SPACE for COPD group they 
were given an appointment for the following week for an introduction to the 
SPACE for COPD manual, how to use it, and prescription of their initial 
walking time and speed. This appointment was either in the patient’s home or 
at Glenfield Hospital (the introduction to the SPACE for COPD manual is 
described in section 3.5, further on in the chapter).  This appointment was 
completed by either Lindsay Apps (LA) or Katy Mitchell (KM) who were 
trained in motivational interviewing. Re assessment at seven weeks and six 
months were performed by a blinded member of the research team (EH and 




they were in. Participants were advised not to inform the assessor which 




3.5.1 Pulmonary Rehabilitation (PR) Programme 
Patients recruited and randomised into the usual care hospital based group 
received a course of outpatient PR in the physiotherapy gym at Glenfield 
Hospital, University Hospitals of Leicester NHS Trust. 
 
The PR programme lasts for 7 weeks and patients attend twice weekly. Each 
session is divided into an hour of supervised exercise and an hour of 
education. The exercise sessions comprise of aerobic and resistance exercise 
training. Patients are encouraged to walk daily at home on the days they do 
not attended their PR programme. Their aim is to increase the duration of 
their walk by 10 to 15 seconds each day. They were also advised to complete 
their strength training programme once per week at home. Home diaries are 
reviewed at the beginning of each PR and progression encouraged, however 




Each patient had an individually prescribed training programme including 
walking (figure 3.2) and cycling exercise. Training intensity was prescribed at 




provided with a daily walking diary to record walking times and Borg 
breathlessness scores. Instructions were given about walking at the correct 
speed (intensity) and guidance given about increasing walking time. Walking 
speeds and times are checked weekly and time targets set for the following 
week. Each patient also completed 5 minutes on a cycle ergometer ensuring 




Fig 3.2 Patients completing their walking programme 
 
Resistance training 
Resistance training was completed once per week within the supervised 
session and patients were also encouraged to complete their programme 
once at home (a conversion table was given to them as to how much liquid is 
needed in a milk bottle for their prescribed weight; i.e. 2 pints = 1.2kg) . The 
programme consists of upper and lower body resistance training of the major 
muscle groups (figure 3.3). Resistance exercises included biceps curls, sit-to-




prescribed and were encouraged to complete three sets of eight repetitions. 





Figure 3.3 Patient completing his strength training programme 
 
Education sessions 
During each rehabilitation session patients received 1 hour of education. 
These sessions were delivered by members of the respiratory medical team 
and support services, including physiotherapists, occupational therapists, 
pharmacists, respiratory physicians, respiratory physiologists and health 




Benefits of exercise 





Chest clearance advice 
Introduction to the respiratory physiology department 
Introduction to Breathe Easy 
Managing breathlessness 
Avoidance and Exacerbations 
Living with COPD 
 
3.5.2 SPACE for COPD - Self-Management Manual 
The Self-management Programme of Activity Coping and Education (SPACE 
for COPD) manual (figure 3.4) was developed by the multidisciplinary 
pulmonary rehabilitation team at Glenfield Hospital, Leicester.  The aim of the 
manual is to help patients with COPD manage living with their chronic 
condition, and develop their self-management skills to control their symptoms, 
increase their physical activity levels and reduce the effect of their condition 
on their everyday life. The SPACE for CPOD manual is based on the PR 
programme delivered at Glenfield Hospital and is crystal marked by the Plain 





Figure 3.4 Front cover of the SPACE manual 
 
The SPACE for COPD manual is divided into four stages including an 
exercise programme which progresses throughout the stages and a number 
of education topics. The manual also has a FAQ’s (Frequently asked 
Questions), Appendix section and an action plan. The manual is designed for 
patients not only to be used as a reference but provides interactive sections 
for patients to complete to encourage engagement and adherence to the 
programme. The education part of each section can be dipped into as 
required and doesn’t need to be read in order. Each section begins with the 
patients’ exercise programme and includes advice about how to progress and 
keep motivated to exercise. ‘Top tips’ are also highlighted which offer useful 
advice and summaries on each topic. Each section also follows a number of 
case studies through their experiences of PR giving insight and reassurance 




encouraged to progress at their own pace, but is designed for the average 
patient to reach stage 4 (Maintenance) in approximately 7 weeks. 
 
Introduction to SPACE for COPD 
The manual was explained to the patients highlighting to them the key areas it 
covered and also how to use it. The manual was introduced to the patient by a 
healthcare professional trained in motivational interviewing (MI) techniques to 
engage the patient in the process and to encourage adherence. MI aimed to 
facilitate behaviour change by identifying the individuals’ willingness to 
participate in the SPACE for COPD programme, how important it was to them, 
how confident they were in taking part and any possible barriers. The duration 
of the MI was approximately one hour, but varied from patient to patient 
depending on their level of ambivalence (The healthcare professional spent 
longer with those with greater ambivalence).  The exercise programme was 
then explained to the patient which was based on a daily walking programme 
in which the intensity / speed was prescribed from 85% of their maximal 
walking speed from the ISWT. Their walking time was initially set from the 
time they completed during the ESWT. It was suggested that they purchased 
a stopwatch and encouraged to build up their daily walking time by 
approximately 10-20 seconds a day. Patients who were only walking for short 
periods were encouraged to do a number of bouts of exercise per day. 
Exercise time and perceived exertion scores were recorded in their manual 
diaries.  Strength exercises (Bicep curls, sit-to-stand, pull ups and step-ups) 
were also shown to the patient and an initial starting weight prescribed to 




times with 8 repetitions. Patients were encouraged to complete their strength 
exercises once they were familiar with their daily walking programme. 
 
Telephone support 
Patients were called twice during the 7 week programme, at week 2 and week 
4 (schedule in Appendix E). Telephone calls were completed by LA or KM. 
Each time it was established if they were having any problems with the 
manual or their exercise programme. Their walking time was discussed and 
were encouraged to continue increasing their walking time. It was established 
if they had started their strength exercises and encouragement was also given 
to progress with this part of the programme. Any GP, hospital visits or medical 
problems were also recorded. During the second telephone call an 
appointment for the next assessment was made. 
 
Content of the SPACE for COPD manual  
Stage 1  
Stage 1 of the SPACE manual gives patients some background information 
on their lung condition, covering how the lungs work, what causes the COPD, 
and how the condition is diagnosed and treated. It also introduces exercise 
training in terms of what is exercise and why everybody needs to participate in 
regular exercise and physical activity. It explains the components of an 
exercise session describing a warm-up, cool down and a number of stretching 
exercises.  Patients were encouraged to read this stage before starting their 
exercise programme. The manual includes a walking diary (figure 3.5) and a  




programme and to highlight some walking targets with the aim to motivate. It 
explains how to progress with the exercise programme to achieve the aim of 
completing a total of 30 minutes of walking. In order for patients to judge 
whether they are working at their prescribed intensity a scale of 1 to 10 is 
provided with 1 being very easy and 10 being almost impossible. Patients are 
encouraged to walk at a pace that is moderate and that would score around 4-
6. It also addresses barriers to exercise encouraging the patient to reflect and 
identify their own barriers and adherence issues to exercise and then to 
complete a goal setting exercise. Stage 1 concludes with some information on 
managing stress, Breathing control and medication. Sections of stage 1 are 
listed below: 
What’s happened to your lungs? 
How to get fitter 
Setting your goals 
Managing your stress 
Your emotions 







Figure 3.5 Walking Diary from Stage 1 of the SPACE manual 
 
Stage 2 
The second stage aims to progress the patients exercise by increasing their 
total walk time with a target of walking 30 minutes in 1 session (figure 3.6). It 
provides a number of ‘Top Tips’ for people struggling to keep motivated to 
exercise regularly. In addition this stage covers how to avoid feeling unwell 
and what to do if an exacerbation occurs, how to identify a severe attack and 
what happens if they do have to go to hospital. Energy conservation is also 
addressed in this stage encouraging patients to become more aware of their 




identify activities that they find difficult and some examples are given about 
how to make activities easier to manage (figure 3.6). This stage also gives 
advice on the right foods to eat when unwell and advice on clearing their 
chest. 
 
Figure 3.6 Example pages from stage 2 of the SPACE manual 
 
The sections covered in stage 2 of the SPACE manual are listed below: 
How to stay fit  
Saving your energy 




The right foods when you feel unwell 




Strength training is introduced in stage 3 (figure 3.7). Starting weights are 
prescribed to patients in their introductory session to the manual. Four 
exercises are advised; bicep curls, sit to stands, pull ups and step ups. A 
handy guide is provided to convert their prescribed weight to volume of water 
in milk containers so that they were not obliged to buy dumbbells. Top tips 
and advice are given about managing stress and some relaxation techniques 
are given. Goal setting is then addressed, reviewing if the patient had found 
anything that had made achieving their goal difficult or easy and a number of 
ideas are presented about how to overcome such obstacles. This stage also 
includes what comprises a healthy diet and some advice about travelling and 






Fig 3.7 How to get stronger from stage 3 of the SPACE manual 
 
Stage 3 covers the topics listed below: 
How to get stronger 
Managing your stress 
Healthy eating 







Once the patients are completing 30 minutes of walking a day, they moved 
onto stage 4 which focuses on how to maintain improvements in their walking 
programme. The manual encourages patients to highlight any barriers they 
have found in completing the walking programme (figure 3.8) and they are 
prompted to address how these barriers could be overcome. Returning to 
other sports and hobbies that patients had previously enjoyed are dealt with 
encouraging patients to draw up an action plan of how to being these 
activities again. Also included in this section is coping with changing 
relationships with family members and friends, how to deal with setbacks and 
sexual relationships. This section includes a number of quotes and case 
studies from patients who have previously gone through PR with advice given 
and some suggested links to other parts of the manual (figure 3.8). Stage 4 
concludes with information about Breath Easy which a support group for 






Figure 3.8 Barriers to exercise from stage 4 of the SPACE manual 
 
Stage 4 focuses of the topics below: 
Your hobbies and staying fit 
Your relationships 
Dealing with setbacks 
Sex and your lungs  
Breathe easy 
Conclusion 




This section includes frequently asked questions, addition information; such 
as how to set your walking speed (in miles per hour as well as kilometres per 
hour), types of activities that could be completed for the different speeds of 
walking, spare walking and strength training diaries, and information that may 
be useful to only a proportion of the patients, for example oxygen therapy, 
smoking cessation and medication (figure 3.9). 
 
 






The FAQs and Appendix is divided into the following section: 
Frequently asked questions 
Setting your walking speed  
Advice about oxygen 
Help for carers 
Smoking: advice on giving up 
Information about your medication 
Spare walking diaries 
Spare strength training diaries 
 
At the back of the SPACE manual is a one page action plan (Appendix F) for 
patients to use as a quick reference. It includes spaces for patients to put 
information about their condition, their GP contact details and a list of their 
medication. It gives advice about how to determine if they are having a 
moderate or severe exacerbation, a sputum colour chart is included to aid this 
decision and what to do in each of those situations.  
 
3.6 Outcome measures 
Outcome measures were assessed before the commencement and 
immediately after completion of either the seven week PR programme or 
home based SPACE for COPD programme. Each patient was then assessed 
six months after completion. The outcome measures can be divided into three 







Chronic Respiratory Questionnaire – Self Report (CRQ-SR; Williams et al. 
2001; Williams et al. 2003; Appendix G). 
This is a reliable and valid measure of health status in patients with COPD. 
The CRQ-SR consists of 20 questions and is completed by the patient. The 
questions are categorised into four domains: dyspnoea, fatigue, emotional 
functioning and mastery. Responses reflect the patient’s experiences in the 
previous two weeks. Higher scores reflect a ‘better’ status. The dyspnoea 
scale is individualised where they are required to identify five activities that 
have made them breathless in the past two weeks and then rate that level of 
breathlessness on a seven point scale. Higher scores indicate more 
favourable HRQoL (Health Related Quality of Life), and a change in the 
domain score of ≥ 0.5 has been identified as being clinically significant 
(Jaeschke, Singer and Guyatt 1989). The dyspnoea domain of the CRQ was 
used as the primary outcome measure. 
 
Hospital Anxiety and Depression Scale (HADs; Zigmond and Snaith 1983; 
Appendix H) 
This is a questionnaire that measures psychological status. It consists of 
fourteen questions; seven contribute to anxiety scores and seven to 
depression. Each question is scored from 0 to 3. Scores from each of the 
questions in each domain are added together to give a score for anxiety and 
depression, high scores indicate poor psychological state. The authors report 





Pulmonary Rehabilitation Adapted Index of Self-Efficacy (PRAISE: Vincent et 
al. 2006; Appendix I) 
This questionnaire measures self-efficacy in patients with COPD undergoing 
PR. It consists of 15 statements, to which the respondent has to respond to 
how much they agree with on a scale from 1 to 4 (1 = not at all true, 2 = hardly 
true, 3 = moderately true, 4 = exactly true). Each score is added together to 
give a total score of self-efficacy. Higher score indicate higher self-efficacy. 
 
Exercise performance 
Incremental Shuttle Walk Test (ISWT: Singh et al. 1992)  
This is a maximal field based walking test of exercise performance validated 
in COPD. All procedures for the test were completed according to the 
standardised instructions. Patients were required to walk around a 10 meter 
course at a speed paced by an audio signal. Every minute during the test the 
speed increased. The aim of the test was for the patient to continue until they 
were too breathless or fatigued to continue or could no longer maintain the 
required speed. Each patient completed 2 ISWT, the first a practice walk and 
the second, from which the results were recorded. Sufficient rest was allowed 
between each test to allow heart rate to return to resting levels. Results from 
the test are measured in metres (i.e. number of shuttles completed). Resting 
and post exercise heart rate and oxygen saturation were recorded using a 
portable pulse oximeter with finger probe (PULSOX-3: Konica Minolta, Osaka, 
Japan). Borg ratings of perceived exertion and breathlessness scores were 





Endurance Shuttle Walk Test (ESWT: Revill et al. 1999) 
This is a sub-maximal field based walking test of exercise performance also 
validated in COPD. It was completed after the ISWT according to the 
standardised instructions. Again sufficient rest was allowed between the ISWT 
and the ESWT to allow heart rate to return to resting levels. The test follows a 
similar procedure to the ISWT where patients walk around a 10 meter course 
at a speed dictated by an audio signal. For this test the walking pace was 
constant. Following a warm up period of 1 minute 30 seconds, patients 
walked at a constant speed which had been calculated at 85% of their 
predicted VO2peak estimated from the ISWT. This was determined using a 
regression equation. The aim of the test was to continue walking until the 
patient was too breathless or fatigued, could not keep up with the set walking 
pace or had reached the end of the 20 minute test. Resting and post exercise 
heart rate and oxygen saturation were recorded. Resting and post-test Borg 
breathlessness and perceived exertion scores were also obtained.  The 
ESWT is measured in seconds (excluding the warm up). A score of zero was 
recorded if a patient was unable to complete the warm up. 
 
Daily physical activity 
During the consent appointment patients were asked if they would be willing 
to wear the SenseWear® armband (SWM; BodyMedia, Pittsburg, US, figure 
3.10) for 5 days (reproducibility and sensitivity of which is presented in 
chapter 4).  Patients were given instruction on how to use the monitor 
(chapter 4) and wore it for 5 day including 2 weekend days from waking to 




SWM during personal hygiene activities or if they went swimming. 
Arrangements for the collection of the SWM were then made. 
 
 
Figure 3.10 The SenseWear Armband 
 
Data from the SWM was downloaded using the InnerView™ software (figure 
3.11) as described in chapter 4. Patient characteristics were loaded into the 
data file so that energy expenditure could be estimated. For each day 
recorded, total and 12 hour data was extracted from the SWM. The MET 
value was also customised to the prescribed level for each patient in order to 
identify how long and how many calories the patient had expended within their 
prescribed activity level. The follow data was recorded from each patient; 
• Total time SWM worn 
• Total daily step counts 
• Total time <2 METs (sedentary) 
• Total time 2-3 METs (light physical activity: LPA) 
• Total time 3-6 METs (moderate to vigorous physical activity: MVPA) 




• Total energy expenditure above 3 METs 
 
The 10 minute bout data was calculated by exporting the minute by minute 
data from the professional software into excel. A formula was used to add up 
the time spent in moderate activity of at least 10 minutes duration. 
 
 
Figure 3.11 Example of the Sensewear professional output. 
 
The analysis of the physical activity component of this study is fully described 










Advice on the sample size was taken from Statistics Advisory Service at 
Coventry University at the point of the protocol being written. The primary 
outcome measure was dyspnoea from the CRQ-SR questionnaire at seven 
weeks. A difference of 0.5 has been recognised as the minimum clinically 
important difference to detect change (Jaeschke, Singer and Guyatt 1989), 
with a common SD of 1.1 (Sewell et al. 2006). By using these values in the 
sample size calculation to assess noninferiority, with an alpha level of 0.025, 
and a 1 sided test with 80% power, the required sample size was 77 per 
group. Based on an attrition rate of 15% typically seen in the Glenfield 
hospital PR group, 89 patients per group were targeted for recruitment. This 





Data was analysed using IBM SPSS statistics 20. An intention to treat and per 
protocol analysis was completed at seven weeks.  SPSS was used to impute 
missing data. This was a pragmatic trial and therefore a pre-specified 
definition of compliance to the intervention protocol was not stated. This 
results in only an intention to treat analysis being completed. All tests of 




at p<0.05. All data was assessed for normality so that appropriate parametric 
or non-parametric tests could be conducted. Normally distributed data are 
described as mean and standard deviation and non-normally distributed data 
and categorical data are described as median, frequency or percentage. 
 
For the primary outcome measure, CRQ-SR dyspnoea score, within group 
differences from baseline and 95% confident intervals (CI) are presented. The 
secondary outcome measures were analysed in the same way. Previously 
reported minimally clinical important difference (MCID)  was 0.5 units for each 
of the 4 CRQ-SR domains (Jaeschke, Singer and Guyatt 1989), 1.5 units for 
the HADs (Zigmond and Snaith 1983), 48m for the ISWT (Singh et al. 2008) 
and 186 seconds for the ESWT (Pepin et al. 2011). The MCID was used as 
the noninferiority margin for each outcome measure. In order to declare 
noninferiority the mean change (difference in SPACE minus difference in PR) 
and the 95% CI must not breach this margin. 
 
Within group differences at seven weeks were analysed with a paired t test 
and between group differences at seven weeks were analysed using 
independent t tests. Correlations between variables were explored using a 
Pearson’s correlation. 
 
At six months between group differences and within group differences were 









Daily physical activity (PA) levels in patients with COPD is low (Pitta et al. 
2005a, Watz et al. 2009) and has been associated with hospitalization and 
mortality (Garcia-Aymerich et al. 2006, Waschki et al. 2011). The aim of PR is 
to improve exercise capacity and increase daily PA (Bolton et al. 2013) and 
hence enhance health status. PA is a central focus for PR and therefore the 
ability to monitor it is necessary in determining the effectiveness of clinical 
practice. In regards to this thesis it is also essential that an accurate measure 
of PA is available to determine if the SPACE for COPD programme is 
effective at increasing PA and is sensitive to detect subtle changes in PA 
levels.  
 
Although the pedometer has been shown to be reliable in providing a step 
count for patients with COPD, it may not be as accurate as it is in healthy 
individuals (Schönhofer et al. 1997, Tudor-Locke et al. 2002). Moreover, 
pedometers may not be sufficiently sensitive to detect step performance at 
slow walking speeds (Turner et al. 2012) . 
 
Accelerometers are more sophisticated and sensitive devices which measure 




accelerometers are able to measure and quantify levels and durations of PA 
in terms of energy expenditure (EE: kcals) and metabolic equivalents (METs). 
 
Various PA monitors are commercially available but the multi-sensor activity 
monitor, SenseWear Pro 2 Armband (SWM) has recently been found to have 
the greatest validity when compared to other activity monitors during 
standardized bouts of PA (Van Remoortel et al. 2012). 
 
The SWM has been described as being a reliable and valid way of monitoring 
step count and EE in patients with COPD during standard exercise tests such 
as the ISWT and 6MWT (Patel et al. 2007). However, due to cumulative 
reporting of data it is not confirmed whether the monitors can detect slow 
speeds of walking. It is known that patients with COPD sacrifice speed of 
walking for duration (Evans et al. 2011),  yet there is still uncertainty as to the 
ability of the SWM to accurately detect steps and EE at very slow walking 
speeds (less than 3.27 km.hr (Hill et al. 2010, Van Remoortel et al. 2012)) 
which are commonly adopted by individuals with COPD. 
 
The data presented in this chapter contributed to the paper published in Heart 
and Lung (Harrison et al. 2013a) 
 
4.2 Aim 
Daily physical activity is a key outcome of this study and therefore, it is 
essential to have a reliable measure to detect changes in activity during the 




monitor errors. There were nine SWMs available for this study and it was 
important to determine if each monitor was equivalent to one another so 
monitors could be used interchangeably. Therefore, the aims of this chapter 
were to assess the SWM for: 
1. Reproducibility of different SWMs over 5 repeat tests at a given 
speed 
2. Between monitor reproducibility at a given speed 
3. The ability of the monitors to discriminate between speeds of 
walking 
4. Validity with indirect calorimetry at a given speed 
 
4.3 Methods 
The protocol required the subject to complete a large number of assessments 
at speeds varying from slow to fast and also to wear a face mask for a 
number of assessments, therefore it was completed on a healthy adult.  
 
Subjects 
A healthy female subject (EH: 33 yrs, 1.74m, 57kg) completed all the test-
retest and indirect calorimetery assessments of the SWM. 
 
Ethical approval 
All procedures for the experimental methods were approved by Coventry 






SenseWear® Pro2 Armband 
The SenseWear® Pro2 Armband (SWM; BodyMedia
®, Inc., Pittsburgh, USA) is 
a commercially available device to estimate energy expenditure. It is worn on 
the back of the upper right arm over the triceps muscle mid way between the 
acromion and the olecranon processes. The SWM contains a biaxial 
accelerometer (longitudinal and transverse planes) and collects physiological 
data via a number of sensors (skin temperature, heat flux, near-body ambient 
temperature and galvanic skin response). It has a mark button on the front to 
highlight set time points. Demographic characteristics (gender, age, height 
and weight) are also required to be programmed into the device to estimate 
energy expenditure using a generalized propriety equation (InnerView™ 
Software Version 6) developed by the manufacturer.  A view of the data 
output window is presented in figure 4.1. From this screen data can be 
manipulated to look at specific times, for example, between two marked time 







Figure 4.1 InnerView™ Software 
 
Experimental methods 
The subject wore a heart rate monitor (Polar Accurex Plus™, Finland) and a 
SWM for each of the tests. The heart rate monitor was worn to ensure 
recovery was achieved between consecutive walk tests and was not used for 
analysis. The SWM (figure 4.2) was worn for 15 minutes before data 
collection to allow acclimation to skin temperature. On separate occasions, 
nine different SWM’s were worn by the subject. For each SWM, the subject 
performed five, five minute bouts of walking, at five different speeds in random 
order paced by the signals from the endurance shuttle walk test (ESWT;1.78, 
2.44, 3, 4.65 and 6km.hr),  which is commonly used as an outcome measure 




estimating endurance capacity in COPD patients (Revill et al. 1999).  Speed 
2.44km.hr was not completed on monitor 1 as this speed was not added to 
the protocol until this monitor had been completed. The walking course was a 
standard 10m shuttle distance with constant walking speeds determined by an 
audio signal. During one of the 5 trials with each of the SWM expired gases 
were collected and analysed to calculate energy expenditure via indirect 
calorimetry. A portable gas analysis system (Cosmed K4b2; COSMED, Rome, 
Italy) was used to measure minute-by-minute oxygen uptake and the 
respiratory exchange ratio (RER). Energy expenditure (kcal.min-1) was 
calculated by multiplying the oxygen uptake (L.min-1) by the caloric equivalent 
based on the RER. The walks completed whist wearing the gas analysis 
equipment were completed over 7 minutes and only the last 5 minutes 
analysed to allow a physiological steady state to occur. In order to ensure 
measurement periods were synchronized both the SWM and the metabolic 








4.4 Outcome Measures 
Energy expenditure was recorded from the activity monitor and indirect 
calorimetry. Step count was also used from the activity monitors. 
  
4.5 Statistical analysis 
As the data was not normally distributed, non-parametric statistical tests were 
utilized. Analysis was completed on the step counts and the estimated energy 
expenditure for the within and between monitor data. Descriptive statistics are 
presented to display within monitor variation of the five tests, at five different 
speeds (mean ± standard deviation (SD), ninety-five percent confidence 
intervals (95% CI), and the coefficient of variation (CV)). The CV is a measure 
of the relative variation of distribution, independent of the unit of 
measurement. It is calculated by dividing the standard deviation by the mean 
and is expressed as a percentage. Acceptable variability is considered to be 
<5%. 95% CI and CV is used as an indicator of the reproducibility of a 
measure. 
 
A non-parametric Kruskal-Wallis test (with post-Hoc Mann-Whitney U tests) 
was used to assess between reproducibility and to explore if all monitors 
could distinguish between the five speeds of walking. 
 








Within monitor Reproducibility 
Data was recorded every minute during each of the five minute trial, each trial 
was repeated five times, therefore, 25 data points were collected for each 
monitor at each speed. However, 2.44km/hr was not completed in monitor 1. 
The mean value represents the average step count or EE collected in one 
minute for each trial. The descriptive statistics for the within monitor data for 
steps is shown in table 4.1 and figure 4.3 and for EE in table 4.2 and figure 
4.4. The mean data presented in table 4.1 and 4.2 represents the mean 
minute by minute data calculated by averaging each individual minute of each 






Table 4.1 Descriptive statistics and within monitor variation for step counts 
Monitor Speed (km.hr) Mean (SD) 95%CI CV % 
1 1.78 39.67 (9.86) 27.42 to 51.97 24.86 
1 3 85.4 (3.36) 81.23 to 89.75 3.93 
1 4.56 106.27 (2.39) 103.30 to 109.23 2.25 
1 6 120.73 (6.67) 112.45 to 129.01 5.52 
2 1.78 36.2 (11.98) 21.32 to 51.08 33.09 
2 2.44 75.17 (1.65) 60.36 to 89.97 2.20 
2 3 82.85 (4.81) 76.88 to 88.84 5.81 
2 4.56 104.53 (7.17) 95.62 to 113.44 6.86 
2 6 118 (13.83) 100.83 to 135.17 11.72 
3 1.78 21.93 (4.43) 16.44 to 27.43 20.20 
3 2.44 69.53 (14.72) 51.25 to 87.81 21.17 
3 3 73.87 (9.12) 62.54 to 85.20 12.35 
3 4.56 102.47 (5.05) 96.19 to 108.75 4.94 
3 6 109.27 (16.52) 88.75 to 129.78 15.12 
4 1.78 23.8 (15.12) 5.03 to 42.57 63.53 
4 2.44 67.4 (7.14) 58.54 to 76.26 10.59 
4 3 83.07 (5.86) 75.80 to 90.34 7.05 
4 4.56 106.20 (2.71) 102.83 to 109.57 2.55 
4 6 122.07 (5.75) 114.93 to 129.20 4.71 
5 1.78 28.20 (8.69) 17.41 to 38.99 30.82 
5 2.44 68.89 (3.40) 60.43 to 77.34 4.94 
5 3 79.60  (3.49) 75.26 to 83.94 4.38 
5 4.56 106.60 (1.48) 104.76 to 108.43 1.39 
5 6 121.00 (7.87) 111.23 to 130.78 6.50 
6 1.78 26.13 (11.15) 12.30 to 39.97 42.67 
6 2.44 68.50 (5.9) 15.52 to 121.48 8.61 
6 3 84.20 (1.54) 82.29 to 86.11 1.83 
6 4.56 108.33 (2.13) 105.68 to 110.98 1.97 
6 6 120.40 (6.23) 112.66 to 128.13 5.17 
 
 







Monitor Speed Mean ± SD 95%CI CV% 
7 1.78 32.40 (10.72) 19.08 to 45.71 33.09 
7 2.44 69.00 (1.23) 67.48 to 70.52 1.78 
7 3 80.87 (4.11) 75.77 to 85.97 5.08 
7 4.56 97.60 (17.93) 75.34 to 119.86 18.37 
7 6 100.40 (46.67) 42.44 to 158.35 46.48 
8 1.78 31.73 (11.8) 17.08 to 46.39 37.19 
8 2.44 71.07 (3.81) 66.33 to 75.80 5.36 
8 3 83.74 (3.88) 78.92 to 88.55 4.63 
8 4.56 103.33 (5.01) 100.11 to 112.55 4.85 
8 6 120.33 (1.73) 118.18 to 122.48 1.44 
9 1.78 33.93 (6.59) 25.74 to 42.12 19.42 
9 2.44 69.53 (6.13) 61.92 to 77.15 8.82 
9 3 80.73 (3.02) 76.98 to 84.48 3.74 
9 4.56 99.6 (20.47) 74.18 to 125.02 20.55 



















Figure 4.3 Monitor reproducibility for steps at the 5 different speeds of the 
ESWT (mean ± 95% CI) 
 
Figure 4.3 shows step counts increasing with increasing speed. Monitor 6 at 
speed 2.44km.hr and monitor 7 at 6km.hr have larger 95% CI than the other 
monitors and other speed. One of the five walks at 2.44km/hr in monitor 6 had 
a very high mean step count (120 steps/min), and monitor 7 also had one 
outlying reading from one of the five walk tests. This reading (monitor 7) was 
lower than the other four at a mean of 18 steps/min. Each of these single 
readings account for the high 95% CI. For each of the SWM’s SD also 
increases as the speed increases. This increase in the variability of the 





4.1). The CV is highest at the slowest speed of 1.78km.hr in the majority of 
the monitors and all monitors demonstrate unacceptable variability at this 
speed. Monitors 2, 3, 7 and 9 also high values for CV at the highest speed of 
6km.hr, with monitor 7 having a CV value of 46.48%. However, monitor 8 has 
its lowest CV at 6km.hr of 1.44%. The middle speed of 2.44, 3 and 4.56km.hr 




Table 4.2 Descriptive statistics and within monitor variation for energy 
expenditure. 
 
Monitor Speed (km.hr) Mean (SD) 95%CI CV% 
1 1.78 13.24 (7.07) 4.46 to 22.02 53.40 
1 3 14.28 (1.51) 12.40 to 16.16 10.57 
1 4.56 13.52 (2.31) 10.64 to 16.4 17.09 
1 6 17.52 (1.58) 15.55 to 19.49 9.02 
2 1.78 10.96 (4.38) 5.52 to 16.4 39.96 
2 2.44 10.90 (0.71) 4.55 to 17.25 6.51 
2 3 14.08 (2.33) 11.19 to 16.97 16.55 
2 4.56 14.28 (4.00) 9.37 to 19.19 28.01 
2 6 21.24 (3.20) 17.27 to 25.21 15.07 
3 1.78 11.96 (4.44) 6.45 to 17.48 37.12 
3 2.44 13.00 (3.66) 8.45 to 17.55 28.15 
3 3 14.44 (1.88) 12.10 to 16.78 13.02 
3 4.56 15.44 (3.91) 10.58 to 20.30 25.32 
3 6 19.36 (4.88) 13.30 to 25.41 25.21 
4 1.78 16.56 (5.08) 10.26 to 22.86 30.68 
4 2.44 11.48 (1.90) 9.12 to 13.84 16.55 
4 3 14.08 (2.00) 12.00 to 16.56 14.2 
4 4.56 13.76 (2.37) 10.82 to 16.70 17.22 
4 6 19.16 (3.78) 14.46 to 23.86 19.73 
5 1.78 15.00 (4.17) 9.82 to 20.17 27.8 
5 2.44 11.20 (1.60) 7.22 to 15.17 14.29 
5 3 12.48 (0.81) 11.48 to 13.48 6.49 
5 4.56 14.40 (2.16) 11.72 to 17.08 15 
5 6 18.00 (2.05) 15.46 to 20.55 11.39 
     
     
 
 





Monitor Speed Mean ± SD 95%CI CV% 
6 1.78 9.40 (3.72) 4.78 to 14.02 39.57 
6 2.44 9.90 (0.42) 6.09 to 13.71 4.24 
6 3 13.24 (1.57) 11.29 to 15.19 11.86 
6 4.56 15.4 (2.1) 12.79 to 18.01 13.64 
6 6 17.44 (2.7) 14.04 to 20.84 15.48 
7 1.78 12.56 (6.61) 4.35 to 20.76 52.63 
7 2.44 10.80 (2.26) 7.99 to 13.61 20.93 
7 3 13.44 (2.35) 10.52 to 16.36 17.49 
7 4.56 14.88 (4.70) 9.04 to 20.72 31.59 
7 6 25.40 (12.83) 9.47 to 41.33 50.51 
8 1.78 9.36 (3.44) 5.09 to 13.63 36.75 
8 2.44 10.96 (1.49) 9.12 to 12.81 13.59 
8 3 12.24 (0.82) 11.22 to 13.25 6.7 
8 4.56 14.48 (2.87) 10.91 to 18.05 19.82 
8 6 15.96 (1.23) 14.44 to 17.48 7.71 
9 1.78 10.32 (3.64) 5.80 to 14.84 35.27 
9 2.44 12.16 (2.61) 8.93 to 15.40 21.46 
9 3 14.92 (4.35) 6.51 to 20.32 29.16 
9 4.56 14.08 (1.25) 12.52 to 15.64 8.88 
















Figure 4.4 Monitor reproducibility for energy expenditure at the 5 different 
speeds of the ESWT (mean ± 95% CI) 
 
Figure 4.4 shows the reproducibility of the 9 SWM’s at increasing speeds 
when measuring EE. The slowest speed of 1.78km.hr shows a larger 95% CI 
in all of the monitors compared to the other speeds, indicating lower reliability 
in these measures. At the fastest speed of 6km.hr monitors 7 and 9 have also 
got high 95%CI. Monitor 7 has one of the five walk at 6km.hr reporting a mean 
EE of double the other readings (47.4 kcal.min-1). Monitor 9 also reported one 





4.2 shows high CV in all the 9 SWM’s, with only monitor 6 at 2.44km.hr having 
an acceptable value of 4.24%. 
 
 
Summary of within monitor reproducibility 
In general, the 9 SWM’s do demonstrate higher step counts and EE at 
increasing speeds (figures 4.3 and 4.4). However, SD, 95% CI and CV is 
consistently higher at the lowest speeds of 1.78km.hr for both step count and 
EE. The highest speed of 6km.hr also show high variability in a number of 
monitors. The middle range of speeds (2.44, 3, 4.56km.hr) demonstrate more 
acceptable values for 95% CI and CV. However, the data suggest that there is 
improved reproducibility when using step counts in comparison to EE (data 
not shown). 
 
Between monitor reproducibility 
As the data was not normally distributed, non-parametric statistical analysis 
was chosen. Kruskal-Wallis analysis indicated there was no significant 
difference between each monitor at a given speed for both step counts and 
EE. This suggesting good between monitor reproducibility and equivalent 
values generated at each speed. 
 
Sensitivity 
A Kruskal-Wallis test was also completed on the data reported by each 
monitors to determine if they could distinguish between each speed. When 




the speeds (Table 4.3). Post Hoc Mann-Whitney U test revealed monitors 1, 3 
and 4 could not distinguish between each of the speeds show in table 4.3. 
The Kruskal-Wallis test for sensitivity in step counts at different speeds 
revealed each monitor to be able to distinguish between each speed (all 
P=<0.001).  
 




Speeds monitors can’t distinguish between 
(Post Hoc test) 
1 NS 3 and 6 km/r; 4.56 and 6 km/hr 
2 0.014  
3 NS 3 and 6 km/hr 
4 NS 2.44 and 6 km/hr; 3 and 6 km/hr; 4.56 and 6 km/hr 
5 0.021  
6 0.008  
7 0.031  
8 0.009  




Figure 4.5 shows the agreement between total EE per speed for each monitor 
as measured by SWM and the calculated EE from the portable metabolic cart. 




five repeated trials at each speed for each of the monitors. The Bland-Altman 
limits of agreement for ±2SD were 7.9 and -15.7kcal with a mean difference of 
-3.9kcal. There was a significant difference between the EE as measured by 






Figure 4.5 Bland Altman plot of agreement in total energy expenditure 




+2 SD = 
7.9 
Mean 
d =     -
3.9kcal 







This chapter presented the finding of one of the first studies to examine the 
ability of the SWM to accurately detect slow speeds of standardised walking. 
In general, the SWM is a reproducible and sensitive method of monitoring 
physical activity levels. This means that the SWM can detect slow velocities of 
walking which is of great importance when monitoring patients with COPD as 
they have reduced physical functioning (Watz et al. 2009). The SWM can also 
detect when small changes in activity occur, such as volume and intensity of 
activity. This is an essential requirement of a monitor as changes may be 
small but they may equate to significant proportional changes in activity. Also 
the data indicates that as each of the monitors report equivalent values at 
each speed the monitors can be used interchangeable so each subject in the 
main trial doesn’t necessarily need to have the same monitor each time. 
However, reproducibility and sensitivity is more acceptable when using step 
counts rather than EE. 
 
These results support Patel et al. (2007) who found the SWM to be a reliable 
measure of EE during exercise testing in patients with COPD. However, they 
have reported cumulative activity during the 6 minute walk and the 
Incremental Shuttle Walk Test (ISWT), rather than the accuracy of the monitor 






Although the SWM has been shown to detect changes in different types of 
PA, including walking, the walking speeds used were selected by the 
individuals as either fast or slow. The slow and fast speeds of walking 
reported in the Hill et al. (2010) study generated 77 and 93 steps/minute 
respectively. These values correspond broadly to the middle speeds of the 
ESWT (2.44 and 3 km.hr; figure 4.3) and therefore do not represent a wide 
range of speeds as seen in the current study. More recently Van Remoortel et 
al. (2012) tested the monitor at slower walking speeds (3.27 km.hr) but this 
still does not equate to the slower speeds of the ESWT. Uniquely this study 
reports the accuracy of the SWM in detecting even slower speeds from 
1.78km.hr to 6 km.hr. 
 
Furlanetto et al. (2010) reported that the SWM was inaccurate at counting 
steps but accurate at estimating EE, however, this is in contrast to this study 
which found step count to be more sensitive to a change in walking speed 
compared to EE. Furlanetto et al. (2010) did not use standardised walking 
speeds making it difficult to conclude if the SWM can distinguish between 
walking speeds and subjects were only monitored for 1 minute, therefore, 
steady state could not have been reached. They also used treadmill walking 
to assess the SWM, but it is important to test the device during free walking 
on the ground as gait and energy requirements are different during treadmill 
walking (Murray et al. 1985, Pearce et al. 1983, Stolze et al. 1997) and may 





Despite the accuracy of the SWM in detecting differences between walking 
speeds in step count the CV were higher at the slowest speed (1.78 km.hr; 
table 4.1). This supports previous research which found the SWM to 
significantly undercount steps when compared with a visual count (Turner et 
al. 2012). This may be related to the amount of force generated during faster 
walking speeds, as low forces generated by a slow gait may not be sufficient 
to overcome the inertia with the accelerometer device. 
 
It is of interest to note that this the first study to report between monitor 
differences. It was important to establish if different SWM give the same 
reading at the same walking speeds. This study found that there was no 
significant difference between each monitor at each speed. This, therefore, 
means that the SWM’s can be used interchangeably and for each subject in 
the main trial they do not need to wear the same monitor at each data 
collection point.   
 
There appears to be some discrepancy in the literature looking at the validity 
of the SWM as a measurement of EE. Patel et al. (2007) found the SWM to 
underestimate cumulative EE compared to indirect calorimetry in COPD 
patients during the 6 minute walk test and the ISWT, whereas Van Remoortal 
et al (2012) reported a high correlation between METs reported by the SWM 
and VO2. This current study indicates that the SWM demonstrates fair validity 
in measuring EE supporting findings by Hill et al. (2010). Other authors 
presented their findings as METs whereas this study has reported data as EE. 




significant, whereas this study found a mean difference between the 2 
methods of -3.9kcal which was a significant difference. From this study 
protocol it can be conclude that the SWM demonstrates fair validity during 
standardised tests of exercise performance unlike Hill et al. (2010) who did 
not examine validity of the device at standardised walking speeds.  Fruin and 
Rankin’s (2004) conducted their testing at faster walking speeds in healthy 
individuals which is not representative of velocities seen in patients with 
COPD.  Previous work has suggested that patients with COPD have 
increased resting and total daily EE and greater oxygen consumption for a 
given workload compared to healthy subjects (Creutzberg et al. 1998). This 
may account for some of the variation between the results from this study and 
Fruin and Rankin’s (2004) results.  The differences in comparison to Hill et 
al.’s (2010) study could be due to the differences in walking velocities. They 
reported their fastest speed to be 93 steps/min which roughly relates to 3 
km.hr (figure 4.3), this current study has completed 2 faster speeds than this 
(4.56 and 6 km.hr) which makes it difficult to do direct comparison. 
 
4.8 Limitations 
Although the protocol design enabled the detailed examination of the 
measurements properties of different SWM’s during various walking speeds, 
all the assessments were conducted by a healthy subject and not a patient 
with COPD. It was believed that a COPD patient may be unable to take part in 
the full range of speeds undertaken, in particular the fast speed of 6 km.hr. 
Also the large number of repetitions required for the study protocol may have 




additional hospital visits. In addition, as there was only one subject in this 
study it may have given rise to bias results, due to less biological variability.  
 
Indirect calorimetry was used as the criterion measure for EE which is a 
widely reported reference measure used in the literature (Fruin and Rankin 
2004, Hill et al. 2010, Patel et al. 2007). Cost and access prevented the use of 
direct calorimetry or doubly labelled water. 
 
Walking is the main activity performed by patients with COPD (Pitta et al. 
2005b) and is the basis of our pulmonary rehabilitation programme. However, 
the current protocol did not look at other activities of daily living such as 
housework, food preparation, climbing stairs and dressing which all contribute 
to the daily EE of patients with COPD. 
 
Another potential limitation of this study is that actual step count was not 
recorded. Therefore the validity of the step counts was not analysed and we 
cannot be certain that as speed increased more steps were taken. It is 
possible that as the monitor is worn on the arm it is better at recording data at 




This study supports the use of the SWM after evaluating the reproducibility, 
sensitivity and validity in detecting different walking speeds in 9 monitors. The 




walking and by considering both step count and EE it can be confidently used 
as an outcome measure for describing PA and detecting change in PA in 




Chapter 5 – The effectiveness of the SPACE for COPD 




There is considerable evidence for the benefits of Pulmonary Rehabilitation 
(PR) and the NICE (2010) guidelines recommend that it should be offered to all 
patients who consider themselves functionally disabled by COPD. Despite this 
accumulation of convincing evidence there is an inadequate provision of PR in 
the UK and a lack of choice of how rehabilitation is delivered. The SPACE for 
COPD programme was developed as a home based supportive self-
management (SM) intervention (described in chapter 3) to increase the scope 
of delivery and increase patient choice. There is potential for the SPACE for 
COPD programme to offer an alternative supportive SM model to conventional 
PR. 
 
As discussed in chapter 2.3, home based and SM studies that have been 
published have been inconsistent in not only their overall findings, but also their 
interventions and outcome measures.  Unlike cardiac rehabilitation there has 
been no Cochrane review of home based rehabilitation for patients with COPD. 
However, the Cochrane review of SM (Zwerink et al. 2014), as previously 




monitoring, highlighted the issue of differential treatment time and 
heterogeneity of interventions. 
 
It is important to asses and report on new and novel approaches over a short 
period of time so that any initial benefits can be measured, and to allow for 
understanding of how these benefits may change over different durations of 
interventions. Studies that have only reported long term follow-up may have 
missed vital evidence on the effectiveness of their programmes and as a 
consequence patient requirements for maintenance and support strategies may 
not be addressed. 
 
The SPACE for COPD programme consists of four stages to progress through 
at the patient’s own pace, However, the intervention period for this study was 
seven weeks to match the PR programme based at Glenfield hospital which, 
acted as the comparison group. 
 
This chapter will describe the short term (seven weeks) outcomes of the 
noninferiority, randomised control trial. Patients with COPD were recruited 
from those referred to PR and were randomised into either a usual care PR 
programme (control) group or a supported SM programme which involved 
using the SPACE for COPD manual. Patients were assessed at baseline and 
then again seven weeks later. This chapter will focus on the following: 
 Baseline characteristics 
 Between group differences from baseline to seven weeks 





The aim was to determine whether the seven week outcomes of SPACE for 
COPD programme were noninferior (as good as) to usual care PR in the 
treatment and management of patients with COPD at seven weeks.  
 
5.3 Methods 
A full description of the methods of this study can be found in chapter 3. 
Chapter 3 gives details related to the power calculation, recruitment, 
randomisation, blinding, outcome measures and a description of the 
intervention and control group treatments. A flowchart of this section of the 





































1162 Patients assessed for 
eligibility 
Consented & Randomised (n=287) 




7 week assessment 
(n=84) 
7 week assessment 
(n=94) 
Manual Introduction 
Phone calls at 2 






 Excluded as not eligible 
(n=635) 
MRC <2 = 28 
Did not attend = 185 
Co morbidities = 32 
Not suitable for PR = 70 
On other study = 45 
Not COPD = 241 
PR in <12 mos. = 12 















Not complete (n= 58) 
Lost to Follow up = 30 
Co morbidities = 12 
Too big a commitment = 2 
Social / family reasons = 4 
Didn’t like PR = 5 
Travel problems = 1 
RIP = 1 
Wanted other form of 
treatment = 3 
Not Complete (n= 51) 
Lost to Follow up = 16 
Co morbidities = 16 
Too big a commitment = 10 
Social / family reasons = 5 
RIP = 2 
Wanted other form of 
treatment = 2  
527 Patients invited to 
participate 
Declined (n=240) 
Declined all rehab = 78 
Wanted PR = 140 
























5.4 Outcome measures 
 
A full description of the outcome measures used in this study is described in 
Chapter 3.6. The key outcome measures at seven weeks explored in this 
chapter are 
 Chronic respiratory questionnaire – self reported (CRQ-SR) 
o Dyspnoea, fatigue, emotion and mastery 
 Hospital Anxiety and Depression Scale (HADS) 
 Incremental shuttle walk test (ISWT) 
 Endurance shuttle walk test (ESWT) 
 Pulmonary Rehabilitation Adapted Index of Self Efficacy (PRAISE) 
 
The primary outcome for this study, to which it was powered, is the dyspnoea 
domain of the CRQ-SR. 
 
5.5 Statistical analysis 
 
Statistical analyses were completed using the statistical package IBM SPSS 
Statistics version 20. Baseline characteristics were analysed for group 
differences using an independent t-test for continuous data and chi square 
test for categorical data. The within and between group data changes over 7 
weeks were analysed using paired t-test and independent t-tests respectively. 
The primary analysis is the between group differences and the secondary 





Noninferiority was determined using the primary outcome of CRQ-SR 
Dyspnoea, if the mean improvement in CRQ-SR dyspnoea score in the 
SPACE for COPD group was no worse than the mean improvement in CRQ-
SR dyspnoea score in the PR group, by a margin of 0.5 units. The 
noninferiority margin of 0.5 units was chosen as this is the minimal clinical 
important difference (MCID) for the CRQ-SR (Jaeschke, Singer and Guyatt 
1989). If the 95% CI breaches this 0.5 units then this may be interpreted as 
having some uncertainty as to its noninferiority (Piaggio et al. 2012). 
Pearson’s correlation was also used to determine the relationship between 
baseline score and the change in score at 7 weeks for dyspnoea and the 
ISWT. 
 
As the protocol did not specify what was an acceptable level of adherence to 
the programme an Intension To Treat (ITT) analysis was adopted. This data is 
labelled at ITT completers in the results section. In addition multiple 
imputations using SPSS was used to impute missing seven week data due to 
drop out. Five models of imputed values were produced, with analysis 
completed on the pooled data. Results from this analysis is labelled at ITT 




287 patients were recruited and randomised to the study, 142 to PR and 145 
to SPACE for COPD. A total of 109 patients withdrew from the study. 




was classified as those subjects not completing the seven week assessments. 
58 people (41%) did not complete the seven week assessment in the PR 
group and 51 people (35%) did not complete the seven week assessment in 
the SPACE for COPD group. Therefore, similar dropout rates were seen with 
both interventions. Those that did not attend their appointments were 
contacted to rearrange. If two appointments were missed without any contact 
they were withdrawn from the study. An independent t-test showed there was 
no statistically significant difference in baseline characteristics of those that 
did or did not complete the seven week assessment (data not shown). 
 
Table 5.1 Reasons for study withdrawal 
Reason for withdrawal PR SPACE 
Lost to Follow up 30 16 
Co morbidities 12 16 
Too much of a commitment 2 10 
Social / family reasons 4 5 
Didn’t like PR 5 N/A 
Travel problems 1 N/A 
RIP 1 2 
Wanted other form of treatment 3 2 
  
Baseline characteristics are outlined in table 5.2. Data are presented as Mean 
(SD) for continuous data and absolute values for categorical data. There were 
no statistically significant differences in baseline characteristics between 











Age (yrs) 67 (8) 68 (9) 0.54 
Male:Female (n:%) 94 (66%):48(34%) 93 (64%):52 (36%) 0.78 
BMI (m/kg2) 27.84 (6.39) 27.40 (6.03) 0.55 
FEV1 (litres) 







FVC (litres) 2.67 (0.90) 2.73 (0.84) 0.59 
MRC (n;%) 
     2 
     3 
     4 
     5 











SpO2 rest % 93.91 (3.66) 94.54 (2.32) 0.86 
Smoking status (%) 
    Current smoker  
    Never smoked  










Pack years 45.78 (26.00) 47.22 (36.21) 0.67 
CRQ-SR 
    Dyspnoea 
    Fatigue 
    Emotion 

















    Anxiety 










PRAISE 44.81 (7.00) 47.24 (8.09) 0.917 
ISWT (m) 268.61 (149.89) 260.24 (147.91) 0.764 





A one way ANOVA was used to assess differences in baseline measures per 
MRC grade (table 5.3). Differences were detected between CRQ-SR 
dyspnoea, fatigue, emotion, mastery, HADS depression, PRAISE, ISWT and 
ESWT. Each measure had the ‘best’ score in MRC 2 and the ‘worst’ score in 
MRC 5.  
 
Table 5.3 Mean (SD) baseline measures by MRC grade 
 










  Dyspnoea 
  Fatigue 
  Emotion 












































PRAISE 47.27 (6.73) 45.43 (7.20) 41.75 (7.41) 43.64 (7.59) <0.0001 
ISWT (m) 399 (137) 285 (125) 196 (124) 124 (89) <0.0001 
ESWT (sec) 331 (260) 201 (93) 180 (156) 118 (69) <0.0001 
 
Part way through the study those recruited were ask to give a preference as 
to which treatment group they would like to be assigned. 155 (54%) of 




COPD, 38 (25%) wanted PR, and 37 (24%) had no preference to a treatment 
group. Table 5.4 below shows the number of patients that were assigned to 
their desired treatment group and those that didn’t. 
 
Table 5.4 Patient preference of treatment choice 
 PR  
n = 76 
SPACE 
n = 79 
Were assigned the 
treatment group they 
preferred 
34 (45%) 58 (73%) 
Were assigned the 
treatment group they did 
not prefer 
22 (29%) 4 (5%) 
No preference given 20 (26%) 17 (22%) 
 
 
Health related Quality of Life (HRQoL) 
Chronic Respiratory Questionnaire – Self Report 
Health related quality of life was measured by the CRQ-SR which is divided 
into 4 domains: dyspnoea, fatigue, emotion and mastery. Between group 
changes were analysed using an independent t-test. The results are show in 






Table 5.5 Primary analysis - Between group differences in the change in 
CRQ-SR from baseline to seven weeks (SPACE minus PR) 









-0.32 (-0.71 to 0.08) 0.113 0.103 
Fatigue 
 





-0.52 (-0.88 to 0.17) 0.004 0.004 
Mastery 
 
-0.43 (-0.77 to 0.09) 0.014 0.009 
 
The primary outcome of this noninferiority trial is the dyspnoea score of the 
CRQ-SR. Between group differences were small (-0.32, 95% CI -0.71 to 0.08) 
and not statistically significant.  However, as the noninferiority margin (0.5 
units) is exceeded by the 95% CI there is still some uncertainty as to the 













Figure 5.2 Change in CRQ –SR Dyspnoea at 7 weeks 
 
 
The minimal clinical important difference (MCID) for the CRQ-SR is a change 
of 0.5 units (Jaeschke, Singer and Guyatt 1989). Table 5.6 shows the 














Table 5.6 Participants meeting the MCID (0.5 units) for the CRQ-SR 
dyspnoea domain in PR and SPACE groups 
 Change <0.5 
% 
Change ≥ 0.5 
% 
Range (-7 to 7) 
PR 41.10 
 
58.90 -1.60 to 3.2 
 





Figure 5.3 The relationship between baseline CRQ-SR Dyspnoea score and 
change at 7 weeks in the PR intervention group. 
 
 
r = -0.412 






Figure 5.4 The relationship between baseline CRQ-SR Dyspnoea score and 
change at 7 weeks in the SPACE for COPD intervention group. 
 
A Pearson’s correlation was used to determine if there was a relationship 
between baseline CRQ-SR Dyspnoea score and the change in scores at 
seven weeks. This was completed to determine if those with lower baseline 
scores improved more than those with higher baseline scores. Results 
demonstrated that there was a significant negative relationship in both groups 
(PR, r = -0.412, p= <0.0001 figure 5.3; SPACE, r = -0.386, p = <0.0001 figure 
5.4). Highlighting that those with lower baseline scores tended to have greater 
improvements in CRQ-SR Dyspnoea. 
 
A paired t-test was completed on the within group changes in the CRQ-SR 
from baseline to seven weeks and the results presented in table 5.7. Results 
showed that there was a significant improvement in all domains in the PR 
group and a significant improvement in the dyspnoea domain only of the 
SPACE group (figure 5.5). 
r = -0.386 




Table 5.7 Within group changes in CRQ-SR from baseline to 7 weeks in PR 
and SPACE 
 
  Mean 
Baseline 
Score       
(SD; n=287) 
Mean 7 weeks 







2.44 (0.86) 3.34 (1.16) 0.91 




3.43 (1.05) 4.02 (1.23) 0.59 




4.41 (1.20) 4.92 (1.08) 0.51 




4.40 (1.27) 4.97 (1.21) 0.57 




2.58 (0.89) 3.16 (1.25) 0.58 




3.54 (1.19) 3.67 (1.19) 0.14 




4.52 (1.23) 4.52 (1.20) 0.003 




4.61 (1.39) 4.74 (1.30) 0.13 








Figure 5.5 Mean (SD) changes in CRQ-SR from baseline to 7 weeks 
 
Pearson’s correlation was also completed on the fatigue, emotion and 
mastery domains of the CRQ-SR. Table 5.8 highlights that in both groups 
there is a relationship between those with lower baseline score to have 








Table 5.8 Relationship between baseline CRQ-SR score and change in score 
at 7 weeks 
 PR SPACE 
 r p r p 
Fatigue -0.395 <0.0001 -0.502 <0.0001 
Emotion -0.577 <0.0001 -0.459 <0.0001 




Hospital Anxiety and Depression Scale (HADS) 
Between group changes in anxiety and depression is presented in table 5.9 
and within group changes in HADs is presented in table 5.10 
 
Table 5.9 Between group differences in HADS scores (SPACE minus PR) 




















Between group differences for anxiety (-0.97, 95%CI -1.98 to 0.04) and 




However, the noninferiority margin (1.5 units) is breached by the 95% CI and 
therefore there is still uncertainty as to the effectiveness of SPACE for COPD 




Figure 5.4 Change in HADs Anxiety at 7 weeks 
 
 
Figure 5.6 Change in HADS Anxiety at seven weeks 
PR 
SPACE 


























Table 5.10 Within group changes in HADS from baseline to 7 weeks in PR 
and SPACE 
 
  Mean 
Baseline 
Score        
(SD; n=287) 
Mean 7 weeks 










7.74 (3.89) 6.65 (3.75) -1.08 




6.38 (3.08) 5.49 (3.19) -0.89 







7.21 (3.82) 7.03 (4.00) -0.18 




6.18 (3.41) 6.18 (3.37) 0.00 
(-0.67 to 0.67) 
1.00 
 
Between group differences in anxiety and depression show no statistically 
significant difference between PR and SPACE. However, PR shows a 
significant improvement from baseline to 7 weeks (change anxiety -1.08, 95% 
CI, -1.74 to -0.43 units; Depression 0.89 95% CI, -1.42 to -0.36) and SPACE 
for COPD shows no statistical difference during the same time period. 
 
Further analysis was completed on 2 subgroups, those patients who scored   
≥8 for at least a possible indication of anxiety, and those patients who scored 




chosen as standard cut points of possible presence of anxiety or depression 
and is an approach previously described in the literature (Harrison et al. 
2012). Mean changes in anxiety was found to be significant in both 
intervention groups with no significant between group differences (table 5.11). 
No significant changes were seen in PR (p=0.895), or SPACE for COPD 
(p=0.075) for those with depression scores ≥ 8 (data not shown in table). 
 
Table 5.11 Within and between group changes in Anxiety scores in those with 
baseline scores ≥ 8 
 Mean change 
(95%CI) 
Within group       
p value 
Between group    
p value 
PR (n=43) 2.07  
(0.05 to 2.60) 
<0.001 0.34 
SPACE (n=34) 1.32              

















Self-efficacy was measured using the PRAISE questionnaire. Between group 
differences in table 5.12 and within group changes are shown in table 5.13. 
 
Table 5.12 Between group differences in PRAISE scores (SPACE minus PR) 









PRAISE -2.29  (-0.02 to 5.16) 0.051 0.043 
 
 
The change in self-efficacy between the two groups is shown to be not 
significant. PR shows a statistically significant difference from baseline to 
seven weeks, whereas SPACE shows no statistically significant change in 
scores. No MCID has been established for the PRAISE questionnaire to date 













Table 5.13 Within group changes in PRAISE scores from baseline to 7 weeks 
in PR and SPACE 
PRAISE Mean 
Baseline 
Score       
(SD; n=287) 
Mean 7 weeks 








    
44.84 (6.99) 47.30 (7.89) 2.46              




    
44.76 (7.42) 44.67 (8.60) -0.09                  
(-1.84 to 1.67) 
0.920 
 
A Pearson’s correlation was used to analyse the relationship between 
baseline PRAISE scores and change in scores at seven week. This was 
completed to determine if those with higher baseline score improved more 
than those with lower baseline scores. Results highlighted a statistically 
significant relationship between these scores in both intervention groups (PR, 
r = -0.437, p = <0.000; SPACE r = -0.365, p = 0.001), suggesting that those 
with lower baseline score have greater increases in seven week scores 
 
Exercise Capacity 
As described in the methods section 3.6 exercise capacity was measured by 




and figures 5.6 and 5.7. The MCID for the ISWT is considered to be 48m 
(Singh et al. 2008) , and 186 seconds for the ESWT (Pepin et al. 2011). As 
the test is measured in 10m increments the MCID is reported here as 50m. 
Table 5.15 shows the percentage of participants in each group meeting this 
threshold. In the PR group 43.04% met this threshold and 33.34% in the 
SPACE for COPD group. The within group changes are presented in table 
5.18.  
 
Table 5.14 Between group differences in exercise capacity (SPACE minus 
PR) 


























Table 5.15 Percent of patients meeting the MCID of 50m in the ISWT 
 Change <50m 
% 





43.04 -240 to 290 
SPACE 67.86 33.34 -150 to 210 
 
The between group differences in ISWT distance was -23.9m (95% CI -46.33 
to -1.47) and was statistically significant (p=0.038; Table 5.14). However, the 
noninferiority margin of the ∆SPACE-PR (50m) was not breached by the 95% 
CI (figure 5.8). This infers that the SPACE for COPD programme is noninferior 
(as good as) PR when considering the ISWT. The between group difference 
in ESWT time was -132.78sec (95% CI -244.63 to -20.94) and was also 
statistically significant (p=0.020). The noninferiority margin of ∆SPACE-PR 
(186 seconds) was breached by the 95% CI (figure 5.9), implying there is still 
some uncertainty as to the noninferiority of the SPACE for COPD programme 





















Figure 5.7 Change in ESWT time (sec) at 7 weeks 
 
 
Figure 5.9 Changes in ESWT time (seconds) at seven weeks 
PR 
SPACE 
Δ SPACE - PR 
PR 
SPACE 








Figure 5.10 The relationship between baseline ISWT performance (m) and 
change at seven weeks in the SPACE for COPD intervention group 
 
Table 5.16 Relationship between baseline exercise performance score and 
change in score at 7 weeks 
 PR SPACE 
 r p r p 
ISWT -0.141 0.198 -0.253 0.020 
ESWT 0.159 0.154 -0.084 0.447 
 
 
Statistical analysis demonstrated that there was only a significant relationship 
in baseline score to change in score at seven weeks in the ISWT of the 
SPACE for COPD group (r = -0.253, p = 0.020; figure 5.8 and table 5.16). No 





The significance of change for ESWT is reported to be between 186 seconds 
(Pepin et al. 2011). The number meeting the minimal threshold is reported in 
table 5.17. 
 
Table 5.17 Patients meeting the MCID of 186 sec for the ESWT 
 Change <186 sec 
% 





43.4 56.6 - 349 to 1071 


















Table 5.18 Within group changes in exercise capacity from baseline to seven 
weeks in PR and SPACE groups 
 
  Mean Baseline 
Score         
(SD; n=287) 
Mean 7 weeks 











269 (146) 310 (156) 41 




193 (98) 546 (409) 353 
(270 to 437) 
<0.001 
 
SPACE ISWT (m) 
 
264 (150) 281 (148) 18 




230 (230) 442 (391) 212 































Figure 5.12 Mean change in ESWT time (sec) from baseline to 7 weeks 
 
 
The changes in the ISWT show there is a statistically significant difference 
between PR and SPACE for COPD from baseline to seven weeks. Within 
group changes of both PR and SPACE for COPD show a statistically 
significant difference from baseline to 7 weeks in the ESWT, and both the PR 
and SPACE group showed a statistically significant improvement in ISWT. 
However, the mean change in ISWT in the PR group was 41m and for 
SPACE 18m which does not met the MCID for this test. 
 
 






Change in outcome measures by MRC grade 
Change in baseline to seven week scores per MRC grade were analysed 
using ANOVA. Results suggested there was no difference in the changes 
seen between the MRC grades (data not shown). The exception was CRQ-
SR fatigue in the PR group where there was a significant difference between 
the change in scores at seven weeks between MRC grades 2 and 4 (p=0.045) 




The data presented in this chapter focuses on the effectiveness of the SPACE 
for COPD manual as a noninferior alternative to PR. The primary outcome for 
this study was the dyspnoea domain of the CRQ-SR. Measures of health 
related quality of life, psychological functioning, exercise capacity and self-
efficacy were also used to determine if SPACE for COPD was ‘no worse’ than 
PR at seven weeks. 
 
There was a large number of patients (n= 240) that declines to take part in the 
study. Twenty two declined as they felt their English was not strong enough to 
follow the SPACE for COPD manual if that was the group they were 
randomised to, 140 wanted the certainty of PR and 78 did not want any form 
of rehabilitation. The premise of SPACE for COPD is that it may be suitable 
for those who would not normally participate in usual care PR, therefore 
completing the study with those already referred to and considering PR is a 




who had declined PR at the point of referral. Allowing patients to choose 
which group there were assigned to was considered, however preference 
based randomisation may not be considered to be rigorous enough and it has 
not been previously reported in PR like it has been in cardiac rehabilitation 
(Dalal et al. 2007). This is therefore a constraint of this study as it is not 
reflective of potential clinical practice. However, this trial does demonstrate a 
proof of concept for the SPACE for COPD programme and future directions 
for the programme will be discussed in chapter 9. 
 
Health Related Quality of Life (HRQoL) CRQ – SR Dyspnoea, Fatigue, 
Mastery and Emotion 
 
The SPACE for COPD programme is similar to interventions used by Moore 
et al. (2009) and Khdour et al. (2009) and their findings are of interest for a 
number of reasons, including the minimal, light touch nature of the 
interventions. Each study demonstrated a significant improvement in HRQoL 
with only limited healthcare input. At a similar time point Moore et al. (2009) 
had a median (interquartile range) improvement of 0.5 (0.2-0.6) for CRQ-SR 
dyspnoea.  Moore’s study consisted of 27 patients so is therefore likely to be 
underpowered, but Khdour’s study reported results from 173 patients and also 
used a similar research design in terms of a manual delivered by motivational 
interviewing and telephone support. However, this study did not report on any 
exercise or PA outcome measure. Both the SPACE for COPD and the Khdour 
programmes showing an improvement in HRQoL it may be that a manual, 




important component of a home based SM programme. However, as exercise 
and PA are important outcomes, it is a limitation of these studies not to have 
considered exercise or PA in their trial design as a more comprehensive 
approach may be more desirable. 
 
The improvements in the other domains of the CRQ were not statistically 
significant from baseline. Generally, home based SM programmes that have 
shown significant improvements in HRQoL tend to be those that involve 
patients with greater disease severity and ‘poorer’ baseline outcome 
measures (Bourbeau et al. 2003, Boxall et al. 2005, Fernández et al. 2009, 
Ghanem et al. 2010, Khdour et al. 2009, Maltais et al. 2008, Moore et al. 
2009). It is, therefore, possible to surmise that it may be difficult to impact on 
patients with milder disease as they have little room for improvement, 
whereas those studies that have recruited more severe patients with lower 
baseline scores have a greater capacity for improvement. One possible 
exception to this is the COPE II study (Effing et al. 2011). As previously 
described, patients recruited to this study had mild disease (FEV1 1.4L; 
FEV1% predicted 50%) and also had higher baseline HRQoL scores (e.g. 
CRQ-Dyspnoea 4.4 units), but still reported a significant improvement in 
HRQoL. The COPE II study was a comprehensive 11 month intervention 
involving supervised exercise and education, whereas the SPACE for COPD 
programme, which also had patients with similar disease severity (FEV1 
1.26L; FEV1% predicted 48%) saw significant improvements in CRQ-SR 
dyspnoea scores from only a 7 week unsupervised programme. The SPACE 




the CRQ questionnaire whereas Effing’s study, although statistically 
significantly improved did not meet the MCID for this domain at seven or 12 
months of supervised SM.    
 
Correlations were completed on baseline CRQ-SR scores with the change in 
score at seven weeks. Results suggested that there was a statistically 
significant negative relationship between baseline score and change in score 
in both intervention groups and all domains of the CRQ-SR (figures 5.3, 5.4 
And table 5.7). This means that those with lower baseline scores improved 
more than those with higher baseline scores. This supports the notion that 
those with higher baseline scores have reduced room for improvement and  
supports the use of the SPACE for COPD programme in patients with low 
baseline CRQ dyspnoea scores.  However, when comparing the difference in 
scores between the different MRC grades no statistically significant difference 
was detected, apart from fatigue in the PR group. This is not fully understood 
why, but could be due to smaller numbers in MRC groups 2 and 5.  
 
Maltais et al. (2008) is the only other relevant study that has reported their 
study in line with the CONSORT guidelines for noninferiority studies. It is, 
therefore, useful to compare this study with SPACE for COPD. Maltais et al. 
(2008) used the CRQ-SR to compare an eight week home based exercise 
programme with outpatient PR after four weeks of self-management 
education in both groups. Patients in this study were similar in age to SPACE 
for COPD, but had slightly more severe disease (FEV1% predicted 46%). After 




the PR group in the primary outcome measure of dyspnoea on the CRQ-SR 
scale (between group difference 0.05 95% CI, -0.21 to 0.29). Similarly, the 
SPACE for COPD study found no difference between groups at seven weeks 
but the result is inconclusive regarding noninferiority. For the other domains in 
the CRQ-SR the Maltais et al. (2008) study found a statistical improvement in 
all domains but only the Mastery subscale was clinically significant (mean 
change 0.51 units, p<0.001). This is in contrast to SPACE where no statistical 
or clinical improvements were seen in fatigue, mastery or emotion sub scale. 
The findings of this current study is in line with a previously published pilot 
study of the SPACE for COPD programme in primary care (Apps et al. 2013).  
It is not known why significant changes were not seen in these domains of the 
CRQ, but it could be speculated that the exercise training has driven the 
change in dyspnoea and the a supervised programme is need to influence 
changes in the other domains, as apparent in the PR group. Maltais et al. 
(2008) home based intervention consisted of a comprehensive four week SM 
educational programme delivered in hospital on an outpatient basis and then 
an eight week home programme where and exercise specialist initiated the 
programme in the patients home. Each patient was also loaned a cycle 
ergometer to complete their programme and called every week to encourage 
adherence and detect any problems. It could be this contact with healthcare 
professional staff that has resulted in the statistically significant changes seen. 
Whereas The SPACE for COPD programme involved a ‘one off’ introduction 
to the SM manual with a healthcare professional and two telephone calls.  
The SPACE for COPD programme is less demanding on staff and participant 




actual scores for the CRQ-SR are not presented in the study by Maltais et al. 
(2008), only the change from baseline to 3 months is reported. If baseline 
scores were low then these patients would have more to gain in comparison 
to those on the SPACE for COPD programme. Patients on this study reported 
higher mean baseline CRQ-SR dyspnoea scores (2.58± 0.93 units) than 
those normally seen in PR at Glenfield Hospital. Two studies recently 
published by Harrison report lower mean CRQ-SR Dyspnoea scores (2.37 
units (Harrison et al. 2013b) and 2.35 units (Harrison et al. 2012)) in 
comparison to this study, despite being conducted from the same site. 
Therefore, as dyspnoea score in the SPACE for COPD  group could be 
regarding as slightly higher  than normally seen in patients referred to 
rehabilitation and therefore a ‘ceiling’ affect could have occurred as higher 
scores have limited opportunity for improvement. It is possible that the 
participant’s recruited to this study were not representative of COPD patients 
normally seen. Those with more limiting disease may have preferred the 
security of a fully supervised programme and therefore not volunteered for 
this trial. 
 
One study that found no improvement with CRQ dyspnoea was Bischoff et al. 
(2012) who compared a SM group (mean (SD) age 66 (12) years; FEV1% 
predicted 66 (17)%) with routine monitoring and usual care. The SM group 
received 4 tailored sessions with ongoing telephone support and the routine 
monitoring group received 2-4 consultations a year with a practice nurse. This 
programme involved no exercise training. At 24 months there was no 




CI) -0.16 (-0.42 to 0.11) in the SM group and no differences between the other 
treatment groups in change in scores. Although baseline scores for dyspnoea 
could be considered very high (mean (SD) 5.68 (1.21) units) the lack of a 
exercise component may have effected the potential for change.  
 
Both Effing et al. (2007) and Maltais et al. (2008) studies have shown an 
improvement in HRQoL in patients with mild to moderate COPD. However, 
these studies had longer interventions of 11 months and 12 weeks 
respectively. Although Maltais reported results at three months on completion 
and Effing at seven months part way through the intervention any earlier 
changes may not have been detected. With assessments conduced after a 
longer period the trajectory of any change may not be detected, this might be 
important as to detect components that are successful and to identify suitable 
support strategies. Moore et al.  (2009) reported a significant improvement 
after only eight weeks but as previously mentioned was underpowered. 
Ghanem et al. (2010) also reported a significant impact on HRQoL at eight 
weeks but the profile of these patients were different than the SPACE for 
COPD patients as they were post exacerbation and therefore potentially had 
greater capacity for change. The evidence based guidelines from NICE (2010) 
suggest improvements can be seen in 6 weeks after supervised rehabilitation.  
 
A summary of how the SPACE for COPD programme compares to other 
home based and SM studies based on the CRQ dyspnoea output is 





Figure 5.13 Mean change in CRQ dyspnoea reported in studies from baseline 
to post intervention 
 
Hospital Anxiety and Depression Scale – (HADS) 
COPD is associated with an increased risk of anxiety and depression (Brenes 
2003, van Manen et al. 2002), and increased anxiety can lead to inferior 
clinical outcomes (Eisner et al. 2010). It has been reported that level of 
dyspnoea is a significant precursor to anxiety (Hill et al. 2008). This link 
between level of anxiety and health outcomes makes it a key area to be 
addressed to optimise COPD treatment. 
 
The SPACE for COPD programme showed no significant improvement in 
either anxiety or depression. However, no significant between group 
differences were found between PR and SPACE for COPD. Effing et al. 
(2011) and Bucknell et al. (2012) used the HADS questionnaire. Effing found 
no difference at 12 months in anxiety (mean difference (95%CI) 0.05, -1.00 to 
0.90) and depression scores (-0.41, -1.31 to 0.49), however patients had low 
baseline scores (mean anxiety 4.82 units, depression 4.6 units) so would not 
be classified as having a presence of or symptoms associated with anxiety or 
depression. Mean baseline scores for this current study were also below the 
Negative effect of intervention 





threshold of 8 for possible signs of anxiety and depression, this could, in part, 
explain why no improvements were seen. However, as significant 
improvements were seen in the PR group it may be that supervision and 
support from others in similar situations is needed to impact on these 
domains. Indeed, Bucknall et al. (2012) reported a significant within group 
improvement in anxiety treatment effect (95% CI) -1.06 (-2.08 to -0.03)), but 
not depression. Their programme involved supervised education sessions, 
with several home visits by healthcare professionals. However, only 61% of 
patients returned the follow up questionnaire, therefore those that may have 
felt they had not made any improvement may be more inclined not to return 
the questionnaire and the data could perhaps be biased. The baseline profiles 
of these patients are different to those in the SPACE for COPD programme. 
Bucknall et al. (2012) subjects were those who had been admitted to hospital 
after an acute exacerbation of COPD and had higher (mean; SD) baseline 
anxiety (10.0; 4.5) and depression scores (8.5; 3.9). 
 
Interestingly, in this current study when sub analysis was completed on only 
those with scores of ≥ 8 a significant treatment effect was seen in anxiety 
scores for both PR (-2.07; 95% CI 0.05 to 2.60; p<0.001) and SPACE for 
COPD (-1.32; 95% CI 1.10 to 3.04; p=0.042), and for this subgroup analysis 
there was no between group differences (p=0.34). This highlights that those 
with a possible or probable presence of anxiety secure benefits by using the 
SPACE for COPD programme. No treatment effect was observed with the 
depression score in either PR (p=0.895) or SPACE (p=0.075) group when 




adjusting for baseline anxiety profile (HADS Anxiety ≥8) these findings 
support Bucknall et al. (2012) for the home based SM group. However, the 
finding that PR did not affect patients with scores ≥8 for depression is not in 
line with current literature. Harrison et al. (2012) reported that those with 
higher baseline depression scores had greater improvements in scores after a 
course of PR. As an overall significant change was detected in the PR group it 
could possibly due to the subgroup being underpowered to detect any 




Self-efficacy was measured using the PRAISE questionnaire. No significant 
difference was found between groups at seven weeks (mean difference -2.29 
95% CI, -0.02 to 5.16, p=0.051). However, PR showed a significant 
improvement in PRAISE scores (mean change, 95% CI; PR 2.46, 0.67 to 
4.25, p=0.008; SPACE -0.09, -1.84 to 1.67, p=0.920) whereas SPACE for 
COPD did not. The PRAISE questionnaire was developed specifically to 
measure self-efficacy for PR (Vincent et al. 2011) and may not be suitable for 
home based SM, for example the question “I feel confident that I will be able 
to perform the exercises asked of me during the course of rehabilitation, even 
if I find them difficult” may only be relevant for those in the PR setting. 
However at the start of the trial the questionnaire was viewed to be 
appropriate. As benefits in other variables, such as dyspnoea, are apparent in 




it is theorised that improvements in self-efficacy drive changes in health 
behaviour. This will be discussed in relation to PA in chapter 8. 
 
No other study has used the PRAISE questionnaire to measure self-efficacy 
in a SM trial and despite it being a corner stone of self management 
improvement few studies have measured it. Bucknall (2012) used the COPD 
self-efficacy scale (CSES) and found no significant improvement or treatment 
effect (95% CI; 2.65 (-5.85 to 11.14), p=0.540). It may also be argued that 
patients willing to volunteer for research studies would have a reasonable 




The ISWT was used to assess functional exercise capacity. The group 
difference was statistically significant (-23.90m, 95% CI -46.32m to -1.47, 
p=0.038). Both SPACE for COPD and PR significantly improved from baseline 
to seven weeks (PR, p= <0.001; SPACE, p= 0.015). It is interesting to note 
that the mean change in the ISWT did not meet the MCID in either group. It is 
possible that patients may not have been walking fast enough during their 
training walks and moreover, a lack of progression in the training intensity 
(speed) may have contributed to the limited improvement seen particularly in 
the SPACE for COPD group. Previous work has shown patients with COPD 
can improve their ISWT distance with the same exercise programme (Evans 




was due to non-adherence to the prescribed speed of walking during home 
training sessions which has not been monitored. 
 
The ESWT was used to measure endurance capacity. The between group 
difference (-132.78sec, 95% CI -244.63 to -20.94sec) was significant, and 
both groups significantly improving from baseline to seven weeks (mean 
change, (95% CI); PR 345.70sec   (260.20 to 431.20) sec; SPACE 212.91, 
(139.49 to 286.34) sec). The mean group change was above the MCID 
threshold for both groups. These results were are expected and are in line 
with previous reports (Apps et al. 2013, Sewell et al. 2006, Evans et al. 2009). 
 
The COPE II study (Effing et al. 2011) used the ISWT as their primary 
outcome measure and found similar improvements to the SPACE programme, 
reported at seven months (12.2m, SE 10.6, within group change). They found 
a significant between group difference (35m.1m; 95% CI 8.4 to 61.8) with their 
control group who received a single 2 hour SM session. The SPACE for 
COPD programme had a larger increase in ISWT (18m 95% CI 3 to 32) at 
seven weeks. The SPACE for COPD study is a noninferiority trial and 
therefore does not have a control group which receive no intervention. It has 
been reported that patients with COPD gradually decline over time in their 
exercise capacity (Griffiths et al. 2000) and therefore even though only small 
improvements have occurred, if no intervention had been received a decline 





This is the first study to show an improvement in ESWT after only seven 
weeks of a home based SM programme. Effing et al. (2011) found no 
significant improvement in ESWT as measure by distance in the COPE II 
study at 7 months (mean (SD) baseline ESWT 679 (553) metres; change at 7 
months 106 (67) metres). However, 12 of their subjects completed the 20 
minute test at baseline and therefore had no room for improvement.  
 
The six minute walk test (6MWT) is a more widely reported measure of 
exercise capacity and is important to consider those studies that have 
employed this test. The 6MWT was not chosen for this study as it is not 
routinely used in PR at Glenfield Hospital.  Of these studies that have used 
the 6MWT as an outcome measure for a home based programme Ghanem et 
al. (2010), Gȕell et al. (2008) and, Mendes et al. (2010) all found a significant 
improvement in distance covered. These studies ranged from an 8 to 12 week 
home based intervention. However, all these studies had less than 35 patients 
in their home based groups so are very likely to be underpowered. 
Interestingly, both Maltais et al. (2008) and Monninkhof et al.  (2003a), whose 
studies were adequately powered, did not find any improvement in 6MWT 
distance measured, respectively, at 3 months and 6 months, post intervention. 
 
The SPACE for COPD intervention involved no supervised exercise sessions 
apart from the initial introductory meeting where patients had their walking 
programme explained and demonstrated to show them the speed to which 
they were prescribed to walk. The Maltais and Monninkhof studies both had 




being provided with exercise equipment and home visits. It is therefore 
surprising that neither of these studies found an improvement in exercise 
capacity. One explanation of why the Monninkhof study may not have seen 
improvements in exercise capacity could be due to the exercise intensity not 
being adequate enough to elicit a training effect. The training intensity was not 
standardised and negotiated between the therapist and participant and 
therefore potentially sub therapeutic. The SPACE programme, although, 
unsupervised prescribes walking at 85% of maximal walking capacity and 
therefore, theoretically high enough to induce a training effect in as little as 
seven weeks. Maltais et al (2008) who reported no improvements in 6MWT 
distance at 12 weeks prescribed cycling exercise at 60% of the maximal work 
rate for 40 minutes 3 times a week. The exercise intensity for the home based 
group was lower than the usual care group due to safety reasons, but their 
target time was greater to compensate. It is highly likely that no improvements 
were detected in the 6MWT as cycling was prescribed as the mode of training 
which may not be specific enough to impact on walking. The mode of training 
chosen did impact on the cycle endurance test completed as significant 
improvements were seen at 12 weeks in cycling endurance time.  
 
These findings above highlight the difference between exercise testing 
protocols. The 6MWT has been shown not to be the most responsive test to 
show the effects of PR (Laviolette et al. 2008), however, it is commonly 
reported, and may be more appropriate at discriminating between the severity 
of disease (Troosters et al. 2002). Improvements in the 6MWT are reliant on 




achieve and does not reflect changes in endurance time. This lack of 
responsiveness in the test protocol may be the reason why minimal effects 
were detected in Maltais’s study. Maltais et al. (2008) also used a constant 
work rate (CWR) test, which measured cycle endurance time at 80% 
VO2peak. CWR is considered to be more responsive at detecting long term 
improvement in functional performance after PR (Ong et al. 2004). It reflects 
endurance capacity which is the focus of most PR programmes, whereby 
programmes prescribe increasing time rather than intensity to instigate 
progression and health benefits. This current study demonstrated a significant 
improvement in the ESWT in both the PR and SPACE for COPD groups. The 
ESWT test is a CWR test and therefore is perhaps more responsive to the 
effects of exercise training than the ISWT. The ISWT progressively increases 
the walking speed throughout the duration of the test and are appropriate at 
indicating peak exercise capacity and has been used to prescribe the intensity 
of the ESWT. However, it may not be the best protocol to assess changes in 
PR which are not based on increasing exercise intensity. 
 
The SPACE for COPD programme significantly and clinically enhanced 
endurance capacity as demonstrated by the improvements detected in the 
ESWT (figure 5.9). However, limited improvements were reported in ISWT 
distance. It is not clear as to why this is the case, but it could be due to the 
nature of the protocol or those being recruited on to the study having higher 
than normally reported ISWT distance at baseline and therefore, limited room 
for improvement. However, it could most likely be explained by participant not 




the PR group showed a statistically significant change, but the mean change 
did not meet the MCID. A possible explanation for why the PR group did not 
improve their ISWT distance as anticipated could be due to them not 
completing the home component of the programme at the appropriate 
intensity. Analysis of change in scores from baseline to seven weeks supports 
this theory in that those with lower baseline scores improve the most. 
However, Evans et al. (2009) reported that baseline ISWT level did not predict 
change in ISWT distance after PR. 
 
A summary of how the SPACE for COPD programme compares to other 
home based and SM studies based on the ISWT outcome is presented in 
Figure 5.14. 
 
    Change in ISWT distance (m) 
Figure 5.14 Mean change in ISWT distance (m) reported in studies from 
baseline to post intervention 
 
Reasons for this inconsistency in finding in HRQoL, HADs and exercise 
performance is in need of further consideration and highlights the difficulty in 
predicting successful outcomes of rehabilitation programmes. Engagement in 
the SPACE for COPD may be a key component. The premise for the 
intervention is to offer an alternative to PR and therefore reach patients that 




been willing to agree to the programme as they have been advised to do PR 
by a healthcare professional and seen the limited supervision provided by the 
programme as an easy way not to adhere to the exercise programme. 
Although progress was assessed during the telephone calls, adherence to the 
exercise component of the SPACE for COPD study was not fully monitored. It 
is also possible that the SPACE for COPD programme was too ‘light touch’ for 
some participants that require supervision to motivate adherence to the 
programme. Out of those asked to comment on their preferred treatment, 51% 
wanted the SPACE for COPD and only 25% want PR. This meant that 29% in 
the PR and only 5% in the SPACE for COPD received a treatment that wasn’t 
their preference. Although patients were aware that they would be randomly 
assigned a group, not getting the treatment they preferred may have affected 
their motivation and engagement in the programme. It is out of the scope of 
this thesis but it would be of use determine the characteristics of those who 
did and didn’t respond to the SPACE for COPD programme. Future work may 
also want to evaluate the SPACE for COPD programme offered earlier at the 
time of referral and not at a point when patients are already expecting 
supervised outpatient PR.   
 
No statistically significant difference was detected with change in scores at 
seven weeks in any outcome measure between baseline MRC dyspnoea 
grades. The exception was the fatigue domain of the CRQ-SR in the PR 
group. This may be due to it being underpowered, or potentially indicates all 
MRC grades improve to broadly the same level. However, correlation analysis 




groups for the CRQ-SR dyspnoea (figure 5.3 and 5.4), and for the ISWT in the 
SPACE for COPD group (figure 5.8). This means that those with lower or 
poorer scores improved the most. It would be interesting to determine the 
characteristics of those who respond to the intervention programme, however, 
is out of the scope of this thesis. 
 
5.8 Limitations 
A number of limitations have been discussed where relevant to the specific 
outcome measure. However, a number of methodological limitations need 
further consideration. 
 
A key limitation is that this study was only single blinded and not double 
blinded and individual preference to treatment modality could have 
significantly affected motivation to take part. The premise of SPACE for 
COPD is to offer an alternative to hospital based PR and not to replace it. 
However, due to study design and rigor it was not considered appropriate to 
allow patients to choose which group they were assigned to. As the two 
interventions are clearly distinct it is highly likely that patients had a 
preference as to which group they would have preferred to be randomised to. 
Hence, if they were randomised to a group they didn’t want this could have 
resulted in non-compliance to either the SPACE for COPD programme or to 
the home exercise aspect of PR. There was a large dropout rate seen in this 
study which is higher than normally seen in PR. 46 participants were 
classified as ‘lost to follow up’, these were the patients that did not complete 




for a proportion of participants the intervention they were allocated to did not 
meet their expectations.  
 
Another limitation of the study procedure was that adherence to the SPACE 
for COPD programme was not recorded and no pre-specified definition of 
compliance was determined at the start of the programme. It would have been 
useful to record this as it could be expected that those who complied with the 
programme achieved more enhanced outcomes. It has also resulted in the 
inability for per protocol analysis to be completed. In addition, as the SPACE 
for COPD programme is unsupervised it may have been difficult for some 
patients to consistently meet the prescribed walking speed without it being 
reviews as in PR, so it may be that a number of patients have either walked at 
a pace too slow to elicit training benefits or a pace too fast so they fatigue 
early and de-motivate themselves by not seeing any improvement. 
 
In future it would be useful to determine which component of PR and the 
SPACE for COPD programme is effective. Those in the PR had weekly 
contact with a healthcare professional and met with a group of patients 
undergoing the same experiences and the same treatment. It could be this 
contact rather than the exercise training and education that have affected a 
number of the outcome measures. Likewise how effective were the telephone 








The aim of this chapter was to determine if the SPACE programme is a 
noninferior alternative to usual care PR. The results of this study show that 
SPACE for COPD significantly improve subjective experiences of dyspnoea to 
a similar level to PR, however, it is inconclusive as to its noninferiority. 
SPACE also enhances endurance capacity which is noninferior to PR. 
Overall, SPACE does elicit some key health benefits over a seven week 
period.  
 
The SPACE for COPD programme did not produce significant improvements 
in anxiety and depression, however, mean values were low. A sub-group 
analysis of those with at least a possible presence of anxiety and depression 
demonstrated a significant improvement. The individual need of each patient 
needs to be assessed when determining the most appropriate form of support 
for exercise training. 
 
This is the first noninferiority trials conducted in the UK that has shown that a 
home based self-managed support model of care elicits significant benefits 
over a short intervention period. The gains in the SPACE for COPD group did 
not fully match those achieved in the PR, but as they were statistically and 
clinically significant warrant consideration for patients who would not 




Chapter 6 - The effectiveness of the SPACE for COPD 
programme in comparison to Pulmonary Rehabilitation six 
months post intervention 
 
6.1 Introduction 
The effectiveness of SPACE for COPD has been reported over the short term 
(discussed in chapter 5). However the challenge for successful intervention 
programmes is how to maintain these improvements over the long term. 
Although a significant decline is seen from completing PR to follow up 
assessment (most commonly reported as six or twelve months post 
intervention), a number of studies (Foglio et al. 1999, Griffiths et al. 2000, 
Maltais et al. 2008, Singh et al. 1998) have reported exercise capacity 
significantly higher than baseline levels.  Internationally, formal maintenance 
programmes vary and consist of anything from weekly telephone calls and 
monthly reinforcement sessions (Ries et al. 2003) to extended PR 
programmes (Berry et al. 2003). Spencer (2010) investigated a maintenance 
programme of weekly supervised exercise incorporating a home exercise 
programme and found that 6 MWD and quality of life were maintained at 12 
months. Spencer and others highlights the impact of a maintenance 
programme. However, it is not clear as to which aspect of the programme that 
has contributed to maintaining these scores. Was it the home programme or 





The potential of SPACE for COPD is in the development of self-management 
techniques and skills which have a lasting effect and result in long term 
behaviour change which will have a positive impact of health status. It is 
possible that the SPACE for COPD programme could result in longer term 
benefits as it promotes lifestyle changes rather than a short term one off 
treatment. Also, as home exercise is the focus this may support behaviour 
change as there is no transition period from an outpatient environment to 
home.   
 
This chapter will describe the long term (six months) changes of the 
randomised control trial. Patients that had completed a seven week 
assessment were contacted six months later and asked to return for a follow 
up assessment. No other contact was made during this period. This chapter 
will focus on the following: 
 Between group differences from seven weeks to six months 
 Within group changes from seven weeks to six months 
 
6.2 Aim 
The aim was to determine if the SPACE for COPD programme is noninferior 
(as good as) to usual care PR in the treatment and management of COPD, six 






A full description of the methods of this study can be found in chapter 3. This 
chapter describes the follow up period of the trial.  
 
All participants who had not withdrawn from the study were invited to attend 
the hospital to be reassessed six months after completing the intervention. 
Patients did not have any contact with the research team during this period 
and therefore assessments were kept blinded. Patients in both intervention 
groups were encouraged to continue with their walking programme at their 
seven week assessment, but no other support was given. 
 
6.4 Outcome measures 
A full description of the outcome measures used in this study are described in 
Chapter 3.6. The key outcome measures explored in this chapter are 
 Chronic respiratory questionnaire – Self reported (CRQ-SR) 
o Dyspnoea, fatigue, emotion and mastery 
 Hospital Anxiety and Depression Scale (HADS) 
 Incremental shuttle walk test (ISWT) 
 Endurance shuttle walk test (ESWT) 
 Pulmonary Rehabilitation Adapted Index of Self Efficacy (PRAISE) 
 
6.5 Statistical analysis 
Statistical analyses were completed using the statistical package IBM SPSS 




characteristics between those that completed the study and those who 
withdrew. Repeated measures ANOVA were conducted on all outcome 
measures to determine any between group differences. For outcome 
measures with a statistically significant level of sphericity the Greenhouse-
Geisser correction was used, and for outcome measures with no statistical 
significance the test of assumed sphericity was used. A significance level of 
p=<0.05 was applied.   
 
6.6 Results 
287 patients with COPD were recruited to the study. 142 were randomised to 
the PR intervention and 145 to the SPACE for COPD intervention. Of these 
patients 84 from the PR group and 95 from the SPACE for COPD group 
completed the seven week assessment. At the time of the six month 
assessment a further 14 (17%) withdrew from the PR group and 20 (21%) 
from the SPACE for COPD group. Therefore 70 from the PR group and 75 
from the SPACE for COPD group completed the six month assessment. 
Reasons for non-completion of the six month assessment are highlighted in 
figure 6.1.  An independent t-test was completed on the continuous data and 
chi squared on the categorical data to determine if there was any differences 
in the baseline profile of those that completed the study and those that did 
not. Although higher mean scores were observed in both the exercise 
performance tests they were not statistically significant, nor were any other 






















Figure 6.1 flow diagram of study from seven weeks to six months with 








Included in 7 
week analysis=84 
Included in 7 week 
analysis=95 
Included in 6 
month analysis=70 



































Not complete = 14 
RIP = 3 
Unable to contact = 8 
Family problems = 1 
Comorbidity = 1 
Restarted PR = 1 
  
Not complete = 20 
Unable to contact = 8 
DNA = 3 
Started PR = 2 
Declined = 3 
Family problems = 1 




Table 6.1 Baseline characteristics of those that completed and did not 






Age (yrs) 67.52 (8.63 65.46 (9.10) 0.958 
Male:Female (n;%) 95(66%):48(34%) 93(64%):52(36%) 0.682 
BMI (m/kg2) 27.06 (6.16) 28.20 (2.22) 0.126 
FEV1 (litres) 1.23 (0.55) 1.29 (0.55) 0.365 
FVC (litres) 2.72 (0.92) 2.69 (0.82) 0.776 
MRC (n:%) 
     2 
     3 
     4 












SpO2 rest % 90.04 (5.42) 90.36 (5.78) 0.630 
Smoking status 
(n:%) 
    Current smoker  
    Never smoked  












Pack years 45.13 (30.44) 47.32 (32.56) 0.566 
CRQ-SR 
    Dyspnoea 
    Fatigue 
    Emotion 

















    Anxiety 










PRAISE 44.59 (7.24) 44.24 (7.74) 0.710 
ISWT (distance) 270.10 (150.68) 237.45 (147.17) 0.066 





Health related quality of life (HRQoL) 
Chronic Respiratory Questionnaire – Self Report 
For the primary outcome of CRQ-SR dyspnoea the repeated measures 
ANOVA showed Machly’s test of sphericity to be not significant (p=0.78), 
therefore, no correction was needed and assumed sphericity was used. Table 
6.2 shows the within subject effects of the time and time and intervention, and 
between group effects of the CRQ-SR dyspnoea score. 
 
 
Table 6.2 Significance values for within and between group effects for CRQ-
SR Dyspnoea at six months 
 Within subject effects Between group 
effects 
 Time Time*Intervention  
CRQ-SR 
Dyspnoea 
<0.0001 0.063 0.38 
 
The mean (SD) CRQ-SR dyspnoea score for each time point is presented in 
table 6.4 and figure 6.2 
 
Table 6.3 shows the percent of patients meeting the MCID for CRQ-SR 






Table 6.3 Percent of patients meeting the MCID for CRQ-SR Dyspnoea in 
both intervention groups 
 Change <0.5 
% 
Change ≥ 0.5 
% 
Range (-7 to 7) 
Pulmonary 
Rehab 
54 46 -1.53 to 4.40 




Table 6.4 Mean (SD) baseline, seven week and six month scores and change 





mean (SD; n=70) 
SPACE 




Baseline 2.42 (0.91) 2.58 (0.93) 0.16 (-0.05 to 0.41) 
7 weeks 3.38 (1.18) 3.11 (1.23) -0.27 (-0.62 to 0.15) 
6 months 3.08 (1.25) 2.80 (1.13) -0.28 (-0.69 to 0.13) 
Mean change 
(baseline to 6 
months) 






Figure 6.2 Mean (SD) CRQ-SR dyspnoea scores for PR and SPACE over the 









Figure 6.3 plots the change and 95% CI in the CRQ-SR dyspnoea score from 
baseline to six months. Overall the results show that for CRQ-Dyspnoea there 
was no difference (p=0.38) between groups at six months (table 6.2). 
However, the noninferiority margin of 0.5 units (MCID for CRQ-SR) is 
breached  by the 95% CI of the ∆SPACE-PR therefore, this still leads to some 
uncertainty as to the effectiveness of SPACE for COPD at 6 months (figure 
6.3).   
 
Secondary outcomes 
The other domains that make up the CRQ-SR of fatigue, emotion and mastery 
were analysed. Mauchly’s test of sphericity was not significant in all three 
domains (fatigue p=0.580; emotion p=0.819; mastery p=0.171). Repeated 
measures ANOVA findings are presented in table 6.4. 
 
Table 6.5 Significance values for within and between group effects for CRQ-
SR Fatigue, Emotion and Mastery 
 
 




 Time (p=) Time*Intervention 
(p=) 
 
Fatigue <0.0001 0.210 0.744 
Emotion  <0.0001 0.031 0.620 




The mean (SD) values for the CRQ-SR domains at baseline, seven weeks, 
six months and mean change from baseline to six months are presented in 
table 6.6 and figures 6.4, 6.5 and 6.6. The findings suggest that after an initial 
increase in scores at seven weeks (although not significant for the SPACE for 
COPD group), they have returned to baseline levels at six months. However, 
this is apparent in both intervention groups as there is no significant difference 





















Table 6.6 Mean (SD) Baseline, seven week and six month CRQ-SR scores 




mean     
(SD; n=70) 
SPACE 









Baseline 3.36 (1.20) 3.42 (1.19) 0.06 (-0.24 to 
0.35) 
7 weeks 4.09 (1.49) 3.71 (1.22) -0.38 (-0.83 to 
0.01) 
6 months 3.47 (1.31) 3.44 (1.40) -0.03 (-0.53 to 
0.39) 






Baseline 4.37 (1.24) 4.41 (1.24) 0.04 (-0.30 to 
0.32) 
7 weeks 4.92 (1.03) 4.56 (1.20) -0.36 (-0.71 to -
0.01) 
6 months 4.51 (1.23) 4.28 (1.32) -0.23 (-0.59 to 
0.28) 






Baseline 4.36 (1.30) 4.50 (1.31) 0.14 (-0.22 to 
0.46) 
 7 weeks 4.94 (1.19) 4.78 (1.31) -0.16 (-0.58 to 
0.20) 
6 months 4.61 (1.27) 4.54 (1.33) -0.07 (-0.55 to 
0.44) 



















Figure 6.6 Change in mean CRQ-SR Mastery at baseline, seven weeks and 
six months 
 
Anxiety and Depression 
Anxiety and depression were measured using the HADS questionnaire. 
Mauchly’s test of sphericity was not significant for anxiety (p=0.649), therefore 
spericity assumed was used, but for Depression scores it was significant 
(p=0.042), therefore, Greenhouse-Geisser was used to correct for this. 










Table 6.7 Significance values for within and between group effects for Anxiety 
and Depression scores at six months 
 
 
Mean baseline, seven weeks, six months and changes from baseline to six 
months for anxiety and depression scores are presented in Table 6.7 and 
figures 6.7 and 6.8. Lower scores indicate lower levels of anxiety or 
depression. The data shows that there is a significant effect of time for both 
anxiety and depression and that there is no difference between the 
interventions at six months. However, as the MCID of 1.5 units is not achieved 
during any time point for either group there is no clinically significant change 






HADS Domain Within subject effects Between group 
effects (p=) 
 Time (p=) Time*Intervention 
(p=) 
 
Anxiety 0.003 0.251 0.599 




Table 6.8 Mean (SD) Baseline, seven week and six month HADS and change 





mean     
(SD; n=70) 
SPACE 



















7.96 (4.13) 7.31 (4.31) -0.65 (-2.06 to 
0.76) 
















6.52 (3.58) 6.26 (3.64) -0.26 (-1.45 to 
0.94) 












Figure 6.8 Change in mean HADS Depression scores at baseline, seven 





The threshold for someone to be considered to have a possible presence 
anxiety or depression is a score of 8 or above in either domain on the HADS. 
Therefore, as the mean anxiety and depression scores were below this level a 
sub group of those with baseline score above or equal to 8 in anxiety and 
depression are presented in table 6.9 and figures 6.9 and 6.10 
 
Table 6.9 Mean (SD) Baseline, seven week and six month HADS and change 
in scores from baseline to six months for PR and SPACE for those with 













































































(-1.64 to 1.68) 

















Figure 6.10 Change in mean HADS Depression scores at baseline, seven 






Self-efficacy was measured using the PRAISE questionnaire. Mauchly’s 
sphericity was not significant (p=0.194), therefore, sphericity was assumed. 
Within and between group effects are presented in table 6.10. Mean (SD) 
scores are presented in table 6.11 and figure 6.11. Results suggest that 
although small, but significant (p=0.001) changes in self efficacy occurred 
over time these changes were in a negative direction meaning self-efficacy 
was lower at six months than at baseline in both intervention groups. 
 









 Within subject effects Between group 
effects (p=) 
 Time (p=) Time*Intervention 
(p=) 
 




Table 6.11 Mean (SD) Baseline, seven week and six month PRAISE scores 




mean (SD; n=70) 
SPACE 






























There was a number of participants in the PR (n=4) and SPACE for COPD 
(n=16) groups that were unable to complete the walking tests at the six month 
assessment period. However, did complete the questionnaires, therefore the 
exercise performance data presented is based on 125 participants. Exercise 
performance was measured using the ISWT and the ESWT. Mauchly’s test of 
sphericity was significant for the ISWT (p=0.029) and the ESWT (p=0.001), 
therefore Greenhouse-Geisser was used. Results from the repeated 
measures ANOVA are presented in table 6.12. Results suggest that there was 
a significant effect of time (ISWT and ESWT both p=<0.0001), and there were 
no difference between interventions in the ISWT (p=0.463) and the ESWT 
(p=0.912). 
 
Table 6.12 Significance values for within and between group effects for ISWT 
and ESWT scores (n=125) 
 
The mean baseline, seven week, six months and change in scores from 
baseline to six months for the ISWT and the ESWT are presented in table 
6.13 and plotted in figures 6.10 and 6.11. The ISWT suggests a significant 
 Within subject effects Between group 
effects (p=) 
 Time (p=) Time*Intervention 
(p=) 
 
ISWT <0.0001 0.344 0.463 




effect of time, but six month scores have returned to near baseline levels. The 
ESWT also significantly changes over time, with the PR group exceeding the 
MCID of 186 seconds through to the six month assessment (mean change 
255.56 seconds). The SPACE for COPD group has a mean score close to the 
MCID (176.85 seconds) and there are no significant differences between 
groups at 6 months.  
 
Table 6.13 Mean (SD) Baseline, seven week and six month ISWT and ESWT 
scores and change in scores from baseline to six months for PR and SPACE 
 














































































Figure 6.12 Change in mean ISWT distance (m) at baseline, seven weeks 
and six months 
 
 
Figure 6.13 Change in mean ESWT time (seconds) at baseline, seven weeks 











Figure 6.15 Change in ESWT time (seconds) from baseline to six months 
 
Figures 6.12 and 6.13 plot the change and 95% CI in the ISWT and ESWT 
score from baseline to six months. Overall the results show that for the ISWT 







6.11). Results from the ISWT would suggest that SPACE in noninferior and 
neither the ∆SPACE-PR or it’s 95%CI breach the noninferiority margin. 
However the mean change in score do not met the MCID of 50m, there is 
some uncertaininty of the effectiveness of PR on this measure. The results 
from the ESWT show that the 95% CI of the  ∆SPACE-PR changes breach 
the noninferiority margin and therefore leave some uncertainty as to the 
noninferiority of SPACE for COPD over PR. 
 
6.7 Discussion 
Chapter 5 presented the findings of the SPACE for COPD trial at 7 weeks. 
This chapter aimed to address the six month follow up results of the SPACE 
for COPD trial in comparison to conventional PR. The overall trial was 
designed to detect changes in CRQ-SR dyspnoea at seven weeks and 
required a minimal sample size of 77 in each group, this was achieved at 
seven weeks. By six months 70 patients completed the six month assessment 
in the PR group and 75 in the SPACE for COPD group. A consequence of not 
achieving enough patients to meet statistical power is the increased risk of a 
type II error, where the null hypothesis is not rejected when it is in fact false. 
Statistical power was met at seven weeks, but the six month data did not, 
therefore, must be interpreted with caution. This section will discuss the 
findings of the six month follow up trial in relation to other research studies, 
evaluate the limitations and draw conclusions. 
 
Fifty per cent of those recruited at baseline did not complete the six month 




that completed and those that did not. Reasons for withdrawal between the 
seven week assessment and the six month assessment are reported in figure 
6.1. As previously highlighted in Chapter 5 baseline characteristics did not 
concur with what has frequently been reported in clinical practice in this centre 
for a number of measures. MRC scores are towards the less severe end of 
the scale compared to the expected profile of patients in PR (Evans et al. 
2009), however, no difference was seen in change in scores at seven weeks 
in the different MRC group scores, this supports Evans et al. (2009) who 
reported that all MRC grades show comparable improvements in ISWT 
distance.  
PR is effective at improving health outcomes of patients with COPD. Griffith 
(2000) demonstrated that a 6 week PR programme enhanced walking 
performance and HRQoL, however, once the programme ceased these 
improvements progressively diminished at 12 months. Interestingly, the 
control group that received no intervention declined at six weeks and 12 
months from baseline. Due to the initial increase in health outcomes during 
PR, but despite the subsequent decline, clinical and statistical differences 
were detected between the groups at 12 months (Griffith et al. 2000). 
 
Although initial improvement were seen in both the PR and SPACE for COPD 
groups maintaining these improvements is crucial. Various strategies for 
maintaining these improvements include repeat PR, home based and 
community based programmes and telephone calls (Berry et al. 2003, Bestall 
et al. 2003, Brooks et al. 2002, Cockram, Cecins and Jenkins 2006, Güell et 




2010), although non are conclusive (Bolton et al. 2013, Spruit et al. 2013). 
This section will discuss the outcome measures and then aim to put the 
SPACE for COPD programme in context to other types of programmes and 
maintenance strategies. 
 
Health Related Quality of Life (HRQoL) CRQ – SR Dyspnoea, Fatigue, 
Mastery and Emotion 
The primary outcome was the CRQ-SR dyspnoea. The repeated measures 
ANOVA suggests there is no statistical difference between the PR and 
SPACE for COPD groups six months after the end of the interventions 
(p=0.38, Table 6.2). The results also show there is a significant effect of time 
regardless to which group patients were randomised to (p=<0.0001, table 
6.2), meaning both groups significantly improved over time. The mean (SD) 
changes from baseline to six months were 0.66 (1.20) for the PR group and 
0.22 (1.24) in the SPACE for COPD group. The mean score only met the 
MCID of 0.5 units in the PR group. However there was little difference 
between groups when looking at the number of people meeting this threshold. 
46% in the PR group met this MCID compared to 45% in the SPACE for 
COPD group. The range of scores were much larger in the SPACE for COPD 
group which could account why there was a lower mean change, but similar 
numbers met the MCID in comparison to the PR group.   Figure 6.3 shows the 
changes in CRQ-SR dyspnoea score from baseline to six months. Despite the 
mean difference in the change scores between SPACE for COPD and PR not 




this level meaning there is still some uncertainty as to the noninferority of the 
SPACE for COPD programme over PR.   
 
There is an inconsistency of outcome and duration of treatment but the most 
relevant papers to consider are the Maltais et al. (2008) and Effing et al. 
(2011) studies. The home based Maltais et al. (2008) study used the CRQ-SR 
dyspnoea as the primary outcome measure for their noninferiority trial of 
home based self-managed rehabilitation in comparison to usual outpatient 
care. This study found that both their interventions led to improvements and 
that the home programme was not inferior to the outpatient programme at 
three months and one year. However, they did not report any findings at four 
weeks to determine the effect of their front loaded education programme. This 
study reported mean differences (95% CI) in CRQ-SR dyspnoea score from 
baseline to three months of 0.82 (0.64 to 1.01) and from baseline to one year 
of 0.62 (0.43 to 0.80) in the home group. These figures show a similar 
increase in dyspnoea score to the SPACE for COPD programme in the short 
term, but the one year change in score in the Maltais et al. (2008) study is 
greater than the six month change in the SPACE for COPD group (mean 
change 0.22 SD 1.24). The difference in the programmes could be explained 
by the more comprehensive packaged offered by the Maltais study. This study 
comprised of eight educational sessions over four weeks followed by three 
times a week for eight weeks exercise based programme. Cycle ergometers 
were loaned to the participants and an exercise specialist initiated the 
programme in the patient’s home. Intensity on a cycle ergometer is easier to 




training may be the driving force behind changes in dyspnoea. During this 
eight week programme patients were also telephoned weekly to reinforce the 
importance of exercise and to detect any problems. This study also had a 
maintenance element to their programme where each patient was given 
personalised exercise training recommendations and were contacted every 
two months to reinforce intended behaviours. Patients were also able to call 
their case manager for advice throughout the one year trial. In contrast 
patients in the SPACE for COPD intervention, although were advised to 
continue with their walking programme and to use the SPACE for COPD 
manual had no contact with the research team between their seven week and 
six month assessments.  
 
Effing et al. (2011) studied patients with mild to moderate COPD in a 
community based programme and also reported CRQ-SR dyspnoea scores. 
This study reported significant mean (SE) changes of 0.37 (0.13) at seven 
months and 0.30 (0.13) at 12 months. SPACE for COPD shows an initial 
mean (SD) change at seven weeks of 0.66 (1.20), which is above the MCID 
and at six months 0.22 (1.24), which is broadly a similar magnitude to Effing 
et al. (2011) findings. Effings study is comparable with Maltais (2008) study in 
that patients received treatment between each assessment point whereas no 
contact was made between the seven week and six month assessments in 
the SPACE for COPD trial. It is therefore possible that more support and 
interaction from healthcare professionals is required to maintain these 





Fatigue, emotion and mastery were also reported as part of the CRQ-SR. All 
domains showed no significant between group effects at six months (table 
6.4). Within group effects do suggest a significant effect of time, however, the 
improvements shown at seven weeks in the SPACE for COPD group do not 
meet the MCID of 0.5, so are clinically not significant, and have returned to 
baseline levels at six months. The PR group do increase their score above the 
MCID at seven weeks but they have also declined at 6 months, falling back to 
baseline levels (Table 6.5). Therefore, SPACE for COPD can maintain 
baseline health related quality of life measures, although a clinically significant 
difference was not detected in the SPACE for COPD programme at six 
months, results were maintained around baseline levels, wheras the PR 
produced an initial increase which then declined. Maintaining these baseline 
levels may be clinically important. 
 
Maltais et al. (2008) found small, but statistically significant improvements 
(mean; 95%CI) at one year in fatigue (0.25; 0.66 to 0.44), emotion (0.28; 0.14 
to 0.43) and mastery (0.39; 0.23 to 0.57) in home based group. Effing et al. 
(2011) demonstrated no statistically significant improvement in these domains 
reporting treatment effects (95% CI) at one year in fatigue of 0.09 (-0.34 to 
0.52), emotion 0.10 (-0.22 to 0.42) and mastery 0.11 (-0.21 to 0.43). However, 
for both these studies (Effing et al. 2011, Maltais et al. 2008) the changes in 
scores are small and clinically insignificant. A possible reason why Effing et al. 
(2011) did not show any changes at one year could be that the study included 
milder patients (FEV1 % predicted 50%) with higher baseline HRQoL scores, 





As previously discussed both the Maltais et al. (2008) and Effing et al. (2011) 
studies were comprehensive programmes involving interventions up to the 
one year assessments, whereas the SPACE for COPD intervention has also 
shown beneficial findings with a programme that is less demanding on 
resources.  
 
Other SM studies have used the SGRQ as the outcome measure (Khdour et 
al. (2009), Bourbeau et al. (2003) and Bucknall 2012). Khdour et al. (2009) 
reported a significant treatment effect in the symptoms, impact and total score 
domains at six months, but by one year this effect had been reduced and was 
only significant in the symptoms (p=0.04) and impact (p=0.03) domains. 
Likewise, Bourbeau et al. (2003) detected an initial significant treatment effect 
in the impact and total score after the intervention and by the one year follow 
up assessment a significant difference was only seen in the total score. 
Bucknall (2012) only found a significant effect on the impact score at one 
year. These studies reflect this current study in that after initial gains from 
their respective interventions, decline follows. By the follow up assessment 
some of the initial gains are evident however, the issue of how best to 
maintain the benefits seen as a result of the intervention remains.  
 
Overall, the SPACE for COPD programme reflects other studies, in that home 
based self-managed interventions do have an impact on HRQoL which 
declines post intervention. Evidence shows an initial increase as a result of 




decline once the programme has finished. The challenge to healthcare 
providers is to devise an appropriate model to sustain these benefits. Possible 
maintenance strategies will be discussed in chapter 9 
 
Hospital Anxiety and Depression Scale – (HADS) 
 
Results presented in figure 6.6 suggest that there was no between group 
difference at six months in anxiety (p=0.599) and depression (p=0.989) and 
that there was a significant effect of time in both domains. Figures 6.7 and 6.8 
show a small reduction in anxiety and depression at seven weeks which 
return to baseline levels at six months. These changes in both interventions 
are clinically insignificant. Scores of ≥ 8 are considered to be at least a 
possible presence of anxiety or depression on the HADS scale. As the mean 
score for both these measure were below this level a subgroup of those with 
baseline score ≥ 8 were preseneted in table 6.9 and figures 6.9 and 6.10 
These figures show a greater decline at seven weeks and six months in 
comparison to the group as a whole. The mean (SD) change in anxiety at six 
months  was -1.17 (2.95) in the PR and 1.10 (3.67) units in the SPACE for 
COPD group. Therefore, analysis would suggest that those with higher 
baseline scores for anxiety have the greatest improovement.  Change in score 
for those with baseline score of  ≥ 8 for depression show a slightly greater 
improvement in comparison to the group as a whole, but the impact is less 





Only a limited number of home based SM studies have reported an impact on 
anxiety and depression. Effing et al. (2011) found no effect on anxiety or 
depression at 12 months, however, had low baseline levels with group means 
of less than the threshold of 8 for both domains. In contrast Bucknall et al. 
(2012) did report a change (mean;95% CI) in anxiety at 12 months (treatment 
effect -1.06; -2.08 to -0.03, p=0.044). Bucknall et al. (2012) participants had 
baseline scores which did breach this threshold for possible presence of 
anxiety (mean; SD, 9.7 (4.6)). The subgroup analysis from this study supports 
the premise that self managed programme can have an effect on those with 
higher baseline levels of anxiety. However, in contrast to this study Bucknall 
et al. (2012) patients had been admitted to hospital with an exaserbation of 
COPD so are likely to have different causes of anxiety in comparison to this 
study of stable COPD patients. This study also involved supervised education 
with home visits. 
 
Self-Efficacy 
Self-efficacy was measured by the PRAISE questionnaire. Lower scores 
mean lower self-efficacy. There was a significant effect of time (p=0.001) and 
no difference between groups (p=0.271) at six months. However, scores at six 
months were lower than baseline, meaning self efficacy had reduced in both 
groups. As described in chapter 5 there is some uncertainty as to the 
appropriatness of the PRAISE tool used to measure self efficacy as it may 
have been too specific to PR. Although only a small reduction is reported an 
explanation for the reduction in self-efficacy could be absence of support after 




Percieved self-efficacy reflects an individuals ability to carry out a specific task 
and has been shown influence intension to exercise and maintainance of 
exercise. As a fundamental aim of PR is to increase exercise capacity, self 
efficacy must also be enhance to faciliate this behaviour change. Self-efficacy 
will be discussed in chapter 8 in regards to PA levels. Self-efficacy also 
influences patients ability to self manage (Davis et al. 2006) and is an 
essential component to engagement of self management programmes 
(Bourbeau and Nault 2007). Therefore, patients may already have had a good 
level of self efficacy at baseline as those with lower self-efficacy may not have 
had the confidence in their ability to take part in the study and therefore not 
consented to the trial. As the PRAISE tool has not been widely used it is 
diffucult to summise if the baseline score for self efficacy are high or low.  
 
Exercise performance 
The ISWT was used to determine maximal exercise capacity. Results at 6 
months show there was a significant impact of time (p=<0.0001) and no 
between group differences (p=0.463). The distance achieved at six months 
has returned to approximately baseline levels in both groups with mean (SD) 
changes of 1.39m (86.47) in the PR group and -12.10m (70.30) in the SPACE 
for COPD group. The ESWT is used to determine sub maximal exercise 
endurance. This demonstrated a significant effect of time (p=<0.0001) and no 
between group differences (p=0.912) at six months. Interestingly scores 
showed only a small decline from seven weeks to six months. Mean (SD) 
change from baseline to six months was 255.56 sec (386.88) in the PR group 




months the mean change in the PR group exceeds the MCID of 186 seconds 
(Pepin et al. 2011) and SPACE for COPD is only marginly below that 
threshold. This would indicate that participants have continued with their PA 
after the end of the programme however, at a lower than prescribed speed. 
 
Despite ISWT performance not reflecting what is normally seen in PR (score 
not meeting the MCID) at Glenfield hospital, there may be potential 
explanations in the baseline characteristics of the study population as 
described in chapter 5. There is also the fact that the exercise programme 
does not involve increasing the training load. Walking speed is prescribed at 
85% of the maximal speed derived from the baseline ISWT and is not 
recalebrated at any time throughout the programme to enable progression.  
 
Although no significant between group differences were seen at 6 months for 
the ISWT the SPACE for COPD group had lower mean scores in comparison 
to PR and had reduced performance compared to baseline. Patients in the 
SPACE for COPD group completed the baseline ESWT at this pace and were 
demonstrated the prescribed speed during their one hour introduction at 
home, but did not have the regular supervision to reinforce them of their 
prescribed speed as did those in the PR group. It is highly likely that those in 
the SPACE for COPD did not walk at the prescribe speed/intensity which has 
been reflected in ISWT performance at seven weeks and six months.  
 
Endurance capacity as measured by the ESWT remained elevated six months 




groups did better on the ESWT compared to the ISWT as their walking 
programme prescribed gradual increases in time and not speed. Time is also 
an easier variable for patients to monitor and record so they may have 
focused on this to the detriment of the speed of walking. Patients may have 
chosen to walk slower so that they could increase the distance and time they 
walked for, however, this is unknown.  It’s important to maintain training load 
(speed) to induce health and fitness benefits and therefore, speed to walking 
needs to be reinforced with patients completing the SPACE for COPD 
programme. 
 
There are a number of self management programmes that have reported no 
effect on exercise performance using the 6MWT after the intervention 
(Bourbeau et al. 2003, Maltais et al. 2008, Monninkhof et al. 2003a). Despite 
the Bourbeau et al. (2003) self management intervention consisting of a 
comprehensive two month programme which was administered by a health 
professional in the patients own home and Maltais et al. (2008) intervention 
involving loaning exercise equipment for patients to use in their own home, 
neither demonstrated an improvement in the 6MWT (mean (95%CI) within 
group changes at 3 months 8 (-1 to 18) metres and 0 (-13 to 12) metres at 
twelve months; Maltais et al. 2008). However, Maltais’s home based study 
focussed on cycling exercise and it is therefore not suprising that there has 
been minimal crossover of training effect to walking performance. Monninkhof 
et al. (2003a) self management programme consisted of a two year 
programme of education and one to two weekly exercise sessions in small 




mean (SD) distance walked reduced by 13 (7) metres in the self management 
and 2 (5) metres in the usual care group from baseline levels. Even though 
these programmes provided considerable support no improvements in 
walking performance were found. It is therefore highly relevant that the 
SPACE for COPD programme has found improvements in exercise 
performance (ESWT) which has been maintained at six months despite it 
offering minimal contact with healthcare professionals. However, the trajectory 
of change after the intervention from the SPACE for COPD study is not clear 
and if followed up at 12 months could have reduced to near baseline levels. A 
possible reason for the elevated ESWT score could be due to the large intial 
increase at seven weeks. 
 
Boxall et al. (2005), Fernandez et al. (2009), Mendes et al. (2010) and 
Ghanem et al. (2010) all reported significant increases in 6 MWT distance 
after home-based programmes. Both Boxall et al. (2005) and Fernandez et al 
(2009) included regular home visits by a physiotherapist and Mendes et al 
(2010) made regular phone calls and provided patients with heart rate 
monitors to ensure prescribed exercise intensity. Ghanem et al. (2010) also 
demonstrated significant improvements in 6 MWT distance but involved 
patients recovering from acute exacerbation who’s baseline profile was quite 
different to stable COPD patients. 
 
Casanova et al. (2007) observed a progressive decline in the 6 MWD over 5 
years in a cohort of mild to moderate COPD patients who were not part of any 




25 m.yr-1 in those that died within the final 2 years of the follow up measures. 
Spruit et al. (2012) examined the annual decline in the 6MWD according to 
GOLD stage and reported a mean decline of 1.6 m in GOLD stage II, 9.8 m in 
GOLD stage III and 8.5 m in GOLD stage IV. Maltais et al. (2008) reported a 
mean (95% CI) change of 0 (-13 to 12) metres, Monninkhof et al. (2003) a 
mean (SD) increase of 13 (7) metres and Ninot et al. (2011) a median (25th to 
75th percentile) increase of 30 (5 to 80) metres all at 12 months. Therefore 
although these differences are small and do not met the MCID for this 
measure, in comparison to the normal decline reported by Casanova et al. 
(2007) clinically relevant. The natural decline in the ISWT and ESWT has not 
been reported. A mean (SD) decline (from baseline) was detected in the SM 
group at six months of 12 (70) metres and a increase of 1 (86) metres in the 
PR group. However, in the ESWT both intervention groups had increased 
mean scores (from baseline), which in the PR still breached the MCID from 
the baseline measure (PR 256 (387) sec; SPACE 177 (401) sec). It would be 
of interest to follow up these patients at 12 months to determine the rate and 
trajectory of change, however this was out of the scope of this thesis. 
However, it would appear at six months endurance capacity has been 
enhanced by the SPACE for COPD programme beyond baseline levels and 
given the natural decline in exercise performance reported (Casanova et al. 
2007) may be clincally significant. 
 
The follow up findings seen in the SPACE for COPD programme were in 
contrast to Strijbos et al. (1996), who is the only other study that has clearly 




After a 12 week programme those in the PR and  home based group 
continued to improve to six months following the intervention. However, by 18 
months only those in the home group had continued to improve maximal cycle 
work rate and four minute walk time. They concluded that the home 
programme had made the participants more independent and self sufficient as 
diary cards reveild they were completing more exercise than the PR group. 
However, it may have been the requirement to complete PA diary cards that 
had motivated them to continue with the programme. 
 
Although these studies have shown home based and supported self 
management  programmes can improve exercise performance they 
consistantly rely on health professional input and additional resources. These 
models of care are not possible in the UK. It may also be difficult to justify 
these comprehensive programmes as there is inconsistancy as to their 
effectiveness. 
 
The SPACE for COPD programme has demonstrated that exercise 
performance can be improved after a seven week programme and that some 
of the initial gain, such as the ESWT,  is still apparent six months later. Other 
outcome measures declined to baseline levels but so do those in the PR 
group. The challenge is how to maintain these broader improvements and to 
stop the decline often reported as a normal course of the disease. The 
SPACE for COPD programme may be an effective tool to help reduce this 






The results of the six month follow up of the PR and SPACE for COPD 
interventions need to be interpreted in light of a number of limitations. In 
addition to those discussed in chapter 5 it is worth exploring the fact that the 
PR group did not respond as expected. This may be due to the baseline 
profile of the patients and to the motivations of patients taking part in the 
study. 
 
Patients recruited to the study were not as severe on the MRC scale as 
normally seen in PR. Those with more severe COPD may have preferred to 
have had the comfort of knowing they would be in a supervised group so did 
not want to participate. This may be reflected in the higher CRQ-SR dyspnoea 
scores seen. There were also a higher percentage of current smokers and 
higher baseline CRQ-SR scores. It is possible that those who are current 
smokers are less likely to change their PA health behaviour as they have 
previous advice and intervention have not been adhered to, or it may be that 
current smokers were more motivated to do the study as they knew they had 
a chance of being in a group where they would have limited health 
professional contact and therefore their smoking habits not challenged.  
 
Another limitation is due to the multiple testing of numerous outcomes and 
comparisons over three time points. This increases the potential for a type I 





This chapter presented and discussed the finding of the six month follow up of 
the SPACE for COPD programme compared to conventional PR. Findings 
show that improvements gained at 7 weeks are not maintained but fall back to 
broadly baseline levels or above for a number of HRQoL variables and peak 
exercise performance. Future consideration should be given to maintenance 
strategies in both interventions. The exception was exercise endurance. The 
results from the ESWT showed that some of the initial improvement gain was 
apparent at 6 months. However, this was also mirrored in the PR group.  
 
The outcome of the SPACE for COPD programme should not be 
underestimated. The natural course of the disease is a progressive decline in 
exercise tolerance and HRQoL (Griffiths et al. 2000). SPACE for COPD has 
shown that key outcome measures have been maintained at levels similar to 




Chapter 7 – Physical activity levels of patients with COPD 
 
7.1 Introduction 
As described in chapter 2 (section 2.3) there is now overwhelming evidence 
that regular physical activity (PA) has significant health benefits and that 
inactivity is a major public health problem. National (Department of Health 
2011) and international (Nelson et al. 2007) guidelines recommend adults 
participate in moderate PA for at least 150 minutes per week to improve and 
maintain health. It is important that this PA is accumulated in bouts of at least 
10 consecutive minutes to lead to these gains. 
 
There is substantial evidence that exercise capacity and PA are reduced in 
patients with COPD (Pitta et al. 2005a, Sandland et al. 2005). PA is an 
increasingly important clinical outcome as low PA levels have been shown to 
negatively impact hospital admissions (Garcia-Aymerich et al. 2006), mortality 
(Waschki et al. 2011, Watz et al. 2008), dyspnoea (Watz et al. 2009), exercise 
performance and muscle weakness (Pitta et al. 2005a).  PA levels have been 
shown to decline with increasing disease severity (Watz et al. 2009). With the 
new GOLD grouping classification (described in chapter 2, section 2.1.7 and 
summarised in Figure 7.1 below) it is of interest to describe PA according to 
this new system. The MRC dyspnoea grade is a nominal scale of disease 
impact from one to five. Patients with MRC one were excluded from the study. 



























Figure 7.1 GOLD groupings 
 
Severe physical inactivity as defined as a PAL <1.40 has been reported to be 
the best predictor of all-cause 48 month mortality in patients with COPD 
(Waschki et al. 2011). PAL is not often reported as a clinical outcome due to 
its requirement for more sophisticated monitoring, but could become an 
important diagnostic and prognostic tool (Garcia-Rio et al. 2012).  
 
Both the PR and SPACE for COPD interventions used in this trial have a PA 
and exercise training component and it is therefore of interest to examine its 
impact. Thus, it is initially important to understand how best to describe PA 










this population and a lack of reporting PA in relation to the national and 
international guidelines. Baseline PA data is presented in this chapter to 
understand how the different thresholds of recommended PA affect the 
interpretation of the data. PA was collected from a number of participants 
recruited to the main trial. 
 
This chapter will describe the baseline levels of PA in a sub-group of the study 
population and compare them with national guidelines as recommended by 
the ACSM and the Department of Health (Department of Health 2011, Nelson 
et al. 2007).  
 
7.2 Aim 
There are three main aims for this study: 
1. To describe the baseline PA levels of a group of patients recruited to 
the study and to determine any differences between GOLD groupings 
and MRC dyspnoea grades. 
2. To determine whether patients with COPD are meeting national and 
international guidelines for exercise.  
3. To understand the impact of using differing criteria on determining 






A detailed description of the study protocol is presented in chapter 3. This 
chapter details the baseline PA as a measure of the SPACE for COPD trial. 
Seven week and six month data will be presented and discussed in chapter 8. 
 
A subgroup (n=181) of patients were invited to take part in PA monitoring at 
baseline, seven weeks and six months. Inclusion to this arm of the trial was 
determined by activity monitor availability at baseline. Initially we only had 
access to a small number of activity monitors (nine). Therefore, participants in 
this sub-group were not randomly selected. 
 
7.4 Measures  
This chapter focuses of the baseline measure of PA as part of the trial. PA 
was measured using the Sensewear® Pro2 Armband (SWM). The SWM’s 
reproducibility, sensitivity and validity are discussed in chapter 4. The patients 
wore the monitor for five days, including three weekdays and two weekend 
days (Friday, Saturday, Sunday, Monday and Tuesday). They were advised to 
wear the SWM during all waking hours and only to remove it during washing, 
showering, bathing and swimming.  
 
Physical activity variables 
A number of variables were taken from the accompanying InnerView™ 
software and included; 
 Total time SWM worn 




 Total time <2 METs (sedentary) 
 Total time 2-3 METs (light physical activity: LPA) 
 Total time 3-6 METs (moderate to vigorous physical activity: MVPA) 
 Total time 6+ METs (vigorous activity) 
 Total energy expenditure above 3 METs 
 











Time in moderate physical activity in ≥ 10 minute bouts 
Data was exported from the InnerView™ software to Excel to enable the 
calculation of bouts of exercise. Exported data gives the minute by minute 
values and therefore length of bouts of PA could be calculated. An Excel 
equation was used to determine total time in at least 10 minute bouts and total 
number of bouts of at least 10 minutes. This was completed for each day 
worn. 
 
Physical Activity Level (PAL) 
The physical activity level (PAL) has become a recognised method of 
expressing total daily energy expenditure (TEE) in multiples of resting 
metabolic rate (RMR). PAL is calculated via the following equation: 
 
PAL = TEE 
            RMR 
 
An individualised PAL can give an indication of how physically active they 
have been during the 24 hour period. Table 7.1 show the classifications of 










Table 7.1 Classification of PALs 
Activity Level PAL 
Extremely Sedentary / Inactive <1.40 
Sedentary 1.40-1.69 
Moderately active 1.70-1.99 
Vigorously active 2.00-2.40 
Extremely active >2.4 
 
The PAL was calculated by using the total daily energy expenditure estimated 
by the SWM and by using the Harris-Benedict equation to estimate basal 
metabolic rate (Harris and Benedict 1918). 
 
Criteria for excluding data 
Data was excluded from analysis if it fell under the following conditions: 
 An error massage occurred when downloading the SWM data 
 Days where there was fewer than 12 hours of data 
 If the monitor was worn for fewer than three days  
 
7.5 Statistical analysis 
Baseline characteristics are presented in table 7.2. Differences in 
characteristics between those that did take part in the activity monitor study 
and those that did not were analysed using independent t-tests or chi square. 
To get an overall picture of individual PA, mean data was calculated across 
the number of days worn. A minimum of three days wear time was chosen as 




accurate picture of an older adults PA and sedentary level (Hart et al. 2011). 
A repeated measures ANOVA was completed on each PA variable to 
determine if there were any differences in PA level between week days and 
weekend days. 
 
A Shapiro Wilks test of normality was completed on the data and data was 
determined to be normally distributed. ANOVA’s, with a Tukey post hoc test, 
were completed to determine if there was a difference in steps, total time 
above 3 METs, total time above 3 METs in at least 10 minute bouts and PAL 
between GOLD grouping and MRC grades.  
 
7.6 Results 
181 patients (63% of those recruited to the main study) took part in the PA 
monitoring at baseline. Six patients were excluded due to error messages on 
the SWM and 21 due to not wearing the SWM for the required length of time. 
This resulted in 154 patients being eligible for analysis. Table 7.2 presents the 
baseline characteristics for these patients in comparison to those that were 
not included in the PA trial. No differences were detected in baseline variables 













Age (yrs) 68 (8.33) 67 (9.46) 0.90 
Male:Female (n) 106:47 81:53 0.11 
BMI (m/kg2) 27.41 (5.88) 27.88 (6.54) 0.53 
FEV1 (litres) 1.29 (0.58) 1.22 (0.52) 0.35 
FEV1 %predicted 49 (18) 47 (18) 0.29 
FVC (litres) 2.74 (0.92) 2.66 (0.81) 0.47 
MRC (n:%) 
     2 
     3 
     4 
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     B 
     C 













SpO2 rest % 94.20 (2.39) 94.27 (3.71) 0.85 
Smoking status (n:%) 
    Current smoker  
    Never smoked  











Pack years 45.99 (31.97) 46.48 (30.98) 0.90 
CRQ-SR 
    Dyspnoea 
    Fatigue 
    Emotion 

















    Anxiety 










PRAISE 44.32 (7.76) 44.55 (7.13) 0.81 
ISWT (distance) 268.69 (146.16) 236.56 (152.21) 0.07 





The analysis of between day differences revealed a difference in step count 
between Fridays (the first day the monitor was worn; mean (SD) steps; 4390 
(3279)) and Sundays (3348 (2502) steps). There were no other statistical 
different between days for any other PA variable. As this was the only 
difference that was detected it was assumed fair to mean the data across the 
number of days worn. 
 
Physical activity by disease severity 
Baseline levels of physical activity across disease severity, using both GOLD 
categories and MRC dyspnoea scales are presented.  
 
GOLD groups 
GOLD (Vestbo et al. 2013) recommends classifying patients into four groups: 
A (low risk, less symptoms), B (Low risk, more symptoms), C (high risk, less 
symptoms), D (high risk, more symptoms), and are summarised in table 7.1.  
Mean (SD) values for steps, PAL, total time in light physical activity (LPA: 2-3 
METs), total time in moderate to vigorous physical activity (MVPA: 3-6 METs), 
total time in vigorous physical activity (>6 METs) and energy expenditure over 
3 METs for each GOLD category are shown in Table 7.3. ANOVA analysis 
revealed differences between groups. A Tukey post-hoc test was completed 
on results that were statistically significant and box plots presented to 
highlight where these differences lie (figures 7.3 and 7.4).  
 
There is a significant difference between GOLD groups for step counts and 




GOLD group D the lowest (table 7.3). GOLD group D also had significantly 
lower time in LPA. Although differences were not significant, GOLD group D, 
those most at risk and with more symptoms, spent most time sedentary and 
the least time in LPA. GOLD group C spend the most time in PA over 3 METs 
and GOLD group A spend the least time in PA over 3 METs, however, this 






















Table 7.3 Baseline physical activity variable in different GOLD groups (mean 
(SD) 
 GOLD group p 
 A 
n = 20 
B 




n = 63 
 
Steps 5731 (3285) 4530 (2437) 5647 (2783) 2661 (1742) <0.0001 
PAL 1.42 (0.24) 1.36 (0.25) 1.43 (0.35) 1.35 (0.25) 0.613 
Sedentary 
(minutes) 
651 (124) 657 (105) 650 (137) 688 (162) 0.539 
LPA 
(minutes) 
131 (66) 118 (66) 156 (66) 101 (65) 0.038 
MVPA 
(minutes) 
65 (56) 65 (58) 83 (80) 60 (61) 0.677 
Vigorous 
(Minutes) 
0.5 (1) 2 (7) 3 (7) 11 (48) 0.387 




























Figure 7.3 A box plot of daily step count by GOLD grouping. Boxes present 
the median, interquartile ranges and highlight the highest and lowest values. o 














Figure 7.4 A box plot of time in LPA in different GOLD groups. Boxes present 
the median, interquartile ranges and highlight the highest and lowest values. o 



























MRC dyspnoea grade 
Mean (SD) values for steps, PAL, total time in light physical activity (LPA: 2-3 
METs), total time in moderate to vigorous physical activity (MVPA: 3-6 METs), 
total time in vigorous physical activity (>6 METs) and energy expenditure over 
3 METs for each MRC grade are shown in Table 7.4. ANOVA analysis 
revealed differences between groups. A Tukey post-hoc test was completed 
on results that were statistically significant and box plots presents to highlight 





















Table 7.4 Baseline physical activity variable across MRC grades 
 MRC Grade p 
 2 
n = 32 
3 




n = 21 
 
Steps 5824 (3027) 3908 (2162) 3278 (2351) 2382 (2046) <0.0001 
PAL 1.45 (0.30) 1.37 (0.23) 1.39 (0.32) 1.27 (0.18) 0.111 
Sedentary 
(minutes) 
634 (135) 663 (100) 668 (155) 718 (184) 0.188 
LPA 
(minutes) 
141 (66) 113 (58) 113 (82) 92 (55) 0.063 
MVPA 
(minutes) 
85 (83) 62 (56) 63 (64) 57 (57) 0.340 
Vigorous 
(MINUTES 
2 (5) 4 (21) 8 (24) 16 (70) 0.369 













MRC grade 5 are the most severe patients and spend the most time 
sedentary and the least time in LPA. They also have the highest time in 
vigorous activity, although the SD is also high. MRC grade 2 spend the most 
time in PA above 3 METs and MRC grade 3 the least, although none of these 
finding were statistically significant. MRC grade 2 have significantly more daily 














Figure 7.5 Box plot of daily step count in the different MRC grades. Boxes 
present the median, interquartile ranges and highlight the highest and lowest 









Physical activity level (PAL) 
 
The Mean PAL was 1.38 (0.27), 76% of participant had a PAL of <1.4 
classifying them as extremely sedentary. Only 7% of participant had a PAL of 
between 1.70-1.99 classifying them as moderately active. 
 
 












When analysing PA data according to the different ways recommended 
values are reported, four target thresholds were identified. Recommended 
daily targets were stated as being met if the mean daily data had breached 
either of the thresholds below: 
 Accumulation of 30 minutes of moderate PA in total 
 Accumulation of 30 minutes of moderate PA in total in at least 10 
minutes of consecutive PA 
 10,000 steps 
 7,000 steps 
 
In total (regardless of GOLD grouping, or MRC score) 67% met the mean 
daily target of at least 30 minutes in non-bouts, which fell to 18% when at 
least 10 minutes of consecutive bouts of PA were used. A paired t-test 
revealed that time spent over 3 METs in non-bout activity was significantly 
higher than time spent over 3 METs in at least 10 minute bouts (p<0.0001). 
Only 4% of patients accumulated 10,000 on an average day, which increased 
to 8% when using the 7,000 step threshold (data not shown). This data is 
presented across MRC grade and GOLD category in figure 7.7 and 7.8 which 
shows that most PA is accumulated in less than 10 minute bouts. With GOLD 
grouping a significant difference was detected using ANOVA with post hoc 
test analysis between the number of patients meeting the 7,000 steps 
between different groups, with GOLD group D reporting a significantly lower 




B and D p=0.049; C and D p=0.007). No other statistical difference was 




Figure 7.7 Percentage of participant by disease impact (GOLD) meeting 
different physical activity guidelines  
 
With the MRC scale, using an ANOVA with a post hoc test a difference was 
also detected using the 7,000 step threshold between the different stages 
(p=0.001; 2 and 3 p=0.004; 2 and 4 p=0.017; 2 and 5 p=0.003).  A significant 
difference was also identified in 10,000 steps threshold between MRC grades 




Figure 7.8 Percentage of participant by disease impact (MRC) meeting 




The aim of this chapter was to describe PA levels in patients classified using 
two categories of disease impact, GOLD grouping which has only recently 
been developed (Vestbo et al. 2013) and MRC dyspnoea grading (Fletcher et 
al. 1959). This section will first explore the PA findings across these 
categories and secondly discuss whether patients in this cohort were meeting 
national and international guidelines for PA and how the different thresholds 






PA across classifications of disease impact 
 
GOLD groupings 
The general pattern of PA by GOLD groups was broadly as expected. 
Patients in GOLD group A (less symptoms and less risk) have the higher PA 
levels and patients in GOLD group D the lowest. Patients in GOLD group D 
accumulated significantly less mean daily steps than each of the other GOLD 
group (p=<0.0001, figure 7.4). GOLD group D are those that are high risk and 
present with more symptoms and therefore are the more severe patients, this 
finding was therefore anticipated.  
 
GOLD category C spent significantly more time in LPA in comparison to 
GOLD group D. GOLD group C present with less symptoms and although not 
significant tend to spend more time in either LPA or MVPA than sedentary 
time in comparison to the other GOLD groups. Interestingly the variation 
between the groups in PA levels tends to be in LPA rather than MVPA and 
therefore it could be the LPA that is impacting on the changes in step counts 
seen between GOLD categories. It may be anticipated that this difference in 
LPA is due to activities that participants take part in are lighter in intensity and 
therefore it is these activities that discriminate between the groups. MVPA is 
broadly around one hour and does not change greatly between the groups, it 
therefore may indicate that around one hour is the minimal requirement for 
activities of daily living, including preparing meals for example. This may be 





PA across the updated GOLD grouping has yet to be fully described.  
Canavan et al. (2013) reported that PA levels are difficult to distinguish 
between the new GOLD groupings. This is due to the groups not being 
sequential in disease impact. GOLD group A are those with lower disease 
severity and lower reported symptoms and GOLD group D those with highest 
disease severity and more reported symptoms. However GOLD groups C and 
B may be described as discordant groups with GOLD group C those with 
higher disease severity and lower reported symptoms and GOLD group B 
those with lower disease severity and higher reported symptoms. The PA 
findings in this current study and the Canavan et al. (2013) study reflect the 
non-sequential nature of the GOLD categories. These guidelines recognise 
that the impact of the disease is not just based on lung volumes alone. 
However, the non-linear nature of the grouping system and the complexity of 
the determinates of PA make the interpretation of these discordant groups 
difficult. Co-morbidities are common in patients with COPD and could 
contribute to the reported symptoms in these discordant groups. 
Comorbidities were recorded as part of the study but unfortunately were not 
uploaded onto the database to allow further analysis. 
 
MRC dyspnoea grades 
Grouping patients according to MRC dyspnoea grade revealed PA activity 
levels as expected given that MRC reflects functional performance. Those in 
MRC grade 2 had the highest PA level and MRC grade 5 had the lowest PA 
level. Findings demonstrated a significant difference between the milder MRC 




agreement with Watz et al. (2009), Troosters et al. (2010) and Waschki et al. 
(2012) who all reported that daily step count decreased as disease impact 
increased. Watz et al. (2009) reported on the physical activity levels in 170 
patients with COPD in Germany. This study reported mean daily step counts 
of over 6,000 in the milder MMRC 1 (equivalent to MRC 2) group which is 
higher than this study with mean daily step counts of 5,824 (30277) of those in 
MRC dyspnoea score 2. Similar levels of daily steps were seen in the more 
severe patients with Watz et al. (2009) reporting mean daily steps counts of 
around 2,000 in MMRC group 5  and in this study mean daily step counts 
were 2,382 (2,046) in MRC dyspnoea grade 5.  
 
Patients in the previous studies worn the activity monitors for 24 hours and 
the threshold for inclusion was 22 - 22.5 hours per day, in this current study 
the threshold for inclusion was 12 hours. Although the main difference in wear 
time would be sleep it is possible that some data in this current study may 
have been missed and those that would be more likely to have missed data 
would be the more active milder MRC 2, GOLD group A patients. This study 
also had fewer patients in the milder groups (GOLD group A). As this group 
are those with fewer symptoms they may not have initially presented for PR 
and the milder patients were also excluded from the study (MRC grade 1 were 
excluded from the trial). 
 
Interestingly, Troosters et al. (2010) and Waschki et al. (2012) also reported 
the PA of healthy controls. These studies highlighted that healthy adults 




current study a drop in step counts has occurred at the very early onset of 
disease in patients with COPD. This supports the notion that PA interventions 
may be beneficial for all regardless of disease severity, as all groups need to 
increase their PA level. It also highlights an important hypothesis as to 
whether reduced PA is an early feature of COPD or if the progression of 
COPD causes the reduced PA (Polkey and Rabe 2009). The current data 
appears to support the former hypothesis as Watz et al. (2009) showed PA 
levels to decline across GOLD grades and that this decline could be attributed 
to behaviour change in that patients were choosing to reduce their PA rather 
than their disease instigating this decline. 
 
In the milder patients (MRC grade 2) with COPD lower PAL levels were 
observed in this study in comparison to Watz et al. (2009). Their study 
reported a mean PAL level of 1.63 (0.25) in GOLD stage I (as determined by 
FEV1) and this study a mean PAL level of 1.45 (0.30) in MRC grade 2. PAL 
levels in the most severe disease categories agree with the finding of  Watz et 
al. (2009) with their GOLD stage IV patients having a mean PAL of 1.27 (0.17) 
and this study the MRC grade 5 patients also had a PAL of 1.27 (0.18). These 
differences reflect the difference in step count observed as previously 
discussed. 
 
The variations in PA seen in the milder patients may due to the different 
classification systems. GOLD stages I to IV is based on spirometry alone and 
MRC grade is a self-report measure of dyspnoea. Those in GOLD stage I had 




MRC had an FEV1 % predicted of 50.72% (17.69) and therefore it may not be 
appropriate to compare these groups directly.  
 
Overall PA levels in patients with COPD  
PAL has been reported to be the best predictor of 48 month mortality in 
patients with COPD (Waschki et al. 2011). The mean (SD) PAL for participant 
in this study was 1.38 (0.27) putting this cohort of patients at increased risk of 
premature mortality. This figure is lower than that reported by Waschki et al . 
(2012), van Gestel et al (2012) and Watz et al. (2009) which were 1.45 (0.20), 
1.47 (0.23) and 1.53 (0.29) respectively, in broadly similar populations. 
However, it’s similar to Depew, Novotny and Benzo (2012) who reported a 
mean PAL of 1.39 (0.28) in 165 patients with COPD reflecting the similar step 
counts in both studies. Intuitively this suggests that daily step count correlates 
with PAL and would be an effective marker of PA and inactivity.  
 
In this current study the Harris Benedict equation was used to estimate RMR 
rate for the determination of PAL. This was in contrast to Waschki et al. 
(2012), van Gestel et al. (2012), Watz et al. (2009) and Depew, Novotny and 
Benzo (2012) who all had their participants wear the SWM day and night. 
Therefore, these studies used EE during sleep time as their measure of RMR 
for calculating PAL. This may be a more precise measure than the Harris 
Benedict equation which may have influenced PAL. The Harris Benedict 
equation has been criticised for not accounting for the participant’s ratio of 
lean muscle mass to body weight, which can have a large effect on resting EE 




population in this trial was not classified as obese results may need to be 
interpreted in light of the method used to determine RMR.     
 
Although PAL is useful prognostically it is more complex to calculate and not 
easily measured. Some initial finding have been reported on the number of 
steps that is associated with severe physical inactivity (PAL <1.4). A daily step 
value of <4580 was the best cut-point for predicting a PAL <1.4 and may be a 
more useful benchmark to identify severe physical inactivity (Depew, Novotny 
and Benzo 2012). What is also useful to understand is whether a patients’ 
activity level meets the recommended guidelines for PA. 
 
The data from this cohort of COPD patients demonstrates that those with the 
greatest disease severity or impact (GOLD group D and MRC grade 5) spend 
the most time sedentary and the least time in LPA, regardless of the time 
spent in PA above 3 METs. LPA appears to be what has impacted on step 
count and is what is attributable to the differences in step counts seen. LPA 
can be a significant component to 24 hour energy expenditure (EE) and has 
shown to effect health related outcomes in other chronic disease (Blair et al. 
2014). Therefore, it may be of interest to explore the role of LPA levels in 








PA levels in patients with COPD in relation to national and international 
guidelines 
 
The ACSM (Nelson et al. 2007) recommend all adults should participate in at 
least 30 minutes of moderate intensity PA on at least 5 days per week in order 
to maintain and improve health. This activity can be accumulated in bouts of 
at least 10 minutes. A number of studies have reported time in moderate 
exercise in patients with COPD, but many have not used this cut-off point of at 
least 10 minute bouts (Troosters et al. 2010, Watz et al. 2009). Therefore, the 
number of people meeting these guidelines will be potentially over estimated. 
This current data (figure 7.7 and 7.8) highlight this issue as a significant 
differences was detected between bout and non-bout activity.  When looking 
at the percentage of participant meeting the guidelines is calculated 
regardless of continuous 10 minute bouts (figure 7.7 and 7.8) 72% meet this 
threshold from GOLD group A and 73% from MRC grade 2. A decline in those 
meeting this particular guideline is seen as disease impact increases through 
the GOLD groupings to 62% of GOLD group D meeting the guideline. 
However, this pattern is not seen with the MRC grades, with MRC 4 having 
the lowest percentage (55%) of participants meeting the guidelines. It is 
unclear as to why this has occurred, but could be due to this study being 
underpowered and uneven numbers in each grade.  
 
In order for improvements to occur PA needs to in consecutive bouts of at 
least 10 minutes. When looking at the data and including only those in at least 




in both GOLD group A and MRC 2 to the lowest level in GOLD category C of 
8% and MRC grade 3 12%. Interestingly, Troosters et al. (2010) used different 
MET value cut-off points to define moderate PA. Troosters study set the 
threshold at 4.5 METs for those under 65 years or at 3.6 METs for subjects 
over 65 years. These values are for the improvement of cardiorespiratory 
fitness rather than the maintenance or improvements of health and given the 
nature and characteristics of those with COPD this may not be appropriate or 
achievable. 
 
The limited published data on 10 minute bout data is possibly due to a 
restricted number of activity monitors presenting minute-by-minute data for 
bout calculation. One study that has reported moderate PA in at least 10 
minute bouts is Donaire-Gonzalez et al. (2012). This study reported the PA 
levels of 177 patients with COPD from across 9 tertiary hospitals in Spain. 
This study used 2 measures of classifying moderate PA, >2.6 METs that was 
determined by 50% of maximal oxygen consumption for an incremental 
exercise test and >3 METs. When using the cut-off of 2.6 METs 61% of 
participant met the guidelines which reduced to 50% when 3 METs was used. 
In the current study, 20% of patients completed 30 minutes of moderate PA 
per day in 10 minute bouts, which is much lower than Donaire-Gonzalez et al. 
(2012). In the UK self-reported levels of PA suggests that 39% of men and 
29% of women meeting the guidelines for PA (British Heart Foundation 2012). 
Therefore it is surprising how high these levels are in comparison to healthy 
adults in the UK, let alone patients with COPD. Patients from Donaire-




this study. PA participation in Spain has also been reported to be at a similar 
level to the UK (British Heart Foundation 2012) so it is not fully understood 
why these differences have been observed. It may be speculated that season, 
temperature and weather variations affect patients with COPD which has 
been shown to impact on PA levels in the UK (Sewell et al. 2010) and 
internationally (Pitta et al. 2009). 
 
Van Remoortal et al. (2013) highlighted the limited reporting in the literature of 
PA in at least 10 minute bouts and proposed a cut-off level of 80 minutes of 
PA per day in non-bout PA. 80 minutes per day of non-bout PA was 
associated with 30 minutes of MVPA in 10 minute bouts in 113 patients with 
COPD (FEV1 % predicted 65% (27)) and subjects without COPD. This may 
offer a more accurate picture to determine if guidelines are being met when 
using monitors that don’t display minute-by-minute data. However, it is not 
clinically useful as individuals still need to be prescribed PA of 30 minutes in 
10 minute bouts to ensure guidelines are met.  
The data from this current study may not truly reflect whether guidelines have 
been met as the SWM was not worn for a full week. This study reports the 
mean daily time >3METs in at least 10 minute bouts and the recommended 
PA is to complete 30 minutes of moderate PA on at least 5 days, people do 
not necessarily need to participate in moderate PA every day. Therefore, 
averaging the time spent in moderate PA over the five days may have missed 
PA on the days the SWM was not worn. Five days of monitoring was chosen 
to allow for a certain level of non-compliance in wearing the monitor, as three 




predict PA and sedentary behaviour in older adults (Hart et al. 2011). This 
number of days may give a reliable picture of PA behaviour and PA behaviour 
change but cannot give an accurate measure of whether weekly guidelines 
have been met.  In future if the aim of PA monitoring is to determine if 
guidelines have been met then it is recommended that monitors need to be 
worn for the full seven day week.  
 
Accumulating 10,000 steps per day is a common marker of achieving PA 
guidelines and improving health (Tudor-Locke and Bassett Jr. 2004). This 
study has shown that there was a significant difference in step count between 
disease severity, suggesting there is a progressive decline in PA for those 
with mild disease to those with severe disease. The mean number of steps in 
the current study was 3,919 (2624) reflecting the low level of PA in these 
patients. This is comparable to Depew, Novotny and Benzo (2012) who 
reported a mean daily step count of 3,827 (3323) in 165 patients with COPD 
(FEV1 %predicted 42.8(17.81)%). Few patients met the 10,000 steps 
threshold with none meeting this guideline in the more severe GOLD group D 
and MRC grades 4 and 5 (figure 7.6 and 7.7).  
 
Until recently with the development of more sophisticated activity monitors, it 
has been difficult to determine if 10,000 steps equates to 30 minutes of MVPA 
given that this figure also needs to incorporate usual daily walking. These 
guidelines have been revisited and it has been reported that 3,000 steps 
roughly equates to 30 minutes of MVPA and therefore including free living 




(Tudor-Locke et al. 2011). When using 7,000 steps as the threshold those 
meting the guidelines increases in the milder patients however it still remains 
the case that no participants in GOLD group D and MRC grade 5 (figure 7.6 
and 7.7) met this guideline. Using this threshold of recommended PA 
discriminated between both the GOLD groups and MRC grades and 
therefore, these revised guidelines may be a more appropriate target for older 
adults and COPD patients with limited functional capacity.      
 
Determining how many steps equates to set times in MVPA is of interest and 
as described above Tudor-Locke et al. (2011) reported 30 minutes of MVPA 
corresponds to 3,000 steps. However, this does not concur with the data 
presented in this current study. GOLD group D participate in an hour of MVPA 
but had a mean step count of 2661 steps, and MRC grade 5 completed 57 
minutes of MVPA and had a mean step count of 2382 steps. The relationship 
between MVPA and step count was not examined in the SWM, so could not 
be clearly explained. However, the discrepancy seen with this current study 
and Tudor-Locke (2011) could be due to the SWM not being sensitive enough 




A number of limitations are acknowledged as part of this study and have been 





This study was observational and investigated PA at one time point. 
Subgroups of those with differing disease severity have been used to highlight 
the possible progress of PA as the severity of disease progresses. 
Longitudinal data of PA during the natural course of the disease is lacking due 
to challenging research design and ethical issues. This was out of the scope 
of this study, but there is a need to understand the pattern of PA over time 
against the background of increasing disease severity. 
 
It is highly likely that PA behaviour has increased during the monitoring 
period. Subjects were aware the study was measuring PA and wearing the PA 
monitor may have motivated patients to increase their normal PA pattern. 
However, even if we do consider the data collected to be their ‘best’ days PA 
levels reported are still well below recommended levels.  
 
A further limitation is in the assumption of a mean value of 30 minutes in at 
least 10 minute bouts equate to meeting the guidelines for PA. The guidelines 
recommend accumulating 150 minutes of MVPA per week and not 
necessarily 30 minutes per day. At least 3 days of data was used in the 
analysis as this is the minimum recommended duration in older adults (Hart et 
al. 2011). In order to obtain a more accurate picture to determine if guidelines 
are met at least 7 days of monitoring is required.  
 
Differences in PA between studies could be due to monitor wear time and that 
participants in this study have been told to wear the monitor for waking hours 




bed and those with milder disease are the ones more likely to continue to with 
PA and therefore this data may have been missed. A difference in calculation 
of PAL was also identified in comparison to this one. In this study basal 
metabolic rate was estimated by the Harris-Benedict equation (Harris and 
Benedict 1918) and the Waschki (2012) study used energy expenditure during 
sleep to calculate PAL.  Energy expenditure in this current study was 
estimated by the SWM which was shown not to have good reproducibility and 
sensitivity. In regards to step count the SWM did not show acceptable 
reproducibility at the very low speeds (1.73km.hr). 16 patients in the PR group 
and 12 in the SPACE for COPD group were prescribed their walking 
programme at this speed and therefore its ability to accurately detect steps 




It is clear that PA levels in patients with COPD are low and those in the 
greatest impact categories are the lowest. This chapter aimed to describe PA 
levels using a number of commonly reported variables across disease 
severity. This highlighted that even those with mild disease (GOLD group A 
and MRC 2) are limited in their daily PA. This suggests that interventions to 
improve PA should be offered to all COPD patients regardless of disease 
severity or impact. 
 
To date most studies have reported total PA as total time in MVPA. The 




maintain health 30 minutes of ≥3METs activity need to be completed on at 
least 5 days of the week and that time should be accumulated in at least 10 
minute bouts. This study reported a significant difference in the time spent 
above 3 METs when calculated as bouts or non-bouts. This highlights that 
most of the time reported was accumulated in less than 10 minute bouts 
which would not necessarily contribute to health improvements. If the 30 
minutes of non-bout MVPA threshold was used to determine if an intervention 
was used, this may not be appropriate and mask the need for PA behaviour 
change in these patients. It is therefore important to interpret studies in 
relationship to how they have reported this data and in future studies aiming 
to improve health should report time in MVPA in at least 10 minute bouts.   
 
The goal for any PA intervention should be to get its participant to meet the 
PA guidelines. However, these guidelines are directed to healthy adults and it 
may be that these guidelines are unachievable in those with limited functional 
capacity and very low baseline levels of PA. There is evidence that LPA can 
improve health in those with chronic disease (Blair et al. 2014). In this study 
those with low MVPA also had low LPA levels. It may be of interest for future 
studies to look at the impact of increasing LPA in patients with low PA levels 




Chapter 8 – The Effect of the SPACE for COPD programme 
on physical activity levels in patients with COPD 
 
8.1 Introduction 
The previous chapter (chapter 7) discussed that physical inactivity is 
associated with poorer prognosis in patients with COPD (Casanova et al. 
2007, Waschki et al. 2011, Garcia-Rio et al. 2012). As part of the SPACE for 
COPD study baseline physical activity (PA) was shown to be low with a mean 
PAL of 1.38 (0.27) which classifies these patients as extremely sedentary. 
Additionally only 18% completed 30 daily minutes of MVPA in at least 10 
minute bouts and only 4% meet the recommended 10,000 steps per day and 
8% 7,000 steps per day. 
 
Behaviour modification is needed to increase PA and potentially optimise long 
term health outcomes. Education and the development of self-management 
skills (SM) are key to facilitate this change. Both Pulmonary Rehabilitation 
(PR) and the SPACE for COPD programmes incorporate education and 
additionally aim to equip patients with skills to problem solve, make informed 
decisions and enhance confidence to take action. By implementing these 
skills it is anticipated that positive long term health behaviour will result, such 
as increased PA levels. Therefore, this chapter will focus on the effect of the 
SPACE for COPD programme on PA levels at seven weeks (at the end of the 
intervention), and six months after the intervention has ceased. The SPACE 





The aim of this chapter is to evaluate the effect of the SPACE for COPD 




The main design of the trial is described in detail in chapter 3. Chapter 7 
(section 7.3) also gives details of the variables measured and extracted from 
the Sensewear Armband (SWM). Patients wore the SWM for five days (three 
weekdays and two weekend days) for all waking hour at baseline, seven 
weeks and six month assessment time points. For comparison between 
groups and time points 12 hour data was used. The 12 hours commenced 
from when the monitor started recording, when the monitor was initially put on 
by the patient. If a subject had worn the monitor of 24 hours, the 12 hour 
period commenced in the first minute that lying down was not detected.  
 
Physical activity above prescribed level 
The SWM was worn during the Endurance Shuttle Walk Test (ESWT) that 
was worn during the seven week visit. The timestamp button on the monitor 
was used to mark the beginning and end of the test. This enabled us to 
determine the intensity of exercise using METs that corresponded to the 
prescribed walking speed of 85% of maximal performance on the Incremental 
Shuttle Walk Test (ISWT; Figure 8.1). This prescribed MET level could then 




MET level’ and ‘Energy expenditure above prescribed MET level’ are 
therefore, described in this chapter. 
 
Figure 8.1 InnerView™ Software, highlighting data extraction for prescribed 
METs (patient example) 
 
8.4 Outcome Measures 
• Total daily step counts 
• PAL 
• Total time <2 METs (sedentary) 
• Total time 2-3 METs (light physical activity: LPA) 
• Total time 3-6 METs (moderate to vigorous physical activity: MVPA) 
• Total time 6+ METs (vigorous activity) 




• Total time above prescribed METs 
• Total energy expenditure above prescribed METs 
• Total time over 3 METs in at least 10 minute bouts 
• Average METs level taken from the ESWT 
8.5 Statistical analysis 
Data was initially analysed for normality. Within group differences, from 
baseline to seven weeks, were tested for by a paired t-test and between 
group differences were tested for by an independent t-test. A significant 
difference was detected between the treatment groups for FEV1% predicted. 
Therefore between group differences over time to six months were analysed 
using an analysis of covariance (ANCOVA) with FEV1% predicted as the 
covariate.   
 
8.6 Results 
Of the 154 that took part in the baseline PA monitoring trial, 59 subsequently 
withdrew. One set of data was discarded due to an error message on the 
SWM and 43 were discarded as they were not worn for at least 12 hours on at 
least 3 days. This left 51 subjects with at least 3 days of 12 hour data at each 
of the time points (baseline, seven weeks and six months) available for 
analysis (figure 8.2). Baseline characteristics from the 25 subjects in the PR 
arm of the trial and the 26 in the SPACE for COPD arm are presented in table 
8.1. A significant difference in percentage of predicted FEV1 was detected 



























Figure 8.2 CONSORT diagram of patient flow through the study 
 
 
26 complete sets of 
data at baseline, 7 
weeks and 6 months 
181 given SWM at 
baseline 
154 sets of date 
received at baseline 
27 dropped out 
6 monitor errors 
21 not adhered to protocol 
73 PR group 81 SPACE group 
25 Complete sets of data 
at baseline, 7 weeks and 
6 months 
103 participants dropped out 
59 withdrew from main trial 
1 monitor error 




Table 8.1 Mean (SD) baseline characteristics between PR and SPACE 
groups who participated in the physical activity monitoring study 





Age (yrs) 69 (6.24) 68 (6.92) 0.443 
Male:Female (n) 18:7 18:8 0.828 
BMI (m/kg2) 27.15 (5.29) 26.65 (5.44) 0.741 
FEV1 (litres) 1.37 (0.51) 1.09 (0.53) 0.060 
FEV1 %predicted 54.83 (20.05) 42.24 (18.81) 0.028 
FVC (litres) 2.86 (0.89) 2.60 (0.84) 0.294 
MRC (n:%) 
     2 
     3 
     4 














     A 
     B 
     C 













SpO2 rest % 93.88 (24.80) 94.15 (2.42) 0.684 
Smoking status (n:%) 
    Current smoker  
    Never smoked  











Pack years 51.34 (24.80) 43.25 (37.39) 0.377 
CRQ-SR 
    Dyspnoea 
    Fatigue 
    Emotion 

















    Anxiety 










PRAISE 42.70 (8.66) 44.27 (8.53) 0.543 
ISWT (distance) 267 (128.18) 281 (170.77) 0.742 





 Table 8.2 Comparison of physical activity baseline variables in the PR and 
SPACE for COPD groups. 12 hour data used. Mean prescribed MET level 3.8 
 PR (n=25) SPACE (n=26) p 
Steps 3683 (1820) 3902 (2120) 0.694 
PAL 1.38 (0.28) 1.40 (0.33) 0.771 
Sedentary time 
(minutes) 
549 (103) 540 (119) 0.782 
LPA time 
(minutes) 
107 (72) 112 (59) 0.771 
MVPA time 
(minutes) 
58 (36) 66 (86) 0.422 
Vigorous Time 
(minutes) 
6 (25) 2 (5) 0.346 
EE over 3 METs 
 
330 (366) 347 (452) 0.893 
Time over 
prescribed METs 
36 (52) 50 (105) 0.570 
EE over 
prescribed METs 
199 (356) 323 (519) 0.807 
Time over 3 
METs in bouts 
15 (25) 11 (15) 0.480 
    
Baseline PA levels are presented in table 8.2. No statistical difference was 





Seven week changes in PA 
Seven week changes in PA in the two treatment groups are presented in table 
8.3 and between group differences in table 8.4. The mean prescribed MET 
level was 3.8 METs. 
 
At seven weeks there was no significant change in any PA measure 
compared to baseline in the PR group. However, a significant improvement 
was seen in step count, PAL, sedentary time and time over 3 METs in at least 
10 minute bouts in the SPACE for COPD group (table 8.3). Differences in the 
change in score were significantly higher in the SPACE for COPD group than 
the PR group for steps and time over 3 METs in 10 minute bouts (table 8.4). 
Change in sedentary time was also significantly less in the SPACE for COPD 
group than the PR group (table 8.4). 
 
When analysing the data with all the available data from baseline to seven 
weeks, 83 participants were available for analysis. A similar pattern was seen 
with this data when comparing pre and post changes in PA. The SPACE for 
COPD group had a significant improvement in PAL, sedentary time and time 
over 3 METs in 10 minute bouts, whereas, no significant changes were 
detected in the PR group (table 8.5). However, the between group differences 







Table 8.3 Mean (SD) Changes in PA from baseline to 7 weeks for PR and 
SPACE groups. Data presented is from those whom have full data sets at 









PR (n=25)     
Steps (count) 3683 (1820) 3219 (1829) -464 (-1445 to 517) 0.459 
PAL 1.38 (0.28) 1.43 (0.17) 0.05 (-0.08 to 0.17) 0.339 
Sedentary 549 (103) 555 (91) 6 (-38 to 45) 0.859 
LPA  107 (72) 113 (73) 6 (-23 to 33) 0.720 
MVPA 58 (36) 50 (39) -8 (-28 to 73) 0.299 
Vigorous 6 (25) 2 (7) -4 (-15 to 7) 0.431 
EE over 3METs 
(Kcal) 
330 (366) 236 (186) -94 (-61 to 63) 0.217 
Time over 
prescribed METs 




199 (356) 129 (167) -70 (-223 to128) 0.878 
Time over 3METs 
in bouts 
15 (25) 11 (15) -4 (-13 to 6) 0.444 
SPACE (n=26)     
Steps (count) 3902 (2120) 4976 (3130) 1074 (289 to 1708) 0.008 
PAL 1.40 (0.33) 1.56 (0.27) 0.16 (0.04 to 0.29) 0.010 
Sedentary 540 (119) 494 (106) -46 (-86 to -11) 0.013 
LPA  112 (59) 136 (73) 24 (-10 to 45) 0.196 
MVPA 66 (86) 84 (64) 18 (-5 to 42) 0.114 
Vigorous 2 (5) 6 (21) 4 (-4 to 14) 0.275 
EE over 3METs 
(Kcal) 
347 (452) 430 (323) 83 (-124 to 288) 0.417 
Time over 
prescribed METs 




232 (519) 183 (171) -49 (-299 to 201) 0.685 
Time over 3 METs 
in bouts 




Table 8.4 Group differences in the change in PA from baseline to 7 weeks 
(SPACE minus PR). Data presented is from those whom have full data sets at 
baseline, seven weeks and six months. Data is minutes unless stated. 
n=51 Between group Difference (95%CI) P Value 
Steps (count) 1463 (280 to 2645) 0.020 
PAL 0.12 (-0.050 to 0.29) 0.122 
Sedentary -52 (-106 to 2) 0.039 
LPA  13 (-26 to 51) 0.526 
MVPA 62 (-56 to 248) 0.242 
Vigorous 9 (-5 to 23) 0.179 
EE over 3METs 
(Kcal) 
181 (-74 to 436) 0.130 
Time over 
prescribed METs 




-1.79 (-299 to 295) 0.597 
Time over 3 
METs bouts 
32 (11 to 54) 0.006 
 
 
The table above (table 8.4) displays the change in PA from baseline to seven 









Six month changes in PA 
Table 8.5 presents the baseline, seven week and six month measures for all 
PA measures. It also displays the change in score from baseline to six months 




Table 8.5 Mean (SD) baseline, seven week and six month scores and change 
in scores from baseline to six months in PA for PR and SPACE 
 PR SPACE Between Group 
Differences 
Mean (95% CI) 
Steps Baseline 3683 (1820) 3902 (2120) 219 (-895 to 1333) 
7 weeks 3219 (1829) 4976 (3130) 1757 (290 to 3224) 
6 months 3408 (2065) 3593 (2160) 185 (-1004 to 1374) 
Change -275 (1777) -309 (1872) -34 (-1062 to 994) 
PAL Baseline 1.38 (0.28) 1.40 (0.33) 0.02 (-0.15 to 0.20) 
7 weeks 1.43 (0.17) 1.56 (0.27) 0.13 (0.01 to 0.27) 
6 months 1.46 (0.27) 1.47 (0.25) 0.01 (-0.13 to 0.16) 
Change 0.08 (0.37) 0.08 (0.25) 0 (-181 to 0.18) 
Sedentary Baseline 549 (103) 540 (119) -9 (-71 to 54) 
7 weeks 555 (91) 494 (106) -61 (-116 to -5) 
6 months 556 (95) 543 (96) -13 (-66 to 41) 
Change 7 (56) 3 (72) -4 (-40 to 32) 
LPA  Baseline 107 (72) 112 (59) 5 (-32 to 42) 
7 weeks 113 (73) 136 (73) 17 (-23 to 59) 
6 months 102 (68) 108 (54) 6 (-29 to 40) 
Change -15 (54) -16 (66) -1 (-35 to 33) 
MVPA Baseline 58 (36) 66 (86) 8 (-209 to 87) 
7 weeks 50 (39) 84 (64) 34 (5 to 65) 
6 months 55 (49) 63 (60) 8 (-22 to 40) 
Change -5 (39) -5 (54) 0 (-27 to 26) 
Vigorous Baseline 6 (25) 2 (5) -4 (-15 to 5.6) 
7 weeks 2 (7) 6 (21) 4 (-5 to 13) 
6 months 7 (22) 6 (17) -1 (-12 to 10) 




Baseline 330 (366) 347 (452) 17 (-234 to 268) 
7 weeks 236 (186) 430 (323) 186 (38 to 335) 
6 months 299 (358) 342 (369) 43 (-162 to 247) 




  PR SPACE Between Group 
Differences 




Baseline 36 (52) 50 (105) 14 (-37 to 66) 
7 weeks 26 (38) 37 (38) 11 (-22 to 30) 
6 months 38 (55) 45 (74) 7 (-32 to 47) 




Baseline 199 (356) 232 (519) 33 (-241 to 307) 
7 weeks 129 (167) 183 (171) 54 (-100 to 135) 
6 months 202 (341) 239 (417) 37 (-194 to 267) 
Change -3 (483) 7 (307) 10 (-245 to 281) 
Time over 
3 METs in 
≥10 min 
bouts 
Baseline 15 (25) 11 (5) -4 (-15 to 8) 
7 weeks 11 (15) 39 (57) 28 (5 to 52) 
6 months 20 (33) 26 (44) 6 (-16 to 28) 


















Table 8.6 differences from baseline to six months and differences between 
PR and SPACE for COPD groups 
 
Table 8.6 presents the repeated measure analysis for PA over six months. 
Data suggests that by six months there is no difference between the groups in 
any PA measure 
PA measure Within group effects 
Baseline to six months 
Between PR v 
SPACE effects 
(p=) 
 Time (p=) Time*Intervention 
(p=) 
 
Steps 0.162 0.017 0.054 
PAL <0.0001 0.357 0.668 
Sedentary 0.043 0.042 0.443 
LPA  0.165 0.705 0.382 
MVPA 0.344 0.232 0.606 
Vigorous 0.730 0.445 0.415 
EE over 
3METs (Kcal) 








<0.0001 0.906 0.851 
Time over 3 
METs in bouts 






Figure 8.3 Mean (SD) scores of step count at baseline, seven weeks and six 







Figure 8.4 Mean (SD) scores of PAL at baseline, seven weeks and six months 
in the PR and SPACE for COPD groups. 
 
Figure 8.5 Mean (SD) scores of time spent over 3 METs in at least 10 minute 







Figure 8.6 Mean (SD) scores of time spent above prescribed METs at 
baseline, seven weeks and six months in the PR and SPACE for COPD 
groups. 
 
Figures 8.3 to 8.6 show the change in PA at baseline, seven weeks and six 
months. Significant between group differences are highlighted at seven 
weeks. Figures 8.3, 8.4 and 8.5 show an intial increase in PA in the SPACE 
for COPD group compared to PR. However, by six months scores return to 
near baseline levels. Figure 8.6 demonstrates the decline in the time spent 
above the individual presrcibed level of PA, decreasing at seven weeks in 
both groups and then returning to baseline at six months.  The mean 
individually prescribed MET intensity prescribed was 3.8 METs. Therefore, 
patients were spending more time in the window between 3 and 3.8 METs, 






Figure 8.7 Proportion of time spent in sedenary and PA categories at 
baseline, seven weeks and six months in the PR group 
Figure 8.8 Proportion of time spent in sedenary and PA categories at 




Figure 8.7 and 8.8 show the distribution of the 12 hour (720 minutes) day in 
PA intensities and sedentary time. The figures demonstrate the increase in 
MVPA and LPA in the SPACE for COPD group in comparison to PR at seven 
weeks. Only minimal changes are detected in the PR group. 
 
Figures 8.8 and 8.9 show the change in PAL category from baseline, seven 
weeks and six months in the PR group (figure 8.9) and SPACE for COPD 
group (figure 8.10). At baseline both groups have a large percentage of 
patients in the <1.40 category which is extremely sedentary. At seven weeks 
this has declined and the 1.40-1.69 category increased, indicating both 
groups have increased their PA. However, by six months PA has reduced 
according to PAL category. There were no statistically significant differences 







Figure 8.9 Change in PAL category from baseline, seven weeks and six 
months in the PR group 
 
Figure 8.10 Change in PAL category from baseline, seven weeks and six 





Describing the level of PA and sedentary behaviour after a home based SM 
programme is novel. The aim of this chapter was to explore the effect of the 
SPACE for COPD programme on various measures of PA and sedentary time 
at seven weeks and six months in comparison to PR. This study was only 
completed on a subgroup of participants and was subject to a large dropout 
rate, therefore the interpretations of the findings are discussed in aliment with 
this limitation. 
 
Patients in the SPACE for COPD group have shown a significant increase in 
step count, PAL, LPA, MVPA, vigorous activity, EE over 3 METs and time 
over 3 METs in bouts of at least 10 minutes, and a reduction in sedentary time 
and time and EE over individually prescribed METs was at seven weeks. This 
demonstrates that this group increased their PA level and reduced sedentary 
time, however, this increased activity was not at a level corresponding to their 
individually prescribed exercise. This reduction in time over prescribed METs 
is potentially reflected by the change in ISWT seen where no significant 
improvement was detected (table 5.10). At seven weeks those in the SPACE 
for COPD had a within group significantly enhanced improvement in daily step 
count (p=0.020; table 8.4), time over 3 METs in 10 minute bouts (p=0.006; 
table 8.4), and reduced sedentary time (p=0.039; table 8.4) compared to PR.  
 
Those in the PR group showed no significant improvements in any of the PA 
variables. This is an unexpected finding as it has been previously reported 




activity monitor counts after seven week (Sewell et al. 2005). Pitta et al. 
(2008) reported faster walking time after three months of PR. However, they 
did not observe a significant increase in walking time until after six months of 
supervised PR and that this increase in walking time was due to small 
increase in short bouts of PA up to 1 minute in length. It is possible that due to 
the higher number in the PR not getting the group they preferred they may not 
have engaged in the programme fully. They attended the supervised 
outpatient sessions that were enough to increase their exercise performance 
but not adhere to their home programme. It may also be speculated that those 
in the PR group abdicated responsibility for their health to the healthcare team 
and relied purely on their supervise exercise session. This may explain why 
their ISWT and ESWT increased but was not reflected in PA levels. The 
emphasis in PR is on exercise and completing bouts of walking. However, no 
increase in time spent in MVPA in at least 10 minute bouts was observed. 
This supports the hypothesis that patients in the PR group have completed 
the course of supervised exercise, but not adhered to the home aspect of the 
programme. 
 
The discrepancy in the exercise performance measures and PA measures is 
not fully understood. However, it is possible that the PA monitoring has not 
fully captured PA levels as only a snap shots of time was recorded. There is 
the possibility that the PR group have increased their exercise capacity purely 
on the basis of the supervised outpatient sessions and they have not 
continued with their walking programme at home. Whereas, the SPACE for 




improvements in exercise capacity (ISWT and ESWT) have increased their 
time walking but this time has been sub therapeutic. However, due to the 
much smaller numbers in the PA monitoring part of the trial, it is most likely 
that statistical power has not been met for this outcome measure. The 
possible characteristics of those more suited to PR and those more suited to 
SPACE for COPD warrant closer examination. Due to the small numbers in 
this trial it has not been possible to analyse the predictors of improved 
physical activity.   
 
At six months PA and sedentary time had returned to baseline levels and no 
significant difference was detected between PR and SPACE for COPD. The 
within subject analysis show a significant effect of time (p=0.03) and 
time*intervention (p=0.008, table 8.6) for the >3METs in bouts which is 
reflected in the percentage of participants meeting the threshold of 30 minutes 
of >3METs in 10 minute bouts in the SPACE for COPD group. Although 
overall PA levels have returned to baseline it appears that when PA does take 
place it is more likely to be in longer durations than at baseline. This is an 
important observation due to its related health behaviour and has not been 
previously reported. Although patients appear to be spending more time in 
continuous bouts of exercise at six months the mean time is still below 
recommended levels. The effect of a PA intervention on adherence to PA 
guidelines in patients with COPD has not previously been reported. Cindy Ng 
(2012) completed a systematic review to determine if exercise training 
impacts daily PA in patients with COPD and concluded that exercise training 




factors influencing PA. While PA levels has been associated with poor 
prognosis (Waschki et al. 2011) it is yet to be fully elucidated if exercise 
training leads to increased PA and hence improved health outcomes. 
 
Although the reliability of the SWM was reduced at lower walking speeds 
(1.78 km.hr; Chapter 4) the median prescribed walking speed was 3.6 km.hr 
and the mean prescribed MET level was 3.8 METs. Therefore we can be 
confident of the 10 minute bout data. 
 
The only other SM trial that has reported PA as an outcome measure is Effing 
et al.(2011) . This study used the Yamax DigiWalker SW-200 pedometer to 
assess the number of steps over seven days at baseline, three months and 
12 months. Over the 11 month intervention there was a mean improvement of 
1190 steps. This is comparable to the SPACE intervention after seven weeks. 
A limitation of Effings et al. study was that only step count was measured and 
that pedometers have been shown to be less reliable to activity monitors at 
slower speeds of walking (Turner et al. 2012), a characteristic of patients with 
COPD (Troosters et al. 2010). Step count is a useful measure but does not 
indicate intensity or patterns of PA and therefore it is not possible to 
determine if the ACSM guidelines have been met. The PA data from this trial 
is more descriptive in determining patterns and intensities of PA and therefore 
provides a more meaningful insight to PA behaviours of patients with COPD. 
Additionally this current study has provided data 6 months after the 
completion of the intervention and the Effing et al. (2011) study shows no 





The continued supervision in the Effing et al. study to the 12 month 
assessment highlights the possible value of continued support. Although the 
SPACE for COPD programme was successful at increasing daily activity it 
was not maintained at six months. The short term interaction with healthcare 
professionals during the seven week intervention may have provided support 
and motivation without the need for supervised sessions to increase PA. 
Maintaining this improvement in PA is the challenge and the best mechanism 
to deliver this is not fully understood and in need of further investigation.     
 
It has been hypothesised that in order for behaviour change to take place an 
individual’s knowledge, self-efficacy and skills need to be enhanced 
(Bourbeau, Nault and Dang-Tang, 2004). It is a limitation of this trial that 
knowledge was not measured. However, the PRAISE questionnaire was used 
to assess self-efficacy. A significant increase in self-efficacy was detected at 
seven weeks in the PR but not in the SPACE for COPD group. In light of this 
chapter findings, this data does not support Bourbeau, Nault and Dang-Tang 
theory (2004). However, as previously postulated (chapter 5.7) the PRAISE 
questionnaire may not be an appropriate tool to measure self-efficacy in the 
SPACE for COPD group or that statistical power was not met. Also the link 
between knowledge, self-efficacy and behaviour change may not be as simple 






In order to standardise within and between group data the first waking 12 
hours of monitoring was chosen. Therefore, monitors worn for longer period’s 
data has not been included. Although it is anticipated that the first 12 hours is 
most likely be more active it is probable that data has been missed. There are 
no clear guidelines as to the most appropriate method for the wear of activity 
monitors and 12 hours was chosen based on previous studies who have used 
this cut point (Pitta et al. 2008, Pitta et al. 2009). Other studies have reported 
PA measures as percentage of wear time (Hill et al. 2012) which may offer a 
more accurate picture. However, a minimum wear time still needs to be 
stipulated as short wear times may not give a truly representative depiction of 
PA.  The minimum number of hours per day required to gain an accurate 
representation of an individual’s PA is currently unknown and warrants further 
investigation. 
 
Compliance with wearing the monitor is a limitation in this study. Of those 
asked to wear the monitor compliance was 54%, which is much lower than 
that reported by Waschki et al (2012) who had a compliance rate of 94%. A 
possible explanation for this difference can be seen is in the protocols. 
Waschki’s study required participants to wear the monitors 24 hours a day 
and only take them off during swimming and personal hygiene activities. This 
would therefore mean they have had less opportunity to forget to put the 
monitor back on as it will have not been taken off at night. This study allowed 
participants to remove their monitors at night. This was done at the time as it 




cause participants less irritation if they did not need to wear monitors 
overnight. On reflection this may have increase the risk of participants 
forgetting to put their monitors on in the mornings and hence not having 
enough data to analyse.  
 
Measuring PA is challenging and activity monitors offer the best predictor of 
activity levels as opposed to self-report and pedometers. However, the SWM 
and other accelerometers are unable to give details as to the precise nature of 
the activity. Perhaps the combination of both accelerometry and 
questionnaires or activity diaries could offer the best picture of PA behaviour 
in this population. 
 
8.9 Conclusion 
This study is the first to report detailed PA data after a home based SM 
programme. Although numbers were small, at seven weeks no significant 
improvement in any PA variable was detected in the PR group. The SPACE 
for COPD group showed a significant increase in step count, PAL and time 
over 3 METs in bouts and a decrease in sedentary time. There were 
significant improvements in step count and time over 3 METs in at least 10 
minute bouts in the SPACE for COPD group in comparison to PR at seven 
weeks. By six months there were no group differences and PA had returned 
to near baseline levels. As the natural course of COPD would indicate a 
continued decline in PA (Griffiths et al. 2000) maintaining baseline levels is 
clinically relevant. The challenge remains to determine who best would 




seen in the SPACE for COPD beyond seven weeks. In order to confirm this 




Chapter 9 – General Discussion 
 
This chapter brings together the key findings from this thesis to provide an 
overview of the effectiveness of the SPACE for COPD programme. 
 
The aim of this thesis was to explore the impact of the SPACE for COPD 
programme by completing a single blinded noninferior RCT in comparison to 
conventional PR. The SPACE for COPD programme is a novel approach to 
delivering rehabilitation in a home based context. It is supported by a manual 
giving advice and developing skills to enhance SM behaviour. 
 
The hypothesis tested in this thesis was that the SPACE for COPD 
programme would be noninferior to conventional COPD at seven weeks in 
regards to self-reported symptoms of dyspnoea. In addition, this thesis also 
explored the impact of the SPACE for COPD programme on other measures 
of HRQoL, psychological functioning, self-efficacy, exercise performance and 
daily PA levels. This thesis commenced with an evaluation of the SWM to 
ensure it was a valid measure of PA in patients with COPD and sensitive to 
small changes in walking speed. 
 
This chapter is divided into four main sections. The first section is a summary 
of the main findings (9.1). An evaluation of the study limitations is presented in 




(9.3) and the final section draws together the final conclusions of this thesis 
(9.4). 
 
9.1 Main findings 
A summary of the main findings is presented in Table 9.1. The significance 
column refers to the primary analysis of whether between group differences 
were apparent. Due to statistical software limitations, it was not possible to 
analyse imputed data at 6 months.  
 
Table 9.1 Summary of the primary analysis 
 ITT completer ITT imputed 
 Significant Noninferiority Significant Noninferiority 
7 weeks follow up 
Primary outcome 
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6 months follow up 
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The hypothesis that the SPACE for COPD programme would improve self-
reported dyspnoea (CRQ – SR dyspnoea) to a noninferior level in comparison 
to conventional PR is broadly supported by this trial. No statistically significant 
difference was detected at seven weeks between SPACE for COPD and PR 
groups (chapter 5). However, in line with the CONSORT recommendations  
(Piaggio et al. 2012) for reporting noninferiority trials as the 95% CI of the 
difference in change between the SPACE for COPD trial and the PR 
breached the MCID of 0.5 units there still remains some uncertainty as to its 
level of noninferiority.  
 
At seven weeks improvements in CRQ-SR dyspnoea, walking endurance 
time, step count and time above 3 METs in at least 10 minute bouts (chapters 
5 and 8) were detected which were equivalent or better than PR. This is the 
first study to describe such changes in a relative short time frame and 
demonstrate how soon changes can take place from a home based 
unsupervised SM programme. 
 
The follow up data demonstrated that gains obtained in the short term were 
lost six months after the formal intervention programme has ceased (chapters 
6 and 8) and values were comparable to baseline except for ISWT data in 
favour of the SPACE for COPD group. This was reflected in both the PR and 
SPACE for COPD group. Given the observed decline in exercise performance 
and HRQoL seen in patients with COPD (Casanova et al. 2007, Griffiths et al. 
2000) maintenance of baseline levels would possibly indicate that both 




helped reduce the rate of this expected decline. This is the first study to follow 
up UK participants after a home based supported SM intervention has 
finished to determine any trajectory of change. 
 
Chapter 7 described the PA and sedentary behaviour of patients with COPD. 
This has not been previously been reported in such detail in a UK based 
population. It highlights the low levels of PA in this cohort and the impact of 
interpreting the recommended guidelines for PA and exercise. Chapter 8 
provides an insight into the change in PA as a result of the interventions and 
indicates that although patients in the SPACE for COPD group increase their 
time in MVPA and step count they did not increase their time at their 
prescribed intensity of activity. Therefore although PA has increase in the 
SPACE for COPD group it was not sufficiently high enough to secure gains in 
maximal exercise capacity (ISWT). 
 
At seven weeks the SPACE for COPD programme has shown to have an 
effect on self-reported dyspnoea, anxiety (for those with at least a possible 
presence) and exercise performance. Although benefits have been identified 
these improvements were not as large as those seen in the PR group. 
Furthermore, despite PR showing significant improvements these changes 
were not as great as anticipated in this group. The Mean (95% CI) change for 
the ISWT was 42 (24 to 59) m which does not met the MCID of 48m for this 
measure. Previous studies from the same centre demonstrate the mean 
change for the ISWT after PR met the MCID in each study (Evans et al. 2009, 




2005, Vincent et al. 2011). This could be explained by the participant in these 
previous studies having lower baseline FEV1, larger numbers of participants in 
MRC 4 and 5 and lower mean ISWT scores. This highlights that this current 
study has possibly recruited patients that are not wholly representative of the 
PR population at this centre. A number of authors from this centre have 
previously reported greater benefits of the PR at Glenfield (Harrison et al. 
2012, Sewell et al. 2006) and that all MRC grades can benefit (Evans et al. 
2009). A possible explanation for this could be that this study has recruited a 
subtly different population and overall have fewer symptoms and therefore are 
less motivated to participate and to adhere to their programme. As patients 
were told about the study during their referral appointment they may have 
seen the unsupervised SPACE for COPD programme as the desired or ‘easy 
option’ and if randomised to PR not fully engaged in the programme (and 
therefore not complete their home exercise at a high enough intensity to elicit 
change in maximal exercise capacity). Although we did not formally measure 
adherence to the programme either within or outside the supervised sessions 
attendance rate was recorded. This is a limitation of this study is that patients 
could not be blinded to the treatment they received and therefore may have 
had a preference to which group to would like to be in. Although not recorded 
in all participants the majority of participants wanted the SPACE for COPD 
treatment and there were 29% in the PR opposed to 5% in the SPACE for 
COPD who were assigned to the treatment group they did not prefer. It is 
therefore possible that this may have influenced their commitment to the 
programme. These numbers were small so analysis was not completed on 




influences outcome of the intervention. It is interesting however, that on the 
surface the SPACE for COPD intervention seemed, in principle, acceptable to 
a number of patients that had been expecting a formal course of rehabilitation. 
 
Interestingly, the SPACE for COPD group demonstrated significant 
improvements in step count and time above 3 METs in 10 minute bouts, 
beyond that seen in PR. Changes in PA was not reflected in changes in 
exercise performance demonstrating the complexity of the link between PA 
and exercise capacity. However, a key reason for the minimal improvement 
seen in the ISWT could be that the home based/unsupervised walking 
programme did not progress in intensity which is a fundamental component of 
exercise training stimuli. This is mirrored in the reduction in time above 
prescribed METs at seven weeks in the SPACE for COPD group. It may be 
that those in the SPACE for COPD group find behaviour change in PA in their 
home environment easier to establish, however, as it was not monitored this 
increased PA level was potentially sub therapeutic. Whereas it is possible that 
the PR group passed on the responsibility of their behaviour change to the 
healthcare professional and not completed their home programme sufficiently, 
but did do enough exercise in their supervised PR sessions to increase peak 
exercise capacity (ISWT). 
 
Overall, the findings of the SPACE for COPD programme suggest it confers 
some benefits in regards to HRQoL, exercise performance and PA levels. 
These are key factors which have all been shown to have a significant impact 




et al. 2006, Waschki et al. 2011). A number of these improvements were not 
as great as PR, however 6 months after treatment the groups were not 
significantly different from one another and back to baseline levels. PR is the 
recommended treatment for patients with COPD (Bolton et al. 2013), however 
demand and drop out is high. The SPACE for COPD programme does result 
in positive benefits and therefore, could be used as an alternative ‘next best’ 
option. What is not clear from this current study is to whom this form of 
delivery is most suited. It could be argued that those with fewer symptoms 
(GOLD groups A and C and MRC 1,2 and 3) may be more suited to a home 
based programme and those with more symptoms (GOLD groups B and D 
and MRC 4 and 5) more suited to supervised PR, however, this has not been 
formally reported or fully debated.  
 
There has been several home based and SM programmes reported in the 
literature and this thesis has aimed to clarify the various interpretations of 
these. A key difference in the SPACE for COPD study is that it is a shorter 
intervention than many others reported which have lasted up to 2 years 
(Monninkhof et al. 2003a). This study is unique in being an adequately 
powered study demonstrating benefit in such a short period which is match to 
the UK model of healthcare. These other reported longer studies would not be 
feasible in the UK. 
 
In addition to the length of programme, supervision and health care 
professional contact is another key distinguishing factor. In this current study 




contact with a healthcare professional took place. Previous studies although 
labelled as SM or home based actually provide more supervision and 
professional contact than PR in the UK (Boxall et al. 2005, Effing et al. 2011, 
Monninkhof et al. 2003a, Ninot et al. 2011). SPACE for COPD is the first 
unsupervised home based programme supported by a SM manual in the UK 
to have an impact on patients with COPD. It is acknowledged that this impact 
is not as great as PR and this issue of supervision could be the key factor in 
the differences seen. On the whole this study supports Puente-Maestu et al. 
(2000) who highlighted that unsupervised programmes can show significant 
physiological improvements but they are to a lesser degree than supervised 
programme.     
 
Maintenance of the benefits seen in PR and SPACE for COPD programmes 
has not been achieved at six months despite both programmes promoting 
long-term adherence to health-enhancing behaviours. Other studies 
examining maintenance strategies support this this finding which suggest pre-
intervention levels are returned to within 12 months of programme completion 
(Beauchamp et al. 2013a, Griffiths et al. 2000, Ries et al. 1995) independently 
of any follow up. This reduction in outcome variables is commonly attributed 
to lack of adherence to a home maintenance exercise programme (Brooks et 
al. 2002, Griffiths et al. 2000). Therefore, it is of interest to determine the 
programme components and individual characteristics which contribute to 
sustained behaviour change offered in formal maintenance programmes. It 
remains unclear in the literature as to the best strategy to support patients 




programmes it is possible that they find difficulty in the transition to community 
based programmes where more responsibility is focussed on the individual. It 
was anticipated that those completing the SPACE for COPD programme may 
have done better at the six month point due to the programme being delivered 
in the patient’s own home. However, this was not the findings of this study. 
Maintenance programmes reported in the literature often involved community 
based supervised exercise (Beauchamp et al. 2013b, Cockram, Cecins and 
Jenkins 2006, van Wetering et al. 2010)  which involved frequent supervision 
and may not be feasible or cost effective in the UK. Alternative strategies for 
supporting maintenance is telephone health monitoring which may be more 
suitable for the UK model of healthcare and maybe a more effective approach 
to post rehabilitation (Walters et al. 2012).  
 
The challenge remains as to the best strategy to enhance and maintain 
positive health related behaviour. This is a complex issue on its own and is 
further complicated by the disease progression and potential exacerbations of 
patients with COPD. Individual characteristic which attribute to maintenance 
needs further exploration. Soicher (2012) monitored PA after PR up to 12 
months and found that those with high baseline PA levels which subsequently 
declined also reported more barriers to exercise and poorer past exercise 
habits in comparison to those who had maintained high PA levels. Therefore 
strategies that focus on enhancing self-efficacy and overcoming barriers to 
exercise are needed to ensure greater success. It may be that the SPACE for 
COPD programme does not go far enough in addressing the maintenance of 




incorporated in the manual. For insight into these issues further qualitative 
investigations are being carried out, but are not within the remit of this thesis. 
 
9.2 Limitations  
An important limitation to this study is that due to the nature of research the 
patients recruited may not have been representative of COPD patients 
generally seen at this centre reported in the literature. Chapter 5, 6 and 8 
have all reported on how baseline characteristics and responses to PR have 
not necessarily characteristic of this population. A reason why this study has 
recruited an unrepresentative population is complex but could possibly be due 
to a portion of participants interpreting the home-based nature of the study as 
an ‘easy option’. They have been referred to PR which is a comprehensive 
programme meaning a significant commitment and progress being closely 
monitored, but by opting for the SPACE programme they could appear to be 
meeting their health professionals advice but not committing too much. Those 
that were then subsequently refered to PR therefore may have been less 
motivated to engage and adhere to the programme and therefore not 
performed as expected. As patients could not be blinded to the treatment 
group it is natural to assume many will have had a preference to which group 
they were assigned to and not getting the group they preferred may have 
impacted on the results. Preference was only recorded in roughly half of the 





Baseline characteristics also suggested those initially recruited were less 
severe than normally seen. This could be as those with more advanced 
symptoms felt like they needed the support of a hospital based setting.   
 
Given the self-directed nature of the SPACE for COPD programme it may be 
that this programme is more suited to certain personality types and is not 
suitable for all with COPD. Future work into SPACE for COPD to identify 
those most likely to benefit from its approach would be valuable. Management 
of long term conditions should be individualised and matched to those most 
able to benefit. There is no ‘one size fits all’ treatment, but SPACE for COPD 
could reasonably offered as a suitable alternative, further investigations needs 
to identify suitable characteristics which make SPACE for COPD the best 
option. 
 
A key limitation to the SPACE for COPD trial is that adherence to the exercise 
programme and engagement in the SPACE for COPD manual was not 
monitored, although during the phone calls patients were required to comment 
on their engagement to the programme. It may be those that did respond to 
the programme were those that adhered to their programme and those that 
did not respond to the programme did not engage in the exercise or complete 
any of the tasks aimed at improving self-efficacy. No formal monitoring of 
SPACE for COPD manual took place in terms of looking at tasks completed 
and completeness of the walking diary. PA monitors were worn at the 3 
measurement time points but this may not truly reflect adherence to the 




may be of use to monitor patients more closely or ask them to complete a PA 
diary to assess adherence. However, future work into the SPACE for COPD 
programme is investigating the use of a website as a platform for delivering 
the intervention and requires patients to input their PA daily. This will enable 
insight into how well patients engage in the programme. The website also 
offers an additional mode of delivering rehabilitation which may be more 
suited to those confident and preferring the use of technology. 
 
The majority of patients with COPD have at least one comorbidity (Divo et al. 
2012). Mapel et al. (2000) reported a mean of 3.7 chronic conditions in those 
with COPD compared with 1.8 chronic conditions in those without. Comorbid 
conditions significantly impact on health status, hospitalization and mortality in 
patients with COPD (Divo et al. 2012). Those who are inactive, and hence a 
target for rehabilitation interventions, are more likely to have more 
comorbidities (Van Remoortel et al. 2014) and this complex association 
between conditions explain the clustering of chronic disease seen in patients 
with COPD. Although this study did record comorbidity it was not put on the 
database which limits analysis of factors influencing adherence and positive 
outcomes on the programme. It may be assumed that those with more 
comorbid conditions and in particular those that affect walking and PA will not 
have performed as well as those with fewer conditions. It possible that a more 
overarching view of chronic conditions, and treatment aimed at addressing the 






Chapter 8 presents the seven week and six month changes in PA in those 
participating in PR and SPACE for COPD programmes. PA was not the main 
outcome of the trial, therefore, with its small numbers (n=51) it is highly 
possible that this study is not sufficiently powered.  
 
9.3 Future Work 
Implementation 
This thesis presents the first adequately powered home based supported SM 
RCT of the SPACE for COPD programme. There next step would be to 
evaluate its effectiveness in clinical practice without the constraints of a 
research trial. This will therefore address the issue of preference and 
potentially draw out those to which this approach is more suitable. Training 
programmes are currently being developed to equip healthcare professionals 
to deliver and support the SPACE for COPD programme. Future studies 
should look at the effectiveness of this mode of delivery across a number of 
centres to determine its feasibility nationwide. 
 
Maintenance 
This thesis reported that initial benefits of the SPACE for COPD programme 
were not maintained at six months. Therefore strategies to support patients 
after the 2 telephone calls are required. A possible option is to continue with 
the telephone support as this approach has shown to positively influence 
patient behaviour (Walters et al. 2012). However, this is not routinely done 
after PR who also declined after the intervention period, therefore a strategy 




used to facilitate and enhance behaviour change. Text messaging and 
telehealth monitoring shows promise and has been used in a number of 
studies (Holland 2013, Tabak, op den Akker and Hermens 2014) 
 
Mode of delivery 
As previously mentioned in this chapter a RCT is underway investigating the 
delivery of the SPACE for COPD programme via the internet. Patients need to 
engage in sections of the programme before they can progress to the next 
stage and are required the upload their daily activity. This would therefore 
allow us insight into how well those that do adhere to the programme do.  
 
Another option is to deliver the introduction to the manual as a group. This 
allows patients to meet others in the same situations as they would if they 
completed PR.  Support from a peer group could be encouraged by each 
group developing its own internet blogs or using social media sites. Group 
dynamics has been shown to be important to successful behaviour change 
(Bandura 1977) a number of other SM programme have used a group based 
approach, such as the Expert Patient Programme (Barlow et al. 2009) and the 
chronic disease self-management programme (Lorig et al. 2001). These 
programmes have been successful and patients reported that the group 
nature enhanced motivation and increased confidence and control (Barlow et 
al. 2005). However, these programmes only report psychological gains and 






Timing of delivery 
In the UK there is a substantial number of patients declining the offer of PR, 
offering patients a choice of venue may improve uptake. This has been shown 
to be the case with cardiac rehabilitation with the increase uptake in the 
service due to the heart manual (Dalal and Evans 2003). Therefore offering 
the SPACE for COPD programme at the point of referral needs investigating.  
 
Health Economics 
There is an assumption that those who successfully self-manage would rely 
less on healthcare services. One previous study has reported an economic 
analysis of a home based SM programme in COPD (Koff et al. 2009)  and 
although the mean cost per patient was lower than hospital based PR there 
was no significant difference between the two groups.  Home based cardiac 
rehabilitation has also been shown to be more costly than centre based due to 
the increase number of home visits (Jolly et al. 2007). Cost of healthcare is 
increasing and any savings alongside clinical effectiveness is desirable. 
Future work on the SPACE for COPD programme needs to do a full economic 
analysis in comparison to conventional PR. Once the cost of the SPACE for 
COPD programme has been established the programme is more likely to be 
commissioned. 
 
9.4 Final conclusions 
A hospital approach to PR may not be feasible for all that would benefit. An 
alternative strategy to deliver rehabilitation in patients with COPD and to 




programme offers a ‘light touch’ approach   and was the main focus of this 
thesis. Findings suggest that the SPACE for COPD programme does achieve 
benefit in aspects of HRQoL and endurance capacity, but in a number of other 
outcomes the impact was not as large as that detected in PR.  
 
Although numbers were small the SPACE for COPD programme positively 
impacted an daily PA levels. Additional studies need to investigate this further. 
With numerous improvements seen after the SPACE for COPD programme it 
warrants consideration for those who would not normally take up the 
opportunity of hospital based PR. 
 
SPACE for COPD could offer great potential and now needs to focus on the 
impact of the programme in practice to determine if it is a suitable alternative 
when offered to those who refuse referral to PR. There is also possible for the 
SPACE for COPD programme to be used after PR to continue with the 














Appendix A: Literature (PICO) Search Terms 
 
Database Search: 
MEDLINE, PubMed, Science Direct 
 
PICO Search Strategy 
Population: 
"pulmonary disease, chronic obstructive" OR COPD OR "chronic obstructive 
pulmonary disease” 
[Limit to: Publication Year 1990-Current and English Language] 
 
Intervention: 
“Home*” OR “home based” OR “home-based”  OR “home-care” OR “home 
care” OR “unsupervised” OR “self-monitored”  
 
educat* OR self-manag* OR "self manag*" OR self-car* OR "self car*" OR 
train* OR instruct* OR "patient cent*" OR patient-cent* OR patientfocus* OR 
"patient focus*" OR patient-education OR "patient education" OR 
"management plan*" OR "management program*" 
[Limit to: Publication Year 1990-Current and English Language] 
 
Comparison: 
"usual care" OR rehabilitat* OR control 






exercise OR "health status" OR "quality of life" OR hospital* OR "healthcare 
utilisation" OR "healthcare utilization" OR knowledge OR activity 

























CONSORT Statement 2006 - Checklist for Non-inferiority and 
Equivalence Trials   




Item Descriptor Reported 
on 
Page # 
TITLE & ABSTRACT 1 How participants were allocated to interventions (e.g., "random 
allocation", "randomized", or "randomly assigned"), 




2 Scientific background and explanation of rationale, 





3 Eligibility criteria for participants  (detailing whether participants in 
the non-inferiority or equivalence trial are similar to those in any 
trial(s) that established efficacy of the reference treatment) and the 
settings and locations where the data were collected. 
64 
Interventions 4 Precise details of the interventions intended for each group 
detailing whether the reference treatment in the non-inferiority or 
equivalence trial is identical (or very  similar) to that in any trial(s) that 
established efficacy,  and how and when they were actually 
administered. 
67 
Objectives 5 Specific objectives and hypotheses, including the hypothesis 
concerning non-inferiority or equivalence. 
4 
Outcomes 6 Clearly defined primary and secondary outcome measures 
detailing whether the outcomes in the non-inferiority or equivalence 
trial are identical (or very similar) to those in any trial(s) that 
established efficacy of the reference treatment and, when applicable, 
any methods used to enhance the quality of measurements (e.g., 
multiple observations, training of assessors). 
82 
Sample size 7 How sample size was determined detailing whether it was 
calculated using a non-inferiority or equivalence criterion and 
specifying the margin of equivalence with the rationale for its choice.  
When applicable, explanation of any interim analyses and 





8 Method used to generate the random allocation sequence, 





9 Method used to implement the random allocation sequence (e.g., 
numbered containers or central telephone), clarifying whether the 




10 Who generated the allocation sequence, who enrolled 
participants, and who assigned participants to their groups. 
66 
Blinding (masking) 11 Whether or not participants, those administering the 
interventions, and those assessing the outcomes were blinded to 
group assignment. If done, how the success of blinding was 
evaluated. 
66 
Statistical methods 12 Statistical methods used to compare groups for primary 
outcome(s), specifying whether a one or two-sided confidence interval 
approach was used.  Methods for additional analyses, such as 





13 Flow of participants through each stage (a diagram is strongly 
recommended). Specifically, for each group report the numbers 
of participants randomly assigned, receiving intended treatment, 
completing the study protocol, and analyzed for the primary 
outcome. Describe protocol deviations from study as planned, 
together with reasons. 
118 
Recruitment 14 Dates defining the periods of recruitment and follow-up. 64 




Baseline data 15 Baseline demographic and clinical characteristics of each group. 122 
Numbers analyzed 16 Number of participants (denominator) in each group included in 
each analysis and whether the analysis was “intention-to-treat” 
and/or alternative analyses were conducted.   State the results in 
absolute numbers when feasible (e.g., 10/20, not 50%). 
Chapters 
5, 6, 7, 8 
Outcomes and 
estimation 
17 For each primary and secondary outcome, a summary of results 
for each group, and the estimated effect size and its precision 
(e.g., 95% confidence interval). For the outcome(s) for which non-
inferiority or equivalence is hypothesized, a figure showing confidence 
intervals and margins of equivalence may be useful. 
Chapters 
5, 6, 7, 8 
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, 
including subgroup analyses and adjusted analyses, indicating 
those pre-specified and those exploratory. 
Chapters 
5, 6, 7, 8 








20 Interpretation of the results, taking into account the non-inferiority 
or equivalence hypothesis and any other study hypotheses, sources 
of potential bias or imprecision and the dangers associated with 
multiplicity of analyses and outcomes. 
Chapter 9 
Generalizability 21 Generalizability (external validity) of the trial findings. Chapter 9 
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A self-management rehabilitation programme for chronic obstructive 
pulmonary disease (COPD): is it a feasible alternative to conventional 
rehabilitation? 
(Version 7 26/08/10) 
 
 
You are being invited to take part in research study being conducted by the pulmonary 
rehabilitation team in conjunction with Coventry University. The research is also been 
undertaken as part of an educational study. Before you decide it is important for you to 
understand why the research is being done and what it will involve.  Please take time to 
read the following information carefully and discuss it with others if you wish.  Ask us if 
there is anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part.  Thank you for reading this. 
 
What is the purpose of the study? 
Recent evidence has shown pulmonary rehabilitation for patients with chronic obstructive 
pulmonary disease (COPD) to be of benefit. However, only 3% of individuals with COPD 
have access to such a service. It may be more appropriate for patients to have access to a 
manual which covers issues such as drug and symptom management, exercise and 
nutrition at home. This would give help and advice concerning managing their own 
condition without having to travel to the hospital. This study is needed in order to inform 
the current delivery of the rehabilitation service, optimise patient care and aid in the 
development of new COPD rehabilitation programmes. 
 
 Why have I been chosen? 
As an individual with COPD that has been referred to the rehabilitation programme you 
have been identified as a suitable participant of the study.  It is important to us to see how 






Tel: 0116 287 1471 
Fax: 0116 258 3950 
Minicom: 0116 287 9852 








1. Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you decide 
to take part you are still free to withdraw at any time and without giving a reason.   
 
 
2. What will happen to me if I take part? 
You will be able to take this patient information sheet home with you and you will be 
contacted by telephone to discuss participating in the study. If you agreed to take part in 
the research you will be placed at random into either the self-management or hospital 
group.  
 
Once you have provisionally agreed to take part in the research you will be contacted to 
arrange a date and time to discuss the project in more detail.  We don’t know how effective 
the self management manual will be. To find out, we need to make comparisons between 
the different treatments. We put people into groups and give each group a different 
treatment; the results are compared to see if one is better. To try to make sure the groups 
are the same to start with, each patient is put into a group by chance (randomly). The 
results are then compared. There will be a 50/50 chance of being allocated to either group.  
 
Overall your involvement will last for 6 months, although the study will go on for much 
longer.  We routinely monitor participants in the rehabilitation programme at the end of the 
course. For the purpose of this study we would ask you to attend for one additional visit, 
this would last about one and a half hours, during which time we would measure your 
exercise capacity and ask you to fill in some questionnaires. All of these tests are normal 
procedure for rehabilitation. You may also be asked to take part in a focus group at the 7 
week visit.  You do not have to do this to be part of this research. 
 
 
We would, with your permission, inform your General Practitioner that you have agreed to 
take part in this study  
 
 
3. What do I have to do? 
If you are assigned to the hospital based rehabilitation programme you will complete the 
normal 7 week (twice weekly) programme of exercise and educational advice. You will be 
requested to complete the standard assessments of lung function, exercise capacity 
(walking test) and be asked to complete some questionnaires about your health status and 
activity patterns.  You will be assessed before you commence the hospital programme, 7 
weeks later and the 6 months after the hospital programme, as is routine. After your 7 week 
appointment you may be invited to take part in a focus group. This will involve a small group 
of other participants who have attended pulmonary rehabilitation classes at the hospital.  It 
is an opportunity for you to feedback what you found useful about rehabilitation and what 
you would like to be included in a self-managed programme of rehabilitation at home. This 






If you are assigned to the self-management group you will undergo the same assessments 
at the same time points as the hospital group, however, you will be given a manual for 
people with pulmonary disease and invited to a workshop on how to use the manual. Your 
manual will outline how to manage your condition including information on drug and 
symptom management, exercise and nutrition. Included will be some home-based exercises 
you can carry out in your own time. You will receive 2 phone calls to see how you are 
progressing with the manual. You will not participate in the exercise and educational 
sessions at the hospital.  After your 7 week appointment you may be invited to take part in a 
focus group.  This will involve a small group of other participants who have used the self-
management manual.  It is an opportunity for you to feedback what you found useful about 
the manual and if anything could be improved.  This should not last longer than an hour and 
will be recorded with your consent.    
 
You may also be invited to wear an activity monitor which is worn on your arm. This is to be 
worn for 5 days during waking hours (please do not allow the monitor to get wet, so please 
remove if going swimming or you are having a bath etc.). You need not change your normal 
activity pattern while wearing this monitor. Again this will be assessed before you start your 
programme and also 7 weeks and 6 months after, as is routine.  
 
4. What are the possible disadvantages and risks of taking part? 
If you are placed in the self-management group you will not participate in the routine 7 
weeks of rehabilitation at the hospital. However, If the self-management manual has 
proved to be ineffective for you, you will be offered the routine 7 week rehabilitation 
sessions at the hospital.  
 
5. What are the possible benefits of taking part? 
We hope that the research will aid you in your understanding of exercise and rehabilitation 
and inform both present and future pulmonary rehabilitation programmes therefore 
benefiting COPD patients.   
 
8. What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangement. If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action but you may have to pay for it. Regardless of this, if 
you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms would be available to you.  
 
9. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept 
strictly confidential. Any information about you, which leaves the hospital, will have your 
name and address removed so that you cannot be recognised from it. Participants will not 
be identified in any subsequent written material; for example, pseudonyms will be used to 
refer to participants’ names.  Results will be reported in such a way that completely 
preserves confidentiality.  
 
10.  What will happen to the results of the research study? 
The results of the study will be disseminated in peer and lay journals, professional 




such a way that preserves confidentiality. All participants will also receive a summary of 





11. Who is organising and funding the research? 
This study is being funded by the Pulmonary Rehabilitation Research Group and the 
Pulmonary Rehabilitation team will be recruiting participants. 
   
 
12. Who has reviewed the study? 
All research that involves NHS patients or staff, information fro NHS medical records or 
uses NHS premises or facilities must be approved by an NHS research Ethics Committee 
before it goes ahead. Approval does not guarantee that you will not come to any harm if 
you take part. However, approval means that the committee is satisfied that your rights will 
be respected, that any risks have been reduced to a minimum and balanced against 
possible benefits and that you have been given sufficient information of which to make an 




13. Contact for further information  
If you have any concerns or other questions about this study or the way it has been carried 
out, you should contact the principal researcher (Sally Singh Tel: 0116 2502535)  
 
 
Contact for further information: 
Elizabeth Horton 





Tel: 024 7688 8915 
Email: apx242@coventry.ac.uk 
 


















CONSENT FORM (Version 6, 26/08/2010) 
 
Identification Number for this study:  
 
A self-management rehabilitation programme for chronic obstructive 
pulmonary disease (COPD): is it a feasible alternative to conventional 
rehabilitation? 
    
          Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 
26/08/2010 version 7 for the above study and have had the opportunity 
to ask questions.         
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at 
by responsible individuals from Coventry University or from regulatory 
authorities where it is relevant to my taking part in research.  I give 
permission for these individuals to have access to my records. 
 
4. I agree to take part in the above study. 
 
5. I agree for my GP to be informed of my participation. 
 
6. I agree to take part in a tape recorded focus group and for anonymous quotes          
to be used in the final report 
 
7. I understand that all the information I give will be treated in confidence. Should I 
disclose any information that highlights a breach of the law, or dangerous 
practice  the interviewer will be duty bound to breach confidentiality. 
 
______________________  _________ ____________ 
Name of Patient         Date   Signature 
______________________  _________ ____________ 
Name of Person taking consent  Date Signature 
(if different from researcher) 
 
______________________  _________ ____________ 
Researcher    Date  Signature 
 






Tel: 0116 287 1471 
Fax: 0116 258 3950 
Minicom: 0116 287 9852 





















Appendix H: Chronic Respiratort Questionnaire 















































General Self-Efficacy Scale. 
Adapted for Pulmonary Rehabilitation. 
 
Please circle where you feel you are now. 
Statement 
Score 
I can always manage to solve difficult problems if I 
try hard enough. 
1 2 3 4 
If someone opposes me, I can find the means and 
ways to get what I want. 
1 2 3 4 
It is easy for me to stick to my aims and accomplish 
my goals. 
1 2 3 4 
I am confident that I can walk for a good distance, 
at my own pace, despite it making me breathless. 
1 2 3 4 
I am confident that I could deal efficiently with 
unexpected events. 
1 2 3 4 
Thanks to my resourcefulness, I know how to 
handle unforeseen situations. 
1 2 3 4 
I feel confident that I will be able to perform the 
exercises asked of me during the course of 
rehabilitation, even if I find them difficult. 
1 2 3 4 
I can solve most problems if I invest the necessary 
effort. 
1 2 3 4 
I feel that I have an adequate amount of knowledge 
about my lung disease, despite it being a complex 
condition. 
1 2 3 4 
I can remain calm when facing difficulties because I 
can rely on my coping abilities. 
1 2 3 4 
When I am confronted with a problem, I can usually 
find several solutions. 
1 2 3 4 
I feel positive that I will be able to complete the 
exercises at home, despite there being no 
supervision from a health professional. 
1 2 3 4 
If I am in trouble, I can usually think of a solution. 1 2 3 4 
I can handle whatever comes my way. 1 2 3 4 
On a day to day basis I feel in control of my lung 
disease and how that affects my lifestyle, even 
when my symptoms become distressing. 
1 2 3 4 
Response Format. 
1= Not at all true 
2= Hardly true 
3= Moderately true  
4= Exactly true 
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